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Abstract 
 
The cardioprotective hormone prostacyclin is a potent inhibitor of platelet activation and is 
produced in vascular endothelium by the concerted actions of cyclo-oxygenase and 
prostacyclin synthase. There is an ongoing, heated debate about which COX isoform (COX-1 
or COX-2) regulates endothelial prostacyclin production. This is an important area of study 
since non-steroidal anti-inflammatory drugs (NSAIDs) or COX-2 selective inhibitors, used to 
treat arthritis, are associated with an increased risk of cardiovascular events, which has 
been linked to a reduction of urinary markers of prostacyclin. Thus, the aim of my thesis was 
to investigate the relative contribution of COX-1 versus COX-2 to endothelial prostacyclin 
production and vascular function.  
Using en face confocal imaging, I found that COX-1 immunoreactivity predominates over 
COX-2 in the endothelium of all blood vessels studied, including aortic arches from healthy 
wild type (WT, C57BL/6J) mice, in WT mice injected with endotoxin, ApoE-/- mice,  rats with 
chronic heart failure and in human pulmonary artery. I have performed bioassays with 
blood vessels from WT versus COX-1-/- and COX-2-/- mice to show that COX-1 not COX-2 
drives the majority of vascular prostacyclin production in both young (3 month old) and 
mature (12 month old) mice of both sexes. Phenotypic differences in the COX-1-/- and COX-
2-/- mice included elevated levels of nuclear ‘primed’ NF-κB in the endothelium of both the 
protected (greater) and atherosclerosis-susceptible (lesser) curvature of the aortic arch.  
Despite COX-2-/- mice having normal endothelial prostacyclin production, more platelets 
adhered to the lesser curvature of the aortic arch.  
The techniques and validation protocols employed have shown COX-1 as the predominant 
endothelial COX isoform, responsible for vascular prostacyclin production. Low levels of 
constitutive COX-2 was found localised to susceptible areas of the vasculature where it may 
contribute to prostacyclin production on a local level to limit inflammation, atherosclerosis 
and platelet adhesion.   
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Non-steroidal anti-inflammatory drugs (NSAIDs) such as aspirin, diclofenac, naproxen and 
ibuprofen are some of the most common and widely available over-the-counter drugs 
worldwide. NSAIDs are generally indicated for the symptomatic relief of common pain 
conditions such as headaches, fever, dysmenorrhea and the cardinal signs of acute 
inflammation following tissue injury (swelling, redness, heat, pain and loss of function). For 
short term use, NSAIDs are generally highly effective, well tolerated and relatively safe with 
few side effects, hence their widespread use for common aches and pains. However, there 
is a large group of patients with chronic inflammatory conditions (autoimmune diseases) 
such as rheumatoid arthritis, osteoarthritis and ankylosing spondylitis that often rely on 
daily dosing of NSAIDs for symptomatic relief from debilitating stiffness and pain in affected 
joints. For this kind of long term, chronic NSAID use, there are a number of well recognised 
side effects that need to be considered and weighed against the benefit of pain relief.  
 
The three main organ systems affected by chronic NSAID use are: 1) the gastro intestinal 
tract, 2) the kidneys and 3) the cardiovascular system. The most common side effect is on 
the gastrointestinal tract, where long term NSAID use can lead to erosions, perforations, 
bleeding and ulcers (Perini et al., 2004; Wallace et al., 1990; Wallace et al., 2000). Another 
side effect is on the renal system where NSAIDs commonly induce a small (1-5 mmHg) rise in 
systemic blood pressure in normotensive as well as hypertensive patients which may 
increase hypertension related morbidity (Singh et al., 2003). These gastrointestinal and 
renal side effects will be briefly introduced later on in this chapter.   
 
A more recent area of concern is the association of chronic NSAID use with an increased risk 
of thrombotic cardiovascular events including myocardial infarction and stroke (Bluhm et 
al., 2011; Bombardier et al., 2000; Bresalier et al., 2005). The focus of my PhD has been to 
investigate some of the basic mechanisms that relate to these cardiovascular side effects of 
NSAIDs.   
 
Before exploring these cardiovascular side effects in greater detail and the specific aims of 
my thesis, I will first give some general background about the pharmacology of NSAIDs.   
 
 
Chapter 1 General Introduction 
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The mode of action of NSAIDs 
Even though different forms of NSAIDs, such as salicylate from willow bark, have been used 
for thousands of years, it was not until the 1970s that the pharmacology behind the 
analgesic, anti-pyretic and anti-inflammatory effects of these drugs could be explained. 
Aspirin (acetylsalicylic acid) is often used as a class example for NSAIDs. For this reason 
NSAIDs are sometimes referred to as ‘aspirin-like drugs’. In 1971, Sir John Vane published 
the paper ‘Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like 
drugs’ (Vane, 1971), which along with 3 other papers (Collier et al., 1971; Ferreira et al., 
1971; Smith et al., 1971), for the first time identified that ‘aspirin-like’ drugs inhibit 
prostaglandin (PG) synthesis by interfering with the active site of PGH synthase (PGHS). As 
detailed below, PGHS is an integral membrane protein comprised of two enzymatic 
components, a cyclo-oxygenase (COX) and a peroxidase (POX) site. PGHS is, however, 
colloquially referred to as COX and this will also be the case throughout the thesis.  
 
Prostanoids 
Prostanoids (PGs, thromboxane and prostacyclin) are a subclass of the eicosanoid family of 
oxygenated derivatives of 20-carbon essential fatty acids. This thesis will focus on the 
prostanoids derived from arachidonic acid which is the most abundant precursor fatty acid 
source in mammals (Narumiya et al., 1999). Arachidonic acid is a poly unsaturated omega 6 
fatty acid with the first double (carbon-carbon) bond in the n-6 position in the 20 carbon 
chain linked to the carboxylic acid. The nomenclature for prostanoids derived from 
arachidonic acid is denoted by the number 2 in subscript to denote 2 double bonds (i.e. 
PGE2). All the prostanoids contain 20 carbon atoms divided up in a cyclopentane ring and 2 
side chains (prostacyclin has got two cylopentane rings). Their nomenclature is further 
decided based on modifications of this cyclopentane ring by the alphabetic letters A-I, 
where PG A-C only occur during artificial extraction procedures and PG D-I occur naturally in 
the body (Narumiya et al., 1999). PGs were first isolated from seminal fluid and therefore 
the name prostaglandin comes from the association with the prostate gland which was first 
believed to be the tissue source of PGs (Goldblatt, 1935; V Euler, 1934). All prostanoids are 
short lived, biologically active lipid mediators crucial to many physiological and 
inflammatory processes. Due to their unstable nature, prostanoids cannot be stored within 
the cell, and are therefore produced on demand following any chemical or mechanical 
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stimuli leading to an increase in intracellular calcium.  They are then released from the 
stimulated cell immediately after synthesis. Due to their chemical instability, they are 
rapidly degraded or metabolised with a half-life in the range of 30 seconds to a few minutes. 
Hence, the activity of prostanoids remain mainly local to the vicinity of their production 
(Narumiya et al., 1999).   
 
Prostanoid synthesis pathway  
When hormones or physical forces activate cells, intracellular calcium increases and 
activates calcium activated forms of calmodulin, which in turn activates cytosolic forms of 
phospholipase A2 (PLA2). Activated PLA2 cleaves arachidonic acid from the membrane 
phospholipids. The free arachidonic acid is then subject to enzymatic conversion by various 
enzymes, including the integral membrane enzyme PGHS. PGHS has two adjacent but 
spatially distinct active sites; the COX site and the POX site.  The arachidonic acid gains 
access to the COX site through the interior of the lipid bilayer, where it undergoes bi-
oxidation (+02) to form the unstable endoperoxidase PGG2 (Figure 1.1). PGG2 is then 
reduced (-e) to PGH2 at the POX site (Figure 1.1 and 1.2). Various synthases and isomerases 
then convert the unstable PGH2 into PGs (D2, E2, and F2), prostacyclin and thromboxane 
(FitzGerald, 2003) (Figure 1.1). The NSAID aspirin irreversibly acetylates a key amino acid 
residue in the COX catalytic site (Serine-530) which interferes with arachidonic acid 
(substrate) binding and thereby renders the COX enzyme inactive (DeWitt et al., 1990). 
While the NSAIDs diclofenac, ibuprofen and naproxen, are reversible competitive inhibitors 
that compete with the substrate (arachidonic acid) for the COX catalytic site (Figure 1.1). 
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Figure 1.1 Prostanoid synthesis pathway  
 
Figure 1.1 Prostanoid synthesis pathway. Following a mechanical, chemical or inflammatory stimuli, 
arachidonic acid is cleaved from the membrane phospholipids by phospholipase A2 (PLA2), then oxidised by the 
catalytic COX site, forming prostaglandin G2 (PGG2) which is then reduced at the POX site to form prostaglandin 
H2 (PGH2). PGH2 is then further metabolised by various downstream tissue specific isomerases, to form 
(prostaglandin (D2, E2 and F2), prostacyclin and thromboxane (figure modified from (FitzGerald, 2003). 
 
The initiation of COX catalytic activity depends on a priming event from the POX site, where 
a free radical (Tyr385) formed by POX activity oxidises the COX site to the active form 
(Ouellet et al., 2001) (Figure 1.2). The two sites are thereby mechanistically interrelated and 
it is held that one priming event from the POX site can sustain many cycles of COX 
enzymatic activity (Gupta et al., 2004).  
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Figure 1.2 Schematic of the priming event required for activation of COX oxidizing activity  
 
Figure 1.2 Schematic of the priming event required for activation of COX oxidizing activity. Heme iron 
oxidation states are indicated by roman numerals (Fe
III
 and Fe
IV
). PP=protophorphyrin π-cation radical. AA = 
Arachidonic Acid. AA* = Arachidonyl radical. Tyr= Tyrosine 385. Tyr*= Tyrosine radical. AH= reducing substrate. 
A*= oxidised co-substrate. PGG2 = hydroperoxyendoperoxide (prostaglandin G2). PGG2*= with a peroxyl radical 
on carbon 15. ROOH= hydroperoxide substrate. ROH=alcohol product. HPETE= hydroperoxide of fatty acids. 1) 
A lipid hydroperoxide dependent electron oxidation transforms the resting Fe
III
 heme enzyme in the POX site, 
into a Fe
IV
OPP heme *
+ 
radical. 2) Two electrons are transferred via intramolecular electron transfer from the 
Fe
IV
OPP heme *
+ 
radical to the Tyrosine 385 (Tyr-385) in the COX active site, creating a tyrosine radical (Tyr*). 
3) Following AA substrate binding into the COX active site, the Tyr* extracts a hydrogen atom from the 
arachidonyl radical (AA*) and initiates the COX reaction. 4) The AA* is oxidised with 2 O2 forming the 
hydroperoxyendoperoxide PGG2*. 5) The PGG2* transfers the radical back to Tyr. 6) PGG2 is then reduced (-2 
electrons) to PGH2 by the POX site.  This reduction yields the oxidised heme radical (Fe
IV
OPP heme *
+ 
radical) 
which starts the cycle over again creating the Tyr* required for the COX catalytic activity. Figure modified from 
(Aronoff et al., 2006). 
 
Even when the COX site is inhibited (non-covalently by NSAIDs and covalently by aspirin), 
the POX site can still continue to operate to form various free radicals species from 
endogenous peroxide substrates (Gupta et al., 2004). There are currently no available 
selective inhibitors of the POX site. However, the analgesic and anti-pyretic properties of 
paracetamol (acetaminophen) have been suggested to be linked to interference with the 
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POX site, thereby affecting prostaglandin synthesis by preventing the essential priming 
event required for COX activity (Figure 1.2) (Boutaud et al., 2002; Lucas et al., 2005). 
Paracetamol differs from NSAIDs in the way that it exhibits no or little anti-inflammatory 
effects and has limited effects on platelets at anti-pyretic doses in humans (Boutaud et al., 
2002). This cellular specificity may be explained by differences in cellular environments in 
regards to endogenous concentrations of hydroperoxides, which may override the POX site 
interference by acetaminophen in platelets and at sites of inflammation (Boutaud et al., 
2002). The low hydroperoxide tone in nerves may explain the analgesic and anti-pyretic 
effects of acetaminophen in the central nervous system (Boutaud et al., 2002).  
 
As mentioned above, even though PGHS contains both the COX site and the POX site, it is 
colloquially known simply as COX, and will be referred to as COX throughout the thesis.  
 
Arachidonic acid liberation by PLA2  
Arachidonic acid can be cleaved from membrane phospholipids by various phospholipase 
enzymes, but PLA2 is the only enzyme that can catalyse the liberation of arachidonic acid (by 
hydrolysis of membrane glucerophospholipids) in one single step and is considered the 
primary phospholipase enzyme involved in prostanoid synthesis. There are many different 
forms of PLA2 including calcium regulated cytosolic PLA2 (cPLA2), secretory PLA2 (sPLA2) and 
calcium independent PLA2 (iPLA2) (Murakami et al., 2002). However, calcium dependent 
activation of cPLA2 and sPLA2 seems to be the most common route for arachidonic acid 
release during prostanoid synthesis, whilst the calcium independent iPLA2 seems to be 
mainly involved in phospholipid remodeling rather than in signaling (Murakami et al., 1999). 
In contrast to cPLA2 which can only contribute to prostanoid synthesis when COX is co-
expressed within a particular cell, sPLA2 has been reported to be excreted extracellularly 
and bind to the cell surface of neighboring COX expressing cells. In this way, a remote 
stimulus can induce transcellular PLA2 activity leading to prostanoid synthesis in a separate 
cell to the initial stimulus and thereby overall prostanoid production can be amplified 
(Murakami et al., 1999). Activation of the calcium dependent cPLA2 and sPLA2 along with the 
COX enzymatic conversion of arachidonic acid to PGH2 are considered the rate limiting steps 
of prostaglandin synthesis (Cirino, 1998). In inflammatory conditions when prostanoid 
production is dramatically increased, there seem to be a two component system, where two 
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stimuli are required (activation of PLA2 and induction of COX), to synergistically render more 
substrate available (arachidonic acid via PLA2 activity) for COX driven enzymatic conversion 
into PGH2 (Hamilton et al., 1999; Saunders et al., 1999). Basal PG production is generally low 
but increases immediately following an inflammatory response, before the recruitment of 
leukocytes and infiltration of immune cells into the affected tissue (Ricciotti et al., 2011). 
Both COX (induction) and PLA2 activity during inflammation is inhibited by the anti-
inflammatory drugs corticosteroids. Indeed the therapeutic benefits of corticosteroids (such 
as prednisone in rheumatoid arthritis) are thought to be in part due to inhibition of PG 
production (Flower et al., 1979). 
 
Tissue specific production of prostanoids  
The profile of PGs produced within a particular tissue or cell type will vary depending on the 
distribution of PG isomerases and synthase enzymes, substrate availability (arachidonic acid 
release via PLA2 activity) as well as the oxidative state (hydroperoxide concentration) of the 
cell (Mitchell et al., 1999; Ueno et al., 2001). Kinetic parameters of the various PG synthases 
enzymes may also influence the ratio of prostanoids formed, in terms of substrate 
sensitivity and saturation (Ueno et al., 2001). Endothelial cells are highly enriched with 
prostacyclin synthase and prostacyclin is therefore the major COX product of vascular 
endothelium (Kawka et al., 2007; Liou et al., 2000; Mitchell et al., 2008; Moncada et al., 
1977). On the other hand, thromboxane is mainly produced by platelets due to the high 
expression of thromboxane synthase (Hamberg et al., 1975). PGE2 is formed by PGE 
synthases (PGES). It was previously held that PGE2 could be formed non-enzymatically 
during times of COX induction and increased substrate (PGH2) supply; which could saturate 
the other isomerases and synthases and result in proportionally higher PGE2 production as 
seen inflammation (Mitchell et al., 1999). However, high levels of PGE2 at the site of 
inflammation has more recently been explained by the action of an inducible microsomal 
PGES-1 (mPGES-1), which is upregulated by pro-inflammatory cytokines, and could 
therefore drive part of the increased PGE2 formation (Jakobsson et al., 1999). This is further 
supported by reports from mice lacking functional mPGES-1 activity, which have impaired 
pain and inflammatory responses compared to normal mice and mPGES-1 is therefore a 
potential new drug target in the NSAID area (Trebino et al., 2003).  
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There are also reports of prostacyclin synthase being inducible for instance following cyclic 
mechanical stretch in the myometrium leading to increased prostacyclin levels during 
pregnancy and labor (Korita et al., 2002), or by cytokines and tumor promoters (Smyth et 
al., 2009), but it has been highlighted that the endogenous regulation of prostacyclin 
synthase requires further investigation (Wu et al., 2005). For example, prostacyclin synthase 
has been shown to be a constitutively expressed enzyme in human endothelial cells and 
substrate availability (PGH2), appears to be the rate limiting step of prostacyclin synthase 
(Spisni et al., 1995).   
 
Biological effects of prostanoids- role of prostanoid receptors  
In contrast to circulating systemic hormones (such as cortisone), prostanoids are autocrine 
or paracrine mediators that are released from a wide range of tissues in the body to 
influence signaling in the immediate environment of their release (Dubois et al., 1998). The 
biological effects of prostanoids will depend on the distribution of prostanoid receptors (7 
trans-membrane G-protein coupled receptors, GPCRs) and/or peroxisome proliferator 
activated receptors (PPARs) on local target tissues as well as the half-life of the prostanoids 
before they are broken down or metabolised (Dubois et al., 1998). There are five major 
subdivisions of prostanoid receptors that have been defined pharmacologically and are 
named based on the first letter of their primary ligands (prostaglandin D2: DP receptors, 
prostaglandin E2: EP receptors, prostaglandin F2α: FP receptors, Prostacyclin: IP receptors, 
thromboxane: TP receptors). Although, all prostanoids can activate different prostanoid 
receptors to various degree, their primary ligand show the highest affinity (Breyer et al., 
2001). The main signal transduction pathways and physiological relevance associated with 
the activation of these receptors are briefly summarised in Table 1.3, but mainly involves: 
contraction or relaxation of vascular smooth muscle, vascular homeostasis through platelet 
activation and inhibition, sensitizing sensory nerves to noxious stimuli, modulating neuronal 
activity including fever and sleep induction, transport of ions and water in the kidneys, 
secretion and motility in the gastro intestinal tract and cytoprotection of the gastric mucosa 
and regulating cell differentiation and apoptosis (Narumiya et al., 1999).      
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Table 1.3 Prostanoid receptor signal transduction  
Prostanoid Receptor(s) Signal Transduction Main Activity 
 
 
 
 
 
 
 
 
PGE2 
 
EP1 [Ca
2+]↑  
(Calcium channel dependent influx of 
extracellular Ca
2+
) (Watabe et al., 1993) 
Bronchoconstriction  
(modulates adrenergic 
receptor responses) 
(McGraw et al., 2006)               
Pain signalling                              
(sensitisation of TRPV1)                            
(Moriyama et al., 2005) 
EP2 Coupled to Gs 
Activates adenylate cyclase →*cAMP] ↑        
(Narumiya et al., 1999) 
Mast cell deactivation             
(Kay et al., 2006)  
Bronchodilation                 
(Maher et al., 2010)                                        
Relax smooth muscle      
Vasodilatation                     
(Breyer et al., 2001)                                                 
EP3 Coupled to Gi 
Inhibits adenylate cyclase →[cAMP] ↓ 
(Breyer et al., 2001) 
Constricts smooth muscle   
Vasoconstriction                   
(Breyer et al., 2001)              
Bronchoconstriction+Cough
(Maher et al., 2009)                 
Fever                                   
(Ushikubi et al., 1998) 
Table 1.3 Prostanoid receptor signal transduction. 
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Table 1.3 Prostanoid receptor signal transduction (continued) 
Prostanoid Receptors Signal Transduction Main Activity 
PGE2 EP4 Coupled to Gs 
Activates adenylate cyclase →*cAMP+ ↑ 
(Narumiya et al., 1999) 
Relax smooth muscle      
Vasodilatation                          
(Breyer et al., 2001)               
Closure of ductus arteriosus 
(Nguyen et al., 1997)             
Bronchodilation                 
(Buckley et al., 2011)                
Pain signalling                        
(Clark et al., 2008)                                
PGF2α FPA                    
FPB 
Coupled to Gq                                                          
Activates Phospholipase C [IP3] 
→*Ca
2+
+↑(Narumiya et al., 1999) 
Parturition+                         
Uterine contraction                        
(Sugimoto et al., 1997) 
Intraocular pressure                 
(Lee et al., 1988) 
PGD2 DP1 
 
DP2/ 
CRTH2 
Coupled to Gs 
Activates adenylate cyclase →*cAMP+ ↑ 
(Narumiya et al., 1999) 
Sleep                                   
(Hayaishi, 1991)                      
Mast cells- allergy                                                   
(Narumiya et al., 1999)                       
Coupled to Gi                                                                 
Inhibits adenylate cyclase →*cAMP+ ↓ 
(Hirai et al., 2001) 
TH2/eotaxin/basophil 
chemotaxis                               
(Hirai et al., 2001) 
Table 1.3 Prostanoid receptor signal transduction. 
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Table 1.3 Prostanoid receptor signal transduction (continued) 
PGI2 
Prostacyclin 
 
 
 
IP 
Coupled to Gs 
Activates adenylate cyclase →*cAMP+ ↑ 
Coupled to Gq 
Activates Phospholipase C → *Ca
2+
+↑                     
(Narumiya et al., 1999) 
Vasodilatation                
(Moncada et al., 1976) 
Platelet Inhibition  
(Moncada et al., 1976)               
Oedema                      
(Murata et al., 1997)                 
Pain signalling                                          
(Murata et al., 1997)  
PPARβ/δ Heterodimerize with retinoid X receptor 
to act as a regulatory transcription factor 
on target genes that contain peroxisome 
proliferator-responsive elements (PPREs). 
→ Gene induction/transcription 
Platelet inhibition                  
(Ali et al., 2006a)                         
Implantation in uterus               
(Lim et al., 2000) 
TXA2 
Thromboxane 
TPα Couples to Gq →                            
Phospholipase C activation                                                                         
Gs →Activates adenylate 
cyclase→*cAMP+↑ 
Platelet activation      
(Hamberg et al., 1975)          
Vasoconstriction                
Smooth muscle cell 
proliferation                  
(Mitchell et al., 2006b) TPβ Couples to Gq →                        
Phospholipase C activation                                                                      
Gs →Inhibits adenylate cyclase→*cAMP+↓  
Table 1.3 Prostanoid receptor signal transduction. 
For the purpose of this thesis I will focus on the two prostanoids and their corresponding 
receptors that are most relevant for cardiovascular physiology; prostacyclin acting on IP/ 
PPARβ/δ receptors (Ali et al., 2006a; Boie et al., 1994) and thromboxane acting on TP 
receptors (Hirata et al., 1996).   
 
Prostacyclin and IP receptors  
Prostacyclin was discovered in 1976 by Salvador Moncada, John Vane and co-workers, when 
they demonstrated that an unstable COX derived product (PGX), generated from vascular 
tissue was a potent inhibitor of platelet aggregation (Moncada et al., 1976). Moncada and 
colleagues also showed that PGX (prostacyclin) generated from the arterial vessel wall, 
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relaxed the smooth muscle of some isolated blood vessels which suggested it could play a 
part in regulating vascular tone and the integrity of vascular endothelium to resist platelet 
adhesion (Moncada et al., 1976). It is now well established that prostacyclin is the main 
arachidonic acid product from all vascular tissue (Moncada et al., 1976; Vane et al., 1995). It 
has been demonstrated that the highest level of prostacyclin production occurs in the 
endothelium of the vessel wall and then the production progressively decreases further in 
the vessel towards the adventitia (Moncada et al., 1977).  
 
Prostacyclin has several cardioprotective properties including vasodilatation, inhibition of 
platelet adhesion and aggregation, reduction of cholesterol uptake and prevention smooth 
muscle remodeling and thereby plays an important part in vascular hemostasis (Mitchell et 
al., 2006b). As mentioned above for other COX products, prostacyclin generation can be 
stimulated by any stimuli that leads to an increase in intracellular calcium in the endothelial 
cells; such as thrombin, bradykinin, serotonin, platelet derived growth factor, contact with 
activated leukocytes, interleukin 1 (IL-1) or mechanical stretching of the vessel due to 
pulsitile pressure from blood flow exerted of the arterial wall (Vane et al., 1990). Activated 
platelets may also affect endothelial prostacyclin production by transcellular redirection of 
platelet PG endoperoxide (PGH2), which can then be utilised by prostacyclin synthase in 
nearby endothelium and result in a rapid increase in prostacyclin production (Vane et al., 
2003). This has been demonstrated in cultured human endothelial cells (Marcus et al., 1980) 
and in healthy volunteers (Nowak et al., 1989).  
 
Following its synthesis and release, prostacyclin has a short half-life of a few minutes before 
it is non-enzymatically hydrolysed to a much less active but more stable compound; 6-keto 
prostaglandin F1α (6-ketoPGF1α) (Vane et al., 1990). This breakdown product is in turn 
hepatically metabolised (within 30 minutes) to 2,3-dinor-6-ketoprostaglandin F1α and 6,15 
diketo 2,3-dinor-prostaglandin F1α, where 2,3-dinor-6-ketoprostaglandin F1α (PGI-M) is the 
major urinary metabolite of prostacyclin in man (Rosenkranz et al., 1980). As mentioned 
earlier about other prostanoids, due to its rapid breakdown, prostacyclin is typically 
considered to be a local hormone rather than a circulating one. Plasma prostacyclin levels 
(as the breakdown product 6-ketoPGF1α) measures to about 3 ng/L, which is generally 
considered to be too low to mediate a systemic effect but may represent an overflow of 
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prostacyclin that has already acted locally (Vane et al., 1990) and when prostacyclin is 
infused in vivo, the effects wear off within 30 minutes (Vane et al., 1995). The unstable 
nature of prostacyclin makes it complicated to use experimentally or therapeutically. 
Therefore, synthetic prostacyclin mimetics (such as iloprost, cicaprost or treprostinil 
sodium) are commonly used when investigating prostacyclin biology. Prostacyclin mimetics 
have also been valuable clinically for reducing pulmonary resistance in people suffering 
from pulmonary hypertension (McLaughlin et al., 1998) and for peripheral arterial disease 
(Mohler et al., 2000). 
 
As defined in table 1.3 the two best studied prostacyclin receptor pathways are (i) cell 
surface IP receptors and (ii) cytosolic PPARβ receptors. IP receptors are expressed 
throughout the vascular tree but an early study reported expression in the kidney 
(interlobular arteries and the glomerular arterioles), liver, lung and neurons (Boie et al., 
1994). A subsequent study showed expression of IP mRNA in smooth muscle from many 
arteries including the aorta, the coronary arteries of the heart, the pulmonary artery and in 
the cerebral arteries, but no expression was found in veins (Oida et al., 1995).  
 
The vasodilatory and anti-aggregatory effects of prostacyclin have been attributed to IP 
receptor coupling to Gs type G protein (Table 1.3) activating adenylate cyclase, which leads 
to increased levels of cyclic adenosine monophosphate (cAMP) (Hata et al., 2004). During 
prostacyclin/ IP receptor induced vasodilatation, elevated levels in cAMP and protein kinase 
A in vascular smooth muscle leads to the phosphorylation of myosin light chain kinase and 
the subsequent dephosphorylation of myosin light chains which antagonizes contractile 
stimuli and results in smooth muscle relaxation. Other effects of prostacyclin involves Gq 
and Gi coupling (Hata et al., 2004). A similar cAMP and protein kinase A dependent pathway 
is also responsible for the anti-aggregatory effects of prostacyclin where deactivated myosin 
light chain kinase reduces the myosin phosphorylation which decreases platelet aggregation 
(Jin et al., 2005). Another route to how IP may limit platelet activation mediated specifically 
by thromboxane is potentially through formation of an IP/TPα heterodimers, which are 
constitutively formed when the two receptors were expressed in vitro which seemed to 
have a similar cAMP elevating effect as prostacyclin/IP interaction (Wilson et al., 2004).  
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The IP receptor is believed to undergo agonist induced desensitisation as well as agonist 
induced internalisation after prolonged agonist exposure leading to tachyphylaxis (Hata et 
al., 2004). Whilst most of our information on prostacyclin sensing is related to IP receptors 
and their signaling pathway, PPARβ receptors are increasingly recognised as intracellular 
prostacyclin receptors (Belvisi et al., 2009). PPARβ receptors also mediate, in part, the 
effects of prostacyclin mimetics on fibroblast proliferation (Ali et al., 2006b) and platelet 
aggregation (Ali et al., 2006a; Ali et al., 2009b). Whilst the physiological and 
pathophysiological relevance of new prostacyclin signaling pathways, such as PPARβ are 
debated, it is widely accepted that the majority of acute effects of prostacyclin are mediated 
by IP receptors and cAMP signaling pathways (Vane et al., 1995). 
 
General phenotype of IP knockout mice 
When homozygote IP homozygote knockout (-/-) (IP-/-) mice were derived from a C57BL/6 
background, they were reported to be viable, reproductive and normotensive (Murata et 
al., 1997). This is contrary to reports from endothelial nitric oxide (NO) knockout (eNOS-/-) 
mice which were hypertensive, indicating a greater role for NO than prostacyclin in the 
maintenance of vascular tone (Huang et al., 1995). Loss of functional IP receptor responses 
was verified based on the lack of responses to different prostacyclin mimetics on platelet 
aggregation, vasodilatation, blood pressure and bleeding time (Murata et al., 1997). To 
confirm that it was an IP receptor specific knockout, PGE2 was injected into the IP 
+/+ wild 
type (WT) and the IP-/- mice, which caused a transient hypotension in both types of mice 
(Murata et al., 1997). It was also established that vessels from IP-/- mice released 
comparable levels of prostacyclin (to WT mice). Furthermore, the IP-/- mice had normal 
heart rate, blood pressure and bleeding time (compared to WT mice). However, he IP-/- mice 
were reported to have reduced oedema and nociceptive responses that were similar to 
NSAID treated animals in models of inflammation, indicating a role for prostacyclin in 
inflammatory swelling and pain (Murata et al., 1997). The most dramatic effects were seen 
in a iron (III) chloride (FeCl3) model of thrombosis, where about two thirds of the IP
-/- mice 
had obstructive thrombi and 30% of mice died within 1 day (during prolonged exposure to 
FeCl3). Death was due to bilateral occlusion of the carotid arteries and/or embolic stroke 
(compared to none of the WT mice) (Murata et al., 1997). It is important to note however, 
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that although the IP-/- mice were clearly more responsive to thrombotic stimuli, there was 
no spontaneous thrombus formation.  
 
General phenotype of PPARβ knockout mice 
PPARβ null mice (PPARβ-/-) were reported to be were smaller than control mice and to have 
an altered myelination of the corpus callosum in the brain, lipid metabolism and epidermal 
cell proliferation (Peters et al., 2000). Furthermore, heterozygote PPARβ+/- mice had 
impaired wound healing (Michalik et al., 2001).     
 
Thromboxane acting on TP receptors 
Thromboxane was discovered one year earlier than prostacyclin (in 1975) by Samuelsson 
and colleagues. They demonstrated that human platelets stimulated with arachidonic acid, 
released an unstable intermediate (which they named thromboxane A2), with a half-life of 
30 seconds, before it was broken down to the more stable but less active hydration product 
thromboxane B2 (Hamberg et al., 1975). They showed that thromboxane A2 induced 
serotonin release from platelets as well as causing platelet aggregation (Hamberg et al., 
1975). Since then, it has been well established that thromboxane is predominantly derived 
from platelets and acts via TP receptors (Hirata et al., 1996) (Table 1.3), but can also be 
produced by other cell types such as endothelial cells (Félétou et al., 2010). Following 
intravenous administration of thromboxane B2, the two major urinary metabolites (TX-M) 
are 11-dihydro-thromboxane B2 and 2,3-dinor-thromboxane B2 (Patrignani et al., 1989) 
where 2,3-dinor-thromboxane B2 appears to be the major urinary thromboxane metabolite 
in man (Roberts et al., 1981).  
 
In addition to inducing platelet shape change, aggregation, secretion and adhesion, 
thromboxane contracts vascular and bronchial smooth muscle, increases smooth muscle 
remodeling, facilitates cholesterol uptake, and promotes leukocyte-endothelial interactions 
through acceleration of endothelial surface expression of adhesion molecules (Nakahata, 
2008). There are two splice variants of TP receptors; TPα (first identified in the placenta) 
and TPβ (first cloned from the endothelium) (Nakahata, 2008) (Table 1.3). Platelets express 
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both TPα and TPβ. Defective TP receptor signaling (due to a single nucleotide 
polymorphism) has been linked to bleeding disorders (Hirata et al., 1996).  
 
Both TP receptors couple to Gq which leads to phospholipase C activation and subsequent 
inositol triphosphate/diacylglycerol (IP3/DAG) generation and increase in intracellular 
calcium which facilitates platelet aggregation (Table 1.3) (Smyth et al., 2009). The pathway 
responsible for the change in platelet shape appears to be mediated via G12/G13 Rho/Rho 
kinase dependent regulation of myosin light chain phosphorylation (Smyth et al., 2009). 
Following activation with the TP agonist U46619, both TP receptors are rapidly 
phosphorylated and desensitised (Habib et al., 1997). Furthermore, TPα has been reported 
to be desensitised in response to prostacyclin and therefore TPα has been postulated to be 
the most relevant TP receptor for the prostacyclin and thromboxane mediated vascular 
hemostasis (Walsh et al., 2000). 
 
General phenotype of TP-/- mice 
TP-/- mice have been reported to have a mild bleeding disorder (with prolonged bleeding 
time and altered platelet responses to collagen and arachidonic acid stimuli) as well as 
altered vascular responses to thromboxane and arachidonic acid (Thomas et al., 1998). 
These findings confirmed that most of the known functions of thromboxane are mediated 
by a single TP gene locus (Thomas et al., 1998).   
 
As outlined above, the effects of thromboxane directly opposes those of prostacyclin and a 
balance between the two has long been suggested to form a central role for cardiovascular 
hemostasis and regulation of platelet interaction with the vessel wall (Vane et al., 1990). I 
will discuss more about the ‘thromboxane/prostacyclin balance’ in later sections of this 
chapter. First I will give some background information about two isoforms of COX and later 
on how these two COX isoforms drive thromboxane and prostacyclin production within the 
cardiovascular system.  
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Two isoforms of COX 
In the 1990’s two isoforms of COX were identified from separate genes; COX-1 and COX-2. 
COX-1 was generally found constitutively expressed in several tissues, whereas COX-2, also 
at the time referred to as mitogen inducible COX (Lee et al., 1992; Xie et al., 1991) from the 
TIS10 gene (Kujubu et al., 1991; Lee et al., 1992; Xie et al., 1991) was not generally present 
constitutively but expressed after stimulation of cells in vitro or at sites of inflammation in 
vivo. This led to the well-known hypothesis that COX-1 is the ‘housekeeping’ isoform that is 
constitutively expressed and responsible for the basal production of prostanoids (Figure 
1.4). Examples of housekeeping prostanoid production included COX-1 driven protective 
PGE2/prostacyclin production in the stomach/kidneys, prostacyclin release from the 
endothelium and thromboxane production in platelets. COX-2 on the other hand was 
identified as the inducible isoform primarily expressed at inflammatory sites and 
responsible for inflammatory levels of PGE2 (and prostacyclin) (Figure 1.4) (Mitchell et al., 
1993). At sites of inflammation, COX-2 products (e.g. PGE2) facilitate edema and sensitize 
sensory neurons to pain stimuli. COX-2 can also be upregulated in the spinal cord where it 
may contribute to prolonged central sensitization (Smyth et al., 2009). Since we know that 
NSAIDs inhibit both isoforms of COX, inhibition of COX-1 was linked to the detrimental 
gastrointestinal side effects of NSAIDs whereas inhibition of COX-2 was linked to the 
therapeutic (analgesic, anti-pyretic and anti-inflammatory) effects of NSAIDs (Mitchell et al., 
1993) (Figure 1.4). However, there are also situations where COX-2 can be anti-
inflammatory. For instance, in situations where the basal protective activity of COX-1 has 
been diminished or lost, (i.e. following vascular injury or inflammation in large blood 
vessels), COX-2 has been reported to be upregulated and have a protective anti-
inflammatory role in adhesion receptor expression, cytokine release and smooth muscle 
proliferation (Mitchell et al., 1998).    
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Figure 1.4 Hypothesis of the 1990s: COX-1 is the constitutive ‘housekeeping’ isoform and 
COX-2 is the therapeutic target of NSAIDs 
 
Figure 1.4 Hypothesis of the 1990s: COX-1 is the constitutive ‘housekeeping’ isoform and COX-2 is the 
therapeutic target of NSAIDs. COX-1 is highly expressed within the stomach (important for cytoprotection of 
the gastric mucosa), the kidneys (important for sodium balance and renal blood flow), within the endothelium 
(important for creating an anti-thrombotic surface) and within platelets (for platelet aggregation). COX-2 is 
mainly found induced at inflammatory sites within infiltrating macrophages where it is responsible for the 
production of pro-inflammatory (and sometimes anti-inflammatory) prostaglandins such as PGE2 leading to 
swelling (oedema) and pain. COX-2 can also be induced in endothelial cells following vascular injury or by 
inflammatory stimuli where it seems to have a protective anti-inflammatory role (Mitchell et al., 1998).   
 
NSAIDs and side effects; relevance of COX-1 and COX-2 
As mentioned earlier, NSAIDs have a number of well recognised side effects mainly affecting 
the 1) gastrointestinal tract, 2) kidney, 3) cardiovascular system. The area of NSAIDs and 
cardiovascular side effects will be discussed in detail later in the introduction. In this section 
I will briefly introduce the basics of the gastrointestinal and renal side effects of NSAIDs. 
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Gastrointestinal side effects of NSAIDs 
The endoscopic evidence for NSAID induced gastric mucosal damage is well documented 
(Wolfe et al., 1999). However, due to broad definitions of NSAID induced gastrointestinal 
side effects, variations in dosage and duration, it is difficult to accurately estimate the exact 
prevalence of these adverse gastrointestinal effects, but it appears that approximately 50% 
of NSAID users develop gastric erosions (small and superficial lesions confined to the 
mucosa) and that a small percentage of these patients go on to develop gastric ulcers (larger 
and deeper lesions) which could result in fatal hemorrhage (Wolfe et al., 1999).  
 
Dyspepsia is a common symptom from chronic NSAID use and is often a reason behind 
discontinuation of a certain NSAID treatment regime. Dyspeptic symptoms are not reliable 
warning signs since severe gastrointestinal complications are often asymptomatic and this 
leads to many thousands of hospitalisations and even some deaths each year (Wolfe et al., 
1999).  
 
Risk factors for susceptibility to NSAID induced gastrointestinal side effects include 
increasing dose and duration of the NSAID use, advanced age, concomitant use of several 
NSAIDs (i.e. low dose aspirin with another NSAID) corticosteroids or anti-coagulants and a 
history of ulcers or gastrointestinal bleeds (Wolfe et al., 1999). Prostaglandins, nitric oxide, 
hydrogen sulfide and neuropeptides are examples of autacoids mediating resistance to 
mucosal injury, and the term cytoprotection is often used to describe the ability of 
prostaglandins to reduce the injury from necrotizing agents (Wallace, 2008). Following 
exposure to gastrointestinal irritants, there is an acute inflammatory response which include 
an increase in blood flow and recruitment of leukocytes to minimize injury and prevent 
entry of foreign substances into the systemic circulation (Wallace, 2008).  
 
NSAIDs have been reported to trigger part of the inflammatory response, including 
upregulation of intracellular adhesion molecule 1 (ICAM-1) leading to recruitment of 
circulating neutrophils to adhere to the gastric vascular endothelium which can cause 
mucosal injury due to the release of free radicals and proteases (Wallace et al., 1990). 
NSAID induced gastrointestinal side effects can be divided into topical and systemic. Topical 
side effects include direct cytotoxic effects of the ingestion of NSAIDs on the gastrointestinal 
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epithelium. Systemic side effects are related to decreased synthesis of mucosal 
prostaglandins resulting in reduced mucosal blood flow, bicarbonate and mucus secretion, 
impaired platelet aggregation, reduced angiogenesis and increased leukocyte adherence 
(Wallace, 2008). At the therapeutic doses required to reduce inflammation and pain, NSAIDs 
inhibit both isoforms of COX and it is held that the gastrointestinal side effects of NSAIDs are 
caused by simultaneous inhibition of both COX isoforms (Wallace et al., 2000). Thus, as 
discussed in later sections, COX-2 selective NSAIDs were developed to spare the 
gastrointestinal tract with some degree of success.  
 
Renal side effects of NSAIDs 
Reported renal side effects from NSAID use include hypertension, hyperkalemia, oedema, 
and nephrotoxicity, some of which are often associated with impaired sodium excretion and 
decreased glomerular filtration rate (Murray et al., 1993). Considering the widespread use 
of NSAIDs, these side effects are relatively infrequent in people with normal and healthy 
kidneys, but remain a clinical concern in patients with a compromised renal system where 
inhibition of vasodilatory prostanoids (primarily prostacyclin and PGE2) can lead to 
decreased renal perfusion and glomerular blood flow and even precipitate renal failure in 
susceptible individuals (Weir, 2002). Importantly, the kidney is an organ where COX-2 is 
recognised to be constitutively expressed and appears to be essential for renal homeostasis 
including salt retention, volume and blood pressure regulation (Yang et al., 2000).  
 
Expression patterns of COX isoforms have been reported to differ between species, but 
immunohistochemical and in situ mRNA analysis have shown that in normal human kidneys 
COX-1 is expressed in kidney endothelial cells, smooth muscle cells, interstitial cells and 
collecting duct cells of both pre and post glomerular vessels, whereas COX-2 is localised to 
the intraglomerular podocytes and endothelial and smooth muscle cells of renal arteries 
and veins (Kömhoff et al., 1997). In general terms, COX-1 derived prostanoids appear to be 
important for hemodynamic control and glomerular filtration rate whereas COX-2 derived 
prostanoids are important for regulating salt and water excretion, but both these functions 
also overlap (Weir, 2002).  
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The role of renal COX-1 and COX-2 was also demonstrated in a study with elderly patients 
treated with NSAIDs, where NSAID induced acute sodium retention was concluded to be 
mediated by COX-2 inhibition, whereas the reduction in glomerular filtration rate was due 
to inhibition of COX-1 (Catella-Lawson et al., 1999). Reduced secretion of sodium may lead 
to oedema, exacerbations of heart failure or elevated blood pressure. Critically NSAIDs 
induce a small (1-5 mmHg) rise in systemic blood pressure in normotensive as well as 
hypertensive patients; however, the relevance of NSAID induced blood pressure elevation 
will be covered in later sections.  
 
Pharmaceutical quest for COX-2 selective or COX-1 sparing NSAIDs 
The identification of COX-2 as the therapeutic target of NSAIDs, started a pharmacological 
quest to find COX-2 selective, or as Sir John Vane and colleagues thought was a more 
accurate and descriptive term: COX-1 sparing NSAIDs (Vane et al., 2000). The overall 
rationale with the development of these drugs was to ‘spare’ the physiologically important 
‘house-keeping’ isoform: COX-1 and thereby hopefully avoid the gastrointestinal and renal 
side effects of traditional NSAIDs. However, the aim was to maintain effective inhibition of 
the ‘real’ therapeutic target of NSAIDs: COX-2, in order to keep the therapeutic utility of 
these drugs, yet improve their overall safety profile. In order to succeed with the rational 
drug design, the two isoforms had to be thoroughly examined for any subtle differences 
that could be exploited in the pharmacological hunt for COX-2 selectivity.   
 
Similarities and differences of COX-1 versus COX-2 
COX-1 and COX-2 share 60% sequence homology but are encoded by different genes; COX-1 
(22 kilo bases located on chromosome 9) and COX-2 (8 kilo bases on chromosome 1) (Smith 
et al., 2000). Both isoforms are homodimeric, glycosylated, integral membrane bound 
proteins (Luong et al., 1996), located in the lumen of the endoplasmic reticulum and in the 
nuclear envelope (Luong et al., 1996; Morita et al., 1995). Both isoforms are comprised of 
three main domains; the helical membrane binding domain, the catalytic domain (largest 
domain containing both the COX and the POX active sites) and the terminal epidermal 
growth factor (EGF) domain (Luong et al., 1996).  
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Enzyme kinetics COX-1 versus COX-2 
The gross enzymatic kinetics are very similar for both isoforms, however, there are 
differences during low substrate conditions, which may give COX-2 an advantage over COX-
1 when competing for newly released substrate (arachidonic acid) (Murakami et al., 1999; 
Smith et al., 2000). Another subtle difference in kinetics is that COX-2 has been reported to 
have a lower threshold than COX-1 for hydroperoxide activation (required for the priming 
event from the POX site; see Figure 1.2) and can therefore oxygenate PGG2 even during low 
peroxide conditions (Murakami et al., 1999). As briefly mentioned earlier, low peroxide 
conditions are typical of endothelial cells and nerves, which are enriched with anti-oxidant 
pathways, whilst high peroxide conditions are typically found in platelets and inflammatory 
sites (Boutaud et al., 2002). It has also been suggested that COX-1 and COX-2 can form 
heterodimers (Yu et al., 2006) where COX-2 may provide the peroxide tone required for 
COX-1 activity in endothelial cells (Bolego et al., 2009).  
 
3D structures of COX-1 versus COX-2 
Elucidation of the three dimensional structures of COX-1 and COX-2 revealed that Serine 
530 (Ser 530), which has been identified as the acetylating site of aspirin and crucial for COX 
enzymatic activity, is conserved within both isoforms (yellow dashed circle, Figure 1.5). In 
addition, Tyr-385, described in earlier sections (see Figure 1.2) as the key residue for the 
priming event by the POX site, is also preserved (Rouzer et al., 2008). However, importantly, 
the main exploitable difference between COX-1 and COX-2 is the amino acid residue 523 
which is found in the active site (Luong et al., 1996). This difference has consequences for 
the shape and size of the binding site for NSAIDs where the valine-523 gives COX-2 an 
additional hydrophobic side pocket within the substrate binding site (compared to COX-1 
isoleucine-523). Valine-523 also results in slightly wider central channel (wider then COX-1 
by approximately 17%), and this makes COX-2 more promiscuous in its substrate and NSAID 
selectivity (Figure 1.5).  All together, the volume of the total COX-2 binding site is 394Å 
versus the 316Å binding site of COX-1 (Kujubu et al., 1991). These structural differences 
between the COX-1 and COX-2 active sites were exploited in the development of COX-2 
selective inhibitors. 
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Figure 1.5 Ribbon diagrams showing similarities and differences between COX-1 and COX-2 
 
Figure 1.5 Ribbon diagrams showing similarities and differences between COX-1 and COX-2. 3D structure of 
COX-1 and COX-2 proteins. Yellow circle indicate isoleucine and valine at amino acid position 523, which is a 
main difference between the two isoforms, resulting in a larger side pocket in the active site of the COX-2 
enzyme. Dashed yellow circle indicate the position of Serine 530 (Ser-530) which is the acetylating site of 
aspirin which is crucial for enzymatic activity within the active site of both COX-1 and COX-2. (Figure modified 
from (Rouzer et al., 2008).    
 
The launch of COX-2 selective (COX-1 sparing) NSAIDs  
The COX-2 selective (or COX-1 sparing) NSAIDs; celecoxib (Celebrex™, developed by 
Searle/Pfizer) was approved by the FDA in December 1998 and rofecoxib (Vioxx™, 
developed by Merck) and was approved in January 1999. These drugs became very popular 
since they were associated with fewer gastrointestinal side effects (by sparing COX-1) 
compared to traditional non-selective (COX-1 and COX-2 inhibiting) NSAIDs but they still 
maintained their therapeutic anti-inflammatory and analgesic utility (by inhibiting COX-2) 
(Bombardier et al., 2000; Silverstein et al., 2000). 
 
Celecoxib (Celebrex™) 
Celecoxib was licensed in the United Kingdom in 2000 for osteoarthritis and rheumatoid 
arthritis (Flower, 2003). The Celecoxib Long term Arthritis Study (CLASS) was a double blind, 
randomised trial that compared celecoxib (400mg x2/day) with ibuprofen (800mg x3/day) 
or diclofenac (75mg x2/day) in 8059 patients with osteoarthritis or rheumatoid arthritis in 
Chapter 1 General Introduction 
48 
 
regards to gastrointestinal side effects as well as other adverse effects (Silverstein et al., 
2000). Concomitant low-dose aspirin use was permitted in the study. This study concluded 
that after 6 months on daily dosing of celecoxib (even at doses 2-4 times the maximum 
therapeutic dosage), there were fewer gastric ulcers, perforations, bleeds and associated 
complications compared with the NSAID group (ibuprofen or diclofenac) used at standard 
therapeutic doses (Silverstein et al., 2000). In addition, celecoxib seemed to be associated 
with fewer adverse effects on the kidney compared to ibuprofen or diclofenac (Silverstein et 
al., 2000).   
 
Rofecoxib (Vioxx™) 
Vioxx was licensed in the United Kingdom for osteoarthritis in 1999 and rheumatoid arthritis 
in 2001 (Flower, 2003). In the randomised and double blinded VIGOR trial (Vioxx 
Gastrointestinal Outcomes Research Study), the efficacy and adverse side effect profile of 
high dose rofecoxib (Vioxx) (50mg/day) was compared with standard dose naproxen 
(1000mg/day) during long term treatment in 8076 patients with rheumatoid arthritis 
(Bombardier et al., 2000). Aspirin use was not permitted in the study; hence patients 
requiring low-dose aspirin for cardioprotection were excluded. It was shown that rofecoxib 
had a similar efficacy as naproxen in terms of therapeutic pain relief, but was associated 
with around half the gastrointestinal side effects compared with naproxen treatment 
(Bombardier et al., 2000). 
 
The launch of two COX-1 sparing COX-2 selective NSAIDs, celecoxib and rofecoxib, was 
therefore at first a pharmacological success story with convincing proof of concept data 
where both these drugs displayed an improved gastrointestinal side effect profile compared 
to traditional NSAIDs, confirming the triumph of the rational drug design. 
 
However, there were also concerns raised about the COX-2 selective inhibitors. Although 
selective inhibition of COX-2 spared the gastrointestinal tract from disruption of the 
mucosal defense (seen with conventional NSAIDs), they were instead shown to interfere 
with ulcer healing (Perini et al., 2004). Furthermore, even before the launch of COX-2 
selective inhibitors, there were also concerns regarding the cardiovascular safety of these 
drugs.        
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Cardiovascular concerns 
Concerns were raised early on in the COX-2 field after preclinical studies showed that COX-2 
could have a protective function during vascular inflammation (Bishop-Bailey et al., 1998; 
Bishop-Bailey et al., 1997; Mitchell et al., 1998). Furthermore, one of the ‘first to man’ 
papers showed that MK-966 (later launched as Vioxx), halved the urinary excretion of the 
prostacyclin metabolite PGI-M (2, 3-dinor-6-keto prostaglandin F2α) compared to placebo, in 
healthy older adults, after 2 weeks of treatment, without affecting the urinary thromboxane 
metabolite TX-M (11-dehydro TxB2) (Catella-Lawson et al., 1999).  
 
Similar results were obtained in a study with celecoxib (McAdam et al., 1999). This caused 
an upheaval of concern since it is a well-established idea that a balance between 
thromboxane and prostacyclin is required for vascular haemostasis, where reduced 
prostacyclin could tip the balance in favor of thromboxane and potentially lead to an 
increased thrombotic risk. With these two lines of concerns, the field was alerted to the 
possibility that COX-2 inhibitors might be associated with an increased cardiovascular risk.  
 
Cardiovascular signal in the VIGOR study 
This concern seemed, by some, to be realised when data from the VIGOR study showed an 
apparent increase in cardiovascular deaths associated with the rofecoxib arm compared to 
the naproxen arm of the now infamous study (Bombardier et al., 2000). It was estimated 
that 45 out of 4047 rofecoxib treated patients versus 20 out of 4039 naproxen treated 
patients had suffered a serious thrombotic cardiovascular adverse event (myocardial 
infarction, cardiac thrombus, unstable angina, resuscitated cardiac arrest, sudden or 
unexplained death and ischemic stroke or transient ischemic attacks) (Mukherjee et al., 
2001). The incidence of these thrombotic cardiovascular event rates (myocardial infarction, 
stroke and cardiac death) were relatively low (~1%) but still significantly different between 
the rofecoxib and the naproxen treated groups with myocardial infarction having the most 
striking event rate (FDA, 2001). There were 37 deaths (from all causes) in the VIGOR trial, 22 
rofecoxib treated patients and 15 naproxen treated patients, and 9 out of 22 cases in the 
rofecoxib treated group died from thrombosis/atherosclerosis related deaths versus 5 out 
of 15 in the naproxen treated group (FDA, 2001).  
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Overall, the relative risk in suffering a thrombotic cardiovascular event on rofecoxib 
treatment versus naproxen treatment was 2.8 (which was statistically significant) and this 
was considered to be a cautionary flag in terms of cardiovascular safety of COX-2 selective 
inhibitors (Mukherjee et al., 2001). However, it was hypothesised that this could be 
explained by either a pro-thrombotic effect of rofecoxib or an anti-thrombotic effect of 
naproxen (or both) (Mukherjee et al., 2001).  
 
Cardiovascular outcomes in the CLASS trial  
The CLASS trial however, did not demonstrate a significant difference in cardiovascular 
signal in the celecoxib arm compared to the ibuprofen or diclofenac arms of the study 
(Mukherjee et al., 2001; Silverstein et al., 2000).  
 
No cardiovascular signal in the TARGET trial 
The TARGET trial (Therapeutic Arthritis Research and Gastrointestinal Event Trial) was 
designed to test the gastrointestinal and cardiovascular safety of the COX-2 selective 
inhibitor lumiracoxib (Novartis) (at 400mg/day) compared with naproxen (500mg x2/day) 
and ibuprofen (800mg x3/day) in 18325 patients with osteoarthritis (Farkouh et al., 2004). 
Lumiracoxib differs structurally from the other coxibs and has a shorter half-life (2-6 hours) 
leading to less systemic drug exposure. Myocardial infarction (which was one of the primary 
endpoints), did not differ between the treatment groups (irrespective of aspirin use) 
(Farkouh et al., 2004).      
 
Arguments concerning the cardiovascular risk of COX-2 selective inhibitors 
 
1. CLASS and VIGOR trials had not been powered to detect cardiovascular events 
It was argued at the time that any cardiovascular risk associated with COX-2 selective drugs 
had not been conclusively investigated since the CLASS and the VIGOR studies were 
designed to identify gastrointestinal events and hence had not been ‘powered’ to detect 
cardiovascular events since these effects were unexpected and as a result, evaluation of 
cardiovascular endpoints had not been pre-specified (Bombardier et al., 2000; Mukherjee et 
al., 2001; Silverstein et al., 2000). Furthermore, due to ethical reasons implicated in clinical 
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trials involving patients with arthritis (where patients often depend on pain relief for daily 
functioning), neither of these studies had a placebo arm. 
 
2. Cases occurred in patients that should have been on aspirin for cardioprotection 
Even though aspirin use for cardiac reasons was an exclusion criterion for the VIGOR study, 
the study still included ‘aspirin-indicated’ patients (with a past medical history of stroke or 
myocardial infarction etc). It was therefore first argued that some of the cases in the 
rofecoxib treated group occurred in patients that should have been on aspirin for 
cardioprotection (hence had underlying cardiovascular disease) (FDA, 2001; Mukherjee et 
al., 2001). However, there were also events in the rofecoxib treated group that did not fall 
into this ‘aspirin-indicated’ subgroup and the number of ‘aspirin indicated patients’ were 
similar between the rofecoxib and the naproxen treatment groups (FDA, 2001; Mukherjee 
et al., 2001).  
 
3. Different dosing  
Other arguments included that the cardiovascular signal could be attributed to that supra-
clinical doses of COX-2 inhibitors (50mg/day rofecoxib and 400mg/day celecoxib) were 
compared to therapeutic doses of the comparative NSAIDs (Mukherjee et al., 2001).  
 
4. The ‘naproxen argument’ 
The ‘naproxen argument’ stated that the difference in myocardial infarction between the 
rofecoxib and the naproxen treated groups could be explained by anti-thrombotic effects of 
naproxen due to potent inhibition of COX-1 in platelets (Rahme et al., 2002; Van Hecken et 
al., 2000).  Ex-vivo whole blood assays from 76 healthy volunteers showed that rofecoxib, 
meloxicam, diclofenac and naproxen all inhibited COX-2 (endotoxin induced COX-2 
generated PGE2) compared to placebo, whereas the corresponding inhibition of COX-1 
(thromboxane generation in whole blood) was most potently inhibited by naproxen and 
least by the ‘COX-1 sparing’ inhibitor rofecoxib (similar to placebo) (Van Hecken et al., 
2000). These results were supported by a population based matched case control study 
comparing naproxen and other non-aspirin NSAIDs in protection against acute myocardial 
infarction, where naproxen had a protective effect compared to the other NSAIDs (Rahme 
et al., 2002). The incidence of myocardial infarction was similar in patients with 
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osteoarthritis when rofecoxib was directly compared to ibuprofen (Day et al., 2000) or to 
diclofenac (Cannon et al., 2000).   
 
5. Patients with rheumatoid arthritis have an underlying increased risk of 
cardiovascular disease 
Patients with rheumatoid arthritis have 1.5-3 fold increased risk of cardiovascular events 
compared to control subjects, where both traditional risk factors as well as disease severity 
are important predictors of future cardiovascular events (Solomon et al., 2010). However, 
there was no measure of cardiovascular risk markers (such as C-reactive protein), in the 
VIGOR study which makes it difficult to differentiate between patients groups. Even if there 
is an increased cardiovascular risk in this group of patients, this would have affected both 
the naproxen group and the rofecoxib group and therefore does not explain the difference 
in cardiovascular events between the two treatments (FDA, 2001). 
 
One of the arguments for why there was a cardiovascular signal with rofecoxib in the VIGOR 
trial and not with celecoxib in the CLASS trial was that the VIGOR trial was focused on 
patients with rheumatoid arthritis whereas the CLASS trial also included patients with 
osteoarthritis. This was considered important since it had been shown that the relative risk 
of a myocardial infarction is elevated (1.4) in patients with rheumatoid arthritis versus 
osteoarthritis or placebo (DeMaria, 2002; FitzGerald, 2003). It is however also important to 
consider that in the ‘real world’, a wide range of patients are taking these drugs many of 
whom may have a medical history or lifestyle associated elevated risk for cardiovascular 
disease.  
 
Each of these arguments was valid with the main issue being that, at that time, no placebo 
controlled study had been performed and no study at all had been designed specifically to 
evaluate the cardiovascular safety of COX-2 selective inhibitors (placebo or otherwise). Over 
the following 4-5 years, several randomised clinical trial and small scale observational 
studies were published which continued to indicate a cardiovascular signal with rofecoxib 
(Graham et al., 2005; Hippisley-Cox et al., 2005; Jüni et al., 2004).  
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The withdrawal of rofecoxib/Vioxx™ 
Finally, two trials, one with rofecoxib; APPROVe (Adenomatous Polyp Prevention On Vioxx) 
(Bresalier et al., 2005) and one with celecoxib: APC (Adenoma Prevention with Celecoxib) 
(Solomon et al., 2005) designed to show utility of COX-2 selective inhibitors in the 
prevention of familiar colon cancer, were performed with placebo arms. The APPROVe trial 
was a randomised, double blinded trial with 2586 patients followed over 3 years: 1287 
patients were randomly assigned 25mg/day rofecoxib (this is the maximal recommended 
long-term daily dose) and 1299 patients took an identical looking placebo pill once a day. 
Potential thrombotic adverse events were reviewed in a blinded fashion by an external 
committee (Bresalier et al., 2005). 46 out of 1287 patients in the rofecoxib treated group 
suffered a thrombotic adverse event versus 26 out of 1299 patients in the placebo group 
and the corresponding relative risk was 1.92 (Bresalier et al., 2005). Out of these thrombotic 
adverse events it was non-fatal heart attack (21 in the rofecoxib treated group versus 9 in 
the placebo group) or ischemic stroke (11 versus 6) that stood out (Bresalier et al., 2005).  
 
The overall cardiovascular mortality was however similar between the two groups. The 
increased risk did not seem to be associated by a higher baseline or use of low dose aspirin; 
however, the relative risk in the rofecoxib treated group was particularly high amongst 
patients with a history of symptomatic arthrosclerosis or diabetes (Bresalier et al., 2005). 
Post-hoc analysis revealed that the thrombotic event rates were similar in the first 18 
months of study (19 events in each group), but the increased relative risk with rofecoxib 
became evident after that (26 events with rofecoxib versus 6 events in the placebo group) 
(Bresalier et al., 2005). However, an increased rate of investigator reported hypertension, 
oedema and congestive heart failure occurred earlier in the study (after around 5 months) 
and the incidence of these adverse events were once again higher in the rofecoxib treated 
group (Bresalier et al., 2005). With this data in hand, the APPROVe study was terminated 2 
months ahead of the planned date of completion after recommendation from the external 
safety monitoring board and the steering committee, and on the same day (30th September 
2004), Merck announced that they had decided to voluntarily withdraw rofecoxib (Vioxx™) 
from the market worldwide (Merck, 2004).        
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APC trial (celecoxib versus placebo) 
The APC trial was also discontinued early due to reported cardiovascular events in the 
celecoxib treated groups (Solomon et al., 2005). There was an apparent dose related 
increased risk of myocardial infarction, stroke or heart failure in the celecoxib treated 
groups (200mg x2/day: 16 patients out of 685) and (400mg x2/day: 23 patients out of 671) 
compared to placebo (7 patients out of 679) (Solomon et al., 2005).  
 
The results from the placebo controlled APPROVe and APC trials, suggested that the 
increased cardiovascular risk associated with these two structurally distinct COX-2 selective 
inhibitors reflected a class effect that was increased with dose and duration of therapy. It is 
however important to remember that these two drugs were also associated with a 
reduction in serious gastrointestinal adverse events compared to traditional NSAIDs and 
that the risk of an adverse cardiovascular events was still very low, especially in patients 
with a low cardiovascular risk profile (Wang et al., 2005). This allowed celecoxib to stay on 
the market, to conserve the benefit of ‘COX-1 sparing’ inhibition, in a segmented patient 
market at low cardiovascular risk (but at high risk of gastrointestinal complications) where 
the benefit of reduced gastrointestinal side effects may still outweigh the risk of 
cardiovascular adverse events (Wang et al., 2005). The American food and drug 
administration (FDA) are still closely monitoring celecoxib and Pfizer are currently doing a 
large randomized clinical trial: Prospective Randomized Evaluation Of Celecoxib Integrated 
Safety Vs Ibuprofen Or Naproxen (PRECISION) (ClinicalTrials.gov, 2006-2014). Two doses of 
celecoxib (100-200mg x2/day) are compared to the two most commonly prescribed 
traditional NSAIDs naproxen (375-500mg x2/day) and ibuprofen (600-800 x3/day), in 
patients with osteoarthritis and rheumatoid arthritis (18 years and older) with (or at risk of 
developing) cardiovascular disease, assessing cardiovascular, renal and gastrointestinal 
safety (as well as therapeutic symptomatic benefit), to answer the question if celecoxib (just 
like rofecoxib) has a riskier cardiovascular profile compared to naproxen or ibuprofen.  
 
Traditional NSAIDs also carries cardiovascular risk 
The evidence supporting the cardiovascular risk profile of COX-2 selective inhibitors were 
mainly derived from clinical trials whereas data about traditional NSAID’s had to be based 
on observational and retrospective studies and meta-analysis (Chan et al., 2006; Johnsen et 
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al., 2005; McGettigan et al., 2006). This is mainly due to the fact that traditional NSAIDs 
were developed long before the requirement of today’s rigorous safety studies, and 
therefore these drugs do not have the same amount of placebo controlled large scale 
clinical trial data expected of new drugs today. The ‘Vioxx story’ served as a whistleblower 
to the whole field, including the ‘traditional NSAIDs’ and raised a cautionary flag that all of 
these drugs may be associated with cardiovascular side effects, since at therapeutic 
clinically relevant doses, all NSAIDs inhibit COX-2 (hence their therapeutic anti-pyretic, 
analgesic and anti-inflammatory effects).  
 
The distinguishing factor between traditional NSAIDs and COX-2 selective inhibitors is, of 
course the level of COX-1 inhibition (Van Hecken et al., 2000; Warner et al., 2008). We know 
that COX-2 selective drugs do not reduce urinary markers of thromboxane production, but 
do inhibit prostacyclin markers. If we consider the thromboxane versus prostacyclin balance 
as the only important factor in cardiovascular risks of these drugs, we would expect COX-2 
selective drugs to be more dangerous than traditional NSAIDs. However, this does not seem 
to be the case and a number of articles now conclude that traditional NSAIDs have a similar 
cardiovascular risk as COX-2 selective drugs (Fosbøl et al., 2010a; Fosbøl et al., 2010b; 
Kearney et al., 2006; McGettigan et al., 2006; McGettigan et al., 2011; Trelle et al., 2011). 
For example, a recent network meta-analysis study reported that rofecoxib was associated 
with the highest risk of myocardial infarction, ibuprofen with the highest risk of stroke and 
diclofenac had a high risk of cardiovascular death, but the conclusion was still that 
cardiovascular risk needs to be considered when prescribing any COX-2 selective inhibitor or 
traditional NSAID (Trelle et al., 2011).  
 
The reasons why traditional and COX-2 selective NSAIDs carry similar risks of cardiovascular 
events is not clear, and research continues in this area.  However, it should be noted that, as 
with COX-2 selective inhibitors, traditional NSAIDs reduce prostacyclin production, but 
debate surrounds the level of inhibition of platelet COX-1 and if this is sufficient, at standard 
doses, to inhibit platelet aggregation. It has been suggested that inhibition of platelet 
derived thromboxane and the persistence of thromboxane dependent platelet aggregation 
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may not be linear since and that pharmacologic inhibition of platelet COX-1 (and 
subsequent depression of serum thromboxane B2) must be virtually complete before 
dramatic changes in platelet activity is seen (Reilly et al., 1987). In addition,  a residual 10% 
capacity to generate thromboxane is enough to sustain thromboxane dependent platelet 
aggregation (Di Minno et al., 1983).  
Black box warning  
In 2005, the FDA concluded that the available data suggest that the increased risk of 
cardiovascular adverse events is a class effect shared by both traditional NSAIDs and COX-2 
selective inhibitors. The general advice is to take the lowest effective dose for the shortest 
duration possible. In the US, all prescription NSAIDs and celecoxib now share the same 
cardiovascular black box warning:  
 
‘These drugs may increase the chance of heart attack or stroke, which can lead to death and that this 
chance increases when NSAIDs are taken for long periods and if you already have established heart 
disease or risk factors for it (such as high blood pressure).’  
 
The current clinical situation suggests that most NSAIDs, including COX-2 selective 
inhibitors, are associated with an increased risk of cardiovascular events but that, as was 
predicted at the start of their development, COX-2 selective inhibitors carry lower risk of 
gastrointestinal events (Mitchell et al., 2006b). These cardiovascular side effects are now 
part of the scientific press as well as the lay press; with headlines like: ‘Painkiller heart alert’ 
(DailyMail, 2011). These headlines came from the results from a recent systemic review 
study investigating NSAIDs at typical doses in community based observational studies and 
the associated cardiovascular events in populations with both low and high cardiovascular 
risk backgrounds (McGettigan et al., 2011). This review concluded that naproxen was least 
likely to increase cardiovascular risk, whereas rofecoxib, diclofenac and celecoxib had a 
dose-related elevation in cardiovascular risk (McGettigan et al., 2011).  
 
However, since most studies concerning the cardiovascular safety profile of NSAIDs derive 
data from studies in patients with established disease (i.e. arthritis) and/or in patients with 
underlying cardiovascular disease and/or in studies with a non-cardiovascular endpoint, a 
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recent study instead focused on cardiovascular risk and NSAIDs in healthy individuals 
(Fosbøl et al., 2010a). This study once again concluded that the use of rofecoxib and 
diclofenac (and high doses of ibuprofen) was associated with higher cardiovascular 
morbidity and mortality. Naproxen on the other hand was once again identified to have a 
safer cardiovascular risk profile (Fosbøl et al., 2010a).   
 
Underlying mechanism of the cardiovascular side effects?  
It seems clear that NSAIDs, including COX-2 selective drugs, increase risk of cardiovascular 
(mainly thrombotic) events; however the underlying mechanism(s) behind these side effects 
are still debated. I will now present the two main arguments: 
 
1) Inhibition of COX-1/COX-2 derived prostanoids in the kidney and associated renal and 
blood pressure effects.  
 
And/or 
 
2) Disruption of the thromboxane/prostacyclin balance through inhibition of COX-2 derived 
prostacyclin in vascular endothelium.  
 
Elevation in blood pressure 
The first argument involves how the renovascular side effects of NSAIDs/COX-2 selective 
inhibitors (primarily blood pressure elevation) may relate to the cardiovascular side effects.   
Critically NSAIDs, including COX-2 selective inhibitors, induce a small (1-5 mmHg) rise in 
systemic blood pressure in normotensive as well as hypertensive patients and antagonise 
and destabilize the blood pressure lowering effects of anti-hypertensive drugs to an extent 
that can increase hypertension related morbidity (Singh et al., 2003). Considering that 
around 40% of patients with osteoarthritis or rheumatoid arthritis receive antihypertensive 
treatment, it is estimated that increases in systemic blood pressure of 1-5 mmHg results in 
thousands of additional strokes and ischemic heart disease events each year (Singh et al., 
2003). 
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Large clinical trials have shown that a sustained increase in systolic blood pressure of 
3mmHg is associated with a 10-20% increased risk of congestive heart failure or stroke 
(ALLHAT, 2000; Whelton et al., 2001). Therefore, whilst NSAID related increases in blood 
pressure are relatively small, it is precisely in line with the predicted rate of cardiovascular 
side effects associated with NSAIDs. In the VIGOR trial, the mean increase in systolic and 
diastolic blood pressure was 4.6mmHg and 1.7mmHg respectively in the rofecoxib treated 
group, versus 1.0mmHg and 0.1mmHg in the naproxen treated group (Mukherjee et al., 
2001). This effect was once again observed when rofecoxib was compared to placebo in the 
APPROVe trial where the mean change in blood pressure in the rofecoxib treated group was 
3.4mmHg increase (systolic) and 0.9mmHg (diastolic) compared to respective changes of -
0.5 and -0.8 in the placebo group (Bresalier et al., 2005). The elevation in blood pressure 
following rofecoxib treatment was evident after 1 month in the APPROVE trial, which could 
have been one of the factors contributing to the acceleration of cardiovascular risk (heart 
attack or stroke) which appeared in the rofecoxib arm of the study after 18 months of 
treatment (Bresalier et al., 2005).  
 
On the contrary, hypertension was lower in the celecoxib group than the ibuprofen or 
diclofenac group in the CLASS study (Silverstein et al., 2000). And the TARGET trial reported 
that lumiracoxib had a smaller mean change in blood pressure (both systolic and diastolic) 
compared to ibuprofen or naproxen (Farkouh et al., 2004). Furthermore, in the double 
blinded SUCcessive Celecoxib Efficacy and Safety Study (SUCCESS IV), 810 elderly patients 
with osteoarthritis were randomised to receive either celecoxib (200mg/day) or rofecoxib 
(25mg/day), and after 6 weeks there was a significant increase in systolic blood pressure in 
the rofecoxib treated group compared to the celecoxib treated group (+2.3mmHg versus -
0.5mmHg) (Whelton et al., 2001). This study also reported a difference in other cardiorenal 
markers such as in the development of oedema, where almost twice as many rofecoxib 
treated patients developed clinical signs of oedema and even congestive heart failure and 
that these symptoms were coupled with disordered sodium retention, starting at day 5-7 of 
treatment and leading to the development of oedema by the first 1-2 weeks of treatment 
(Whelton et al., 2001).  
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Overall these reports seem to match the cardiovascular outcome of the drugs studied, since 
in these particular trials, it was only rofecoxib that elevated blood pressure (and oedema) 
compared to the comparative NSAID/placebo and was associated with the increased risk of 
thrombotic events. It is also important to bear in mind that when blood pressure findings 
are expressed as group averages of mean increase in blood pressure, it may underestimate 
individual changes in blood pressure, and that may when sustained over time and alongside 
other risk factors have detrimental implications on cardiovascular health.  
 
Hence, the renovascular and blood pressure elevating side effects may well play a significant 
part, contributing to an increased thrombotic risk in susceptible patients on chronic dosing 
with NSAIDs or COX-2 selective inhibitors. However, even though these renal side effects 
are important to consider, the focus of my thesis has been to more closely investigate how 
COX pharmacology in vascular endothelium may relate to the cardiovascular side effects of 
NSAIDs and COX-2 selective inhibitors.   
 
Thromboxane/prostacyclin balance for vascular homeostasis-relevance of endothelial COX-2  
As covered in earlier sections, the activities of the two short lived prostanoids thromboxane 
and prostacyclin counteracts one another and a balance between the two is crucial for 
vascular homeostasis (Bunting et al., 1983). It has long been suggested that an imbalance in 
the ratio of pro-thrombotic thromboxane and anti-thrombotic prostacyclin underpins 
arterial thrombosis (Bunting et al., 1983) (Figure 1.6). As outlined in earlier sections, 
thromboxane, which is a vasoconstrictor and a potent activator of platelet aggregation, is 
mainly formed through the concerted actions of COX-1 and thromboxane synthase in 
platelets (Bunting et al., 1983; Reiter et al., 2001), but can also, to a lesser degree be 
synthesised by endothelial cells, leukocytes and lung fibroblasts (Bunting et al., 1983; 
Félétou et al., 2010).  
 
Prostacyclin, which is a vasodilator and one of the most potent naturally occurring inhibitors 
of platelet activation, is predominantly formed by macrovascular endothelium (Moncada et 
al., 1977), and is the main arachidonic acid product from large arteries, veins and the 
microcirculation (Bunting et al., 1983).  
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The anti-thrombotic and cardioprotective effects of low dose aspirin for cardiovascular 
disorders, is attributed the ability of aspirin to irreversibly acetylate/inhibit COX in anucleate 
platelets, leading to a tipping of the thromboxane/prostacyclin balance in favour of 
prostacyclin, since the nucleated endothelial cells can overcome the irreversible acetylation 
by synthesis of new COX within a few hours which alongside prostacyclin synthase can kick- 
start the production of prostacyclin again, whilst the acetylation of COX in the anucleate 
platelets is extended until new platelets (with new functional COX) are produced by 
megakaryocytic cells in the bone marrow (Vane et al., 1990).  
 
Considering that the half-life of platelets is around 8-11 days, regular low doses of aspirin 
results in accumulative inhibition of thromboxane production in platelets, but with little 
effect on endothelial prostacyclin production, which leads to a reduction in platelet 
reactivity and the favored anti-thrombotic cardioprotective environment (Figure 1.6) 
(Mitchell et al., 2006b; Vane et al., 1990). Due to gastrointestinal and increased bleeding 
time safety considerations, the lowest effective dose of aspirin is used in at-risk individuals 
as anti-platelet prophylaxis which is associated with a significantly reduced risk of 
thrombotic stroke or myocardial infarction (Patrono, 2001).  
 
On the contrary, the increased thrombotic risk of traditional (non-aspirin) NSAIDs and COX-2 
selective inhibitors has been postulated to be due to a tipping of the balance in favor of 
thromboxane (at the expense of reduced prostacyclin) thereby potentially increasing 
platelet reactivity (Figure 1.6). As described in earlier sections about the initial 
cardiovascular concerns about COX-2 selective inhibitors; this hypothesis was mainly 
derived from two early ‘first to man’ studies examining how daily dosing of rofecoxib and 
celecoxib (compared to other NSAIDs) affected urinary markers of thromboxane versus 
prostacyclin (Catella-Lawson et al., 1999; McAdam et al., 1999; Van Hecken et al., 2000). 
The first study was designed to assess the renal effects of MK-966 (rofecoxib), compared to 
indomethacin or placebo, for 2 weeks of treatment, randomised and blinded in 26 healthy 
elderly patients (Catella-Lawson et al., 1999). There was transient sodium retention with 
both active drugs, but only indomethacin was associated with a reduction in glomerular 
filtration rate. Furthermore, both rofecoxib and indomethacin decreased levels of the 
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urinary marker of the prostacyclin metabolite PGI-M, whilst the levels in placebo remained 
unchanged (Catella-Lawson et al., 1999). 
 
Importantly, the urinary marker of thromboxane biosynthesis TX-M was inhibited by 
indomethacin but not by rofecoxib, which indicated that the thromboxane/prostacyclin 
balance had been tipped in favour of thromboxane in the rofecoxib treated patients 
(Catella-Lawson et al., 1999) (illustrated in Figure 1.6). A different study in 76 healthy 
volunteers also demonstrated that rofecoxib had no significant effects on urinary TX-M, 
despite lowering PGI-M and 6-keto PGF1α to a comparable level with the other NSAIDs 
studied (diclofenac, ibuprofen, naproxen, meloxicam) (Van Hecken et al., 2000).  
 
Another study comparing celecoxib to ibuprofen or placebo, in 37 healthy young volunteers 
also obtained similar results as the two rofecoxib studies; celecoxib was shown to halve the 
urinary excretion of PGI-M compared to placebo, without affecting urinary TX-M (McAdam 
et al., 1999). This paper concluded that it seems to be a class effect of COX-2 selective 
inhibitors to inhibit markers of prostacyclin (without affecting markers of thromboxane) and 
that this implies a major role for COX-2 in both renal and systemic prostacyclin biosynthesis 
in young and healthy volunteers (McAdam et al., 1999).  
 
Since vascular endothelium is the major source of prostacyclin production, this led to the 
assumption that COX-2 is constitutively expressed in vascular endothelium and responsible 
for the biosynthesis of cardioprotective prostacyclin (Figure 1.6) (Grosser et al., 2006; 
Grosser et al., 2010; Smyth et al., 2009).  
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Figure 1.6 Thromboxane/prostacyclin balance 
 
Figure 1.6 Thromboxane/prostacyclin balance. Arterial thrombosis is dependent on a balance between pro-
thrombotic thromboxane synthesised in platelets and anti-thrombotic prostacyclin produced in vascular 
endothelium. Filled red lines indicate strong inhibition, dotted red lines indicate relatively less inhibition. 
Traditional NSAIDs aspirin, ibuprofen and diclofenac have been shown to inhibit urinary markers of both 
thromboxane and prostacyclin, whereas the COX-1 sparing or COX-2 selective inhibitors have been shown to 
inhibit urinary markers of prostacyclin without concomitant inhibition of thromboxane (Catella-Lawson et al., 
1999; McAdam et al., 1999). This has been taken as pharmacological evidence for a predominance of 
constitutively expressed COX-2 in vascular endothelium responsible for systemic prostacyclin biosynthesis. An 
imbalance in the ratio between systemic levels of COX-1 derived thromboxane from platelets and COX-2 
derived prostacyclin in endothelium has been proposed as a hypothesis behind the increased thrombotic risk 
(via vasoconstriction, platelet activation and atherothrombosis) associated with COX-2 selective inhibitors (and 
NSAIDs). 
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In the remaining sections of my introduction chapter I will focus on information and 
questions directly relevant to my PhD thesis.  
 
Fundamental questions about endothelial COX expression and prostacyclin biosynthesis 
There are currently some key preclinical questions which require answering before we can 
make informed interpretations of the clinical data obtained using NSAIDs, including COX-2 
selective inhibitors. First and foremost it is essential to establish which isoform of COX 
predominates in vascular endothelium and responsible for the production of prostacyclin 
and the extent to which this mediates cardioprotection and reduces thrombosis.  
 
Traditionally, the ‘house-keeping’ isoform COX-1 was shown to predominate in endothelial 
cells and responsible for driving prostacyclin production in healthy blood vessels (Mitchell et 
al., 1993). However, after the COX-1 sparing, or COX-2 selective inhibitors (rofecoxib and 
celecoxib) were surprisingly shown to reduce urinary markers of prostacyclin, this was taken 
as evidence that constitutively active COX-2 in endothelial cells (rather than COX-1), drives 
the systemic prostacyclin biosynthesis (Figure 1.6) (Funk et al., 2007; McAdam et al., 1999). 
The results from the clinical studies were also replicated in mice, where COX-2-/- mice and 
celecoxib treated WT mice had significantly reduced levels of urinary PGI-M (without any 
alterations in urinary TX-M levels) (Cheng et al., 2006). This together with the clinical data 
discussed above was used to substantiate the idea that COX-2 is the dominant COX isoform 
in endothelium (Fitzgerald, 2004).    
 
The view about COX-2 predominance in vascular endothelium has been challenged (Mitchell 
et al., 2006a; Mitchell et al., 2006b) since immunohistological studies have invariably shown 
COX-1 constitutively expressed within the endothelium with COX-2 only expressed at sites 
of vascular inflammation or damage (Belton et al., 2000; Kawka et al., 2007; Mitchell et al., 
1998; Mitchell et al., 2006a; Schönbeck et al., 1999). Consequently, whilst there is a general 
consensus that COX-1 predominates in platelets (and that COX-2 is absent in mature 
platelets) (Mitchell et al., 2006b; Reiter et al., 2001) controversy surrounds the isoform 
present in endothelial cells. Understanding the expression pattern and activity of COX-1 and 
COX-2 in the vascular endothelium and how this potentially relates to the cardiovascular 
side effects of NSAIDs and COX-2 selective inhibitors is the key focus of my thesis.  
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I will now provide a brief overview of what is known about COX expression in vascular 
endothelium in health and disease. 
 
COX pathways in the endothelium- during health and disease  
A thin lining of endothelium covers the luminal surface of every blood vessel in the body. 
This lining is made up by a mosaic of individual endothelial cells, joined together forming a 
monolayer interface between the blood circulating in the lumen and the underlying 
structures of the vessel wall. A typical endothelial cell is typically thicker around the nuclear 
area and then flattens out towards the cell membrane periphery.  
 
The endothelium was initially thought to be a simple cell lining that prevented the blood 
from accessing subendothelial tissues, but in 1966 Florey commented that the endothelium 
was more than a nucleated cellophane wrapper (Florey, 1966). A more active anti-
thrombotic role of the endothelium became apparent when it was discovered that 
endothelial cells synthesise prostacyclin (Moncada et al., 1976). The current, well 
established view of the endothelium is that it is a widely disseminated and dynamic organ 
composed of trillions of endothelial cells with a combined weight of ~1kg, with complex 
barrier functions, essential production of autocrine and paracrine vasoactive substances, 
key metabolic processes and important immunological functions (Cines et al., 1998). 
Furthermore, the endothelial cell layer has anti-coagulant (non-stick) properties and plays 
an important part in vasoregulation, vascular permeability, acute and chronic inflammation, 
wound healing and atherogenesis. The key vasoactive substances released from the 
endothelium include the vasoconstrictor endothelin-1 (ET-1), the endothelium-derived 
hyperpolarizing factor (EDHRF) and the potent anti-platelet and vasodilators NO and 
prostacyclin (Mitchell et al., 2008). However, for the purpose of my thesis, I will focus only 
on COX derived products, principally prostacyclin.  
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COX expression/activity in the endothelium and shear stress  
A major disadvantage with studying endothelial cells in static culture conditions in vitro is 
that the endothelial cells are removed from their natural dynamic environment. In the body 
endothelial cells are chronically exposed to mechanical forces such as shear stress (frictional 
force per unit area) and cyclic strain caused by the action of blood flowing continuously over 
the vessel wall. Endothelial cells are very sensitive to their biomechanical environment and 
shear stress is known to affect gene expression, cell turnover, cell signaling, receptor 
expression, the endothelial membrane and cytoskeleton, wall permeability, inflammation, 
angiogenesis, development of atherosclerosis and the overall morphology of endothelial 
cells (Weinberg et al., 2007).  
 
One hypothesis that has been used to explain the lack of COX-2 in vascular tissue in vitro is 
that COX-2 may be ‘constitutively induced’ by hemodynamic shear forces in the 
endothelium (FitzGerald, 2002), and therefore not detectable when studied in static 
conditions. Various studies have reported an upregulation of COX-2 in endothelial cells 
following exposure to shear stress in vitro (Di Francesco et al., 2009; Okahara et al., 1998; 
Topper et al., 1996), but there have also been conflicting results (Dancu et al., 2004; Potter 
et al., 2011) and there is by no means consensus on this point. Thus, one key area of 
investigation in my thesis has been to study expression of COX-1 and COX-2 in vivo at areas 
of polarised shear stress, most notably in the greater and lesser curvature regions of the 
aortic arch (see below).  
 
The area of shear stress biology in the endothelial field is controversial in its own right and 
one which continues to evolve. It has been suggested, for example, that relative differences 
in magnitude and directionality of shear stress (measured as dynes/cm2) may be more 
relevant to study than absolute magnitude (Suo et al., 2007). Indeed, early studies of effects 
of shear stress on COX expression were performed in vitro using cultured endothelial cells 
where generally laminar shear was applied and for relatively short periods (Di Francesco et 
al., 2009; Okahara et al., 1998; Topper et al., 1996). Therefore the use of isolated cells in the 
study of COX and shear stress is inevitably complicated by disagreement on the 
physiological relevance of the model. It is therefore better in many respects to examine 
enzyme expression in blood vessels where shear patterns have been mapped. The aortic 
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arch (with its direct anatomical connection to the heart) is an ideal structure in this respect. 
Whilst on the whole, the aortic arch may experience shear stress of a high magnitude, there 
are relative differences in magnitude and directionality of the shear stress patterns in the 
greater versus lesser curvature respectively which categorically influence inflammatory 
responses (Ali et al., 2009a; Hajra et al., 2000; Iiyama et al., 1999; Jongstra-Bilen et al., 2006; 
Zakkar et al., 2008). The endothelium in the greater curvature of the mouse aortic arch is 
subject to unidirectional and high wall shear stress with an estimated magnitude of 600 
dynes/cm2, whereas the lesser curvature is associated with wall shear stress of a relatively 
lower magnitude (of approximately 150 dynes/cm2) which is highly oscillatory 
(multidirectional) in direction during the cardiac cycle (Figure 1.7) (Suo et al., 2007). 
 
Figure 1.7 Map of the hemodynamic shear stress patterns in the mouse aortic arch 
 
Figure 1.7 Map of the hemodynamic shear stress patterns in the mouse aortic arch. Computational fluid 
dynamics model of shear stress patterns in the mouse aortic arch. Since the flow is pulsitile the shear stress 
vector changes in both magnitude and direction during different stages of the cardiac cycle. (A) The shear 
stress pattern in the greater curvature is relatively high in magnitude (~600 dynes/cm
2
) and changes little in 
direction (unidirectional), whereas the shear stress pattern in (B) the lesser curvature have a relatively lower 
shear stress magnitude (~150 dynes/um
2
), which is highly oscillatory during the cardiac cycle (multidirectional). 
Figure modified from (Suo et al., 2007).  
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Endothelium of the greater and the lesser curvature of the aortic arch are referred to as 
‘protected’ and ‘susceptible’ to atherosclerotic plaques respectively (Iiyama et al., 1999). It 
has long been recognised that the pattern of atherosclerosis is site specific in laboratory 
animals and in humans and therefore follows a predictable pattern with higher susceptibility 
in bifurcations, curvatures and near arterial branches where there is a diversion away from 
the protective high and unidirectional shear stress to low and oscillating shear stress (Caro, 
2009; Davies, 2009; Glagov et al., 1988).  
 
COX expression in the endothelium during inflammation 
As mentioned in earlier sections, COX-2 is an immediate early gene that can be readily 
induced in cells by inflammatory or angiogenic agents (McAdam et al., 2000) (see Figure 
1.4). Thus, there are numerous papers showing that COX-2 is induced in vascular cells after 
stimulation with a range of inflammatory agents including endotoxin or lipopolysaccharide 
(LPS), IL-1, tumor necrosis factor α (TNFα) and growth factors (McAdam et al., 2000). As 
mentioned in earlier sections, COX-2 has been reported to be upregulated following 
vascular injury or inflammation in large blood vessels where it seem to have a protective 
anti-inflammatory role in adhesion receptor expression, cytokine release and smooth 
muscle proliferation (Bishop-Bailey et al., 1997; Mitchell et al., 1998). Thus, the notion that 
COX-2 is induced at sites of inflammation by inflammatory mediators in vessels in vivo is 
well accepted and not in contention. However, the role of COX-2 in vascular inflammation 
remains incompletely understood. Hence, in my thesis I intentionally induced COX-2 in vivo 
using LPS in order to study COX-1 and COX-2 expression and activity during endothelial 
inflammation.  
 
Gender differences   
COX activity and isoform expression may differ between male versus females.  Estrogen has 
been shown to be able to upregulate COX-2 expression and prostacyclin release in 
endothelial cells in vitro which has been linked to the cardioprotective effects of estrogen in 
pre-menopausal women (Akarasereenont et al., 2000; Egan et al., 2004). I have therefore 
considered potential gender differences in endothelial COX expression and activity in my 
thesis. 
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Age related endothelial dysfunction 
Endothelial dysfunction is typically described as an impaired endothelial dependent dilation 
of blood vessels in response to physical or chemical stimuli, which could be due to an 
alteration in the endothelial release of vasoactive substances (Mombouli et al., 1999). It is 
important to note that the literature suggests that COX-2 in the endothelium is increased as 
we age and/or with endothelial dysfunction associated with chronic cardiovascular 
conditions (Heymes et al., 2000; Wu et al., 1998). This is a relevant argument considering 
that the target patient group for chronic dosing of NSAIDs and COX-2 selective inhibitors are 
often elderly patients with arthritis. It has been shown that acetylcholine dependent dilation 
is impaired in mice at 12 month of age compared to 3 month of age which is one of the 
characteristics of age related endothelial dysfunction (Gendron et al., 2007). I have 
therefore assessed where relevant the effect of age on COX expression and activity.  
 
Heart failure 
Heart failure is a common, disabling and deadly cardiovascular disease affecting 1-2% of the 
adult population (6-10% of the over 65s) in developed countries (McMurray et al., 2005). It 
is characterised by the inability of the heart to supply enough blood flow to meet the needs 
of the body, mainly due to ventricular dysfunction, which is often caused by myocardial 
infarction or prolonged hypertension (McMurray et al., 2005). It has been shown that 
plasma levels of prostacyclin and PGE2 metabolites are significantly higher in patients with 
severe chronic heart failure compared to normal subjects (Dzau et al., 1984). Furthermore, 
there has been reports about COX-2 expression in myocardial tissue from patients with end 
stage heart failure, that was absent in tissue from normal control hearts (Wong et al., 1998). 
COX-2 expression was also reported to be higher in venous endothelial cells harvested from 
patients with chronic heart failure compared to healthy subjects (Colombo et al., 2005). In 
this thesis I will present data from a rat model of chronic heart failure, where the aim was to 
investigate if the prostanoid profile and/or relative expression of endothelial COX-1 and 
COX-2 from major arterial vessels had changed in a compromised cardiovascular system.  
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Atherosclerosis 
Atherosclerosis and subsequent cardiovascular disease is the leading cause of morbidity and 
mortality in the industrialised world. It is now thought that atherosclerosis starts in 
adolescence (Strong et al., 1999) and silently progress but remains asymptomatic for 
decades until clinical symptoms typically manifests from middle age (Deanfield et al., 2007). 
Atherosclerosis is an inflammatory disease that is potentiated by systemic risk factors such 
as high plasma levels of modified (oxidised) low density lipoprotein (LDL), free radicals from 
smoking, hypertension, obesity and diabetes.  
 
It is characterized by lesions (or atheroma/atherosclerotic plaques) forming in large to 
middle sized arteries that consist of a fibrous cap and a lipid-rich core, accompanied by 
intense immunological activity and inflammation, cell death and fibrosis (Hansson et al., 
2006). Early plaques (also known as fatty streaks) are typically enriched in foam cells/ lipid-
laden macrophages which have engulfed oxidised LDL and T-cells. These fatty streaks can 
either disappear with time or develop into intermediate plaques characterised by 
proliferating smooth muscle that becomes intermixed with the area of inflammation (Ross, 
1999). Mature plaques (atheroma) are characterised by a core of lipids and debris from 
dead cells that are surrounded by activated macrophages, T-cells and mast cells producing 
cytokines, proteases and vasoactive substances. A mature plaque is covered with 
endothelium and stabilised by a fibrous cap of smooth muscle and collagen fibers. The most 
detrimental clinical outcome is plaque rupture when pro-thrombotic material in the plaque 
is exposed to the blood, leading to a thrombus formation, which in the coronary arteries can 
result in a myocardial infarction and heart failure or in case of the carotid arteries lead to an 
ischemic stroke (Hansson et al., 2006).  
 
Endothelial dysfunction plays a key role at all stages of atherogenesis and is characterised by 
alterations in the interactions between the endothelium with the circulating blood and the 
vessel wall including hyper-adhesiveness (adherence of monocytes and platelets to intact 
endothelium due to upregulation of adhesion molecules), enhanced permeability to 
lipoproteins and an imbalance in local vasoactive and pro- and anti-thrombotic factors 
(Ross, 1999).  
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There are numerous publications linking COX isoform expression, prostacyclin, 
thromboxane and NSAID usage to atherosclerosis, although again, there is no common 
consensus. Most studies are in agreement that both COX-1 and COX-2 are present in 
atherosclerotic plaques, but the role each isoform may play in disease protection or 
progression is not clear. Early studies showed COX-1 and COX-2 in human atheroma, mainly 
colocalising with macrophages in the shoulder region and in the lipid core periphery and 
lower levels detected in smooth muscle cells (Schönbeck et al., 1999). Furthermore, urinary 
levels of PGI-M and TX-M were found to be elevated in patients with arthrosclerosis 
compared to normal subjects (Belton et al., 2000) suggesting increased COX activity and or 
expression was significant. Given the association between prostacyclin and cardioprotection  
it has been postulated that accelerated atherogenesis, due to a reduction in prostacyclin 
may be fundamental to the development of an increased cardiovascular hazard in patients 
on long term chronic dosing with NSAIDs and COX-2 selective inhibitors (Grosser et al., 
2006) and could be a factor behind the 18 month ‘latent period’ in the APPROVe trial, 
before the cardiovascular risk profile of rofecoxib diverged from placebo (Rudic et al., 2005).  
I have therefore specifically investigated the expression and activity of COX-1 and COX-2 in 
animal models of atherosclerosis.  
 
NF-κB 
Nuclear Factor kappa-light-chain-enhancer of activated B cells (NF-κB) is a transcription 
factor crucial regulator of cellular responses as well as innate and adaptive immune and 
inflammatory responses. The NF-κB/Rel family consists of homo or heterodimeric proteins, 
and the p50/p65 (Rel A) heterodimer is the predominant NF-κB subunit in endothelial cells 
(Read et al., 1994). NF-κB is constitutively present in an inactivated state in the cytoplasm of 
almost all cell types, ready to be activated/translocated to the nucleus for control of 
transcription of DNA (Li et al., 2002).  
 
During the cytosolic inactivated state, NF-κB is bound to an inhibitory protein referred to as 
IkB, where IkB-α preferentially binds to the p65 subunit. Following activation (i.e. LPS 
stimulation), IkB kinases are activated which phosphorylates the IkB-α inhibitor leading to 
polyubiquitination and degradation whereas the p50/p65 heterodimer is transported to the 
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nucleus where it interacts with other transcription factors and coactivators to transactivate 
target genes. A negative feedback loop leads to upregulation of IkB-α expression which 
associates with the DNA bound NF-κB and a nuclear export sequence in the IkB-α binds to 
exportins and brings back the NF-κB to its inactivated state in the cytoplasm (Arenzana-
Seisdedos et al., 1995).  
COX activity via prostacyclin release may influence NF-κB since the prostacyclin analogues 
have been reported to inhibit NF-κB translocation/activation in human alveolar 
macrophages (Raychaudhuri et al., 2002), in CD4 positive T-cells (Zhou et al., 2007a) and in 
dendritic cells (Zhou et al., 2007b). Furthermore, activated NF-κB is thought to play a key 
role in the development of vascular inflammation and atherosclerosis (Collins et al., 2001). 
Interestingly, the endothelium lining the lesser curvature of the aortic arch has been shown 
to be ‘primed for activation’ with elevated levels of nuclear NF-κB and cell adhesion 
molecules, which may have relevance to the increased susceptibility of atherosclerotic 
plaques forming in this area (Hajra et al., 2000).  I have therefore investigated how NF-κB 
activity in the endothelium is affected by COX-1 or COX-2 gene deletion. For these studies I 
have used untreated and LPS treated mice in order to compare control versus inflammatory 
conditions.  
 
Platelet adherence and interactions with the endothelium  
As described in earlier sections, COX-2 selective inhibitors (and) NSAIDs depress urinary 
markers of prostacyclin substantially (but incompletely) in humans (Catella-Lawson et al., 
1999; McAdam et al., 1999). Prostacyclin is one of the most potent, endogenous inhibitors 
of platelet activation and is also known to inhibit the interaction between platelets and the 
vascular wall and thereby contribute to the anti-thrombotic surface of the endothelium 
(Moncada et al., 1977). After all, one of the main functional characteristics of intact 
endothelium is non-reactivity to platelets (Vane et al., 1995). However, prostacyclin has 
been shown to inhibit platelet-platelet interactions more potently than inhibition of platelet 
adhesion (platelet/collagen interaction) (Higgs et al., 1978), which allows for repair of a 
damaged vessel wall whilst limiting thrombus formation (Vane et al., 1995). Data from mice 
completely deficient in the prostacyclin (IP) receptor, indicate that a loss in this prostacyclin 
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signaling pathway does not lead to spontaneous thrombosis, but instead is associated with 
an increased thrombotic tendency following thrombotic stimuli (Murata et al., 1997). Since 
it has been reported that COX-1 and COX-2 knockout mice have altered urinary levels of TX-
M and PGI-M (Cheng et al., 2006), it is important to consider how this may affect 
platelet/endothelial interactions in vascular endothelium. I therefore investigated the 
presence of any adhered platelets in the greater and the lesser curvature of wild type (WT) 
versus COX-1-/- and COX-2-/- mice. For this study I used an antibody against glycoprotein 
IIb/IIIa; commonly referred to as CD41 (also known as integrin αIIββ3, which is a cell surface 
receptor for fibrinogen on mature platelets) in order to selectively detect platelets (not 
endothelial cells/other nucleated cells) adhered to the vessel intima. CD41 is reported to be 
expressed on the platelet plasma membrane, intraluminal side of the platelet open 
canalicular system and on the platelet α-granule membrane (Schmitt et al., 2001).    
 
Summary 
Almost a decade has passed since Vioxx was dramatically withdrawn from the market on a 
wave of publicity linking COX-2 inhibitors to cardiovascular deaths. We now know that 
regular NSAIDs, including over-the-counter drugs such as diclofenac and ibuprofen, share 
the potential to cause heart attack and strokes. However, we still do not understand some 
of the very basic concepts relating to COX-1 and COX-2 expression and activity in 
cardiovascular tissues.  
 
The focus of my thesis is to study COX-1 and COX-2 expression and activity in blood vessels 
in health and in disease. I have focused on the study of relative expression patterns of COX-
1 and COX-2 in endothelium of different anatomical regions relevant to shear stress 
responsive endothelial phenotypes, particularly those prone or protected to atherosclerosis.  
 
Hypothesis 
‘COX-2 is present in vascular endothelium and regulates prostacyclin release 
and functional responses in health and disease’ 
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Aims 
The aims and research questions of my thesis can be summarised as follows: 
 
1) How is the morphology of the endothelium and the underlying smooth muscle 
defined in the gross area of the mouse aortic arch? 
 
2) Which COX isoform predominates in vascular endothelium and how does this relate 
to endothelial cell morphology? 
 
 
3) Which COX isoform drives endothelial prostacyclin production in vascular tissue? 
 
 
4) Does the relative expression pattern and/or bioactivity of endothelial COX-1 and 
COX-2 change following cardiovascular disease? 
 
 
5) What are the functional consequences of COX-1 and COX-2 gene deletion in the 
aortic arch endothelium in health and disease? 
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Animals 
All experiments were carried out in accordance with the United Kingdom Home Office Guide 
on the Animals (Scientific Procedures) Act 1986. All animals were housed in dedicated 
biomedical research husbandry facilities under the supervision of certified animal care 
technicians according to institutional guidelines and international laws. The regulated 
scientific procedures in this thesis include administration of substances by intraperitoneal 
injection (i.p.) and ear clipping (sampling small pieces of ear tissue) for genotyping. These 
procedures were carried out in accordance with the specified animal allowance in our 
project licence (70/6913) as well as my personal licence (70/21691). Throughout the course 
of my PhD, I have endeavoured where possible to share tissue from animals and optimise 
the powering of studies in order to use the minimum number of animals possible, in line 
with the direction and philosophy of the ‘3 Rs’ at the National Centre for the Replacement, 
Refinement and Reduction of animal research guidelines (NC3Rs, 2012). 
Genetically modified mice; COX-1 or COX-2 knockout mice  
I have used genetically modified mice, where either the COX-1 or COX-2 gene has been 
deleted (COX-1-/- and COX-2-/- respectively). The COX-1-/- and COX-2-/- mice used in this 
thesis were from our own colonies that were derived from breeding pairs donated by 
Professor Ballou’s lab at the University of Tennessee Health Science Centre (Memphis USA). 
The colonies are on a C57BL/6J background (Jackson labs, USA) and were originally created 
by Professor Oliver Smithies’ group at the University of North Carolina, USA (Langenbach et 
al., 1995; Morham et al., 1995). The genotypes of the breeding pairs for the COX-1-/- and 
COX-2-/- colonies as well as their offspring were tested rigorously throughout the breeding 
process. The COX-1-/- colony was bred by homozygote breeding; both male and female were 
homozygote for COX-1 (-/-) generating 100% homozygote COX-1-/- litters. The COX-2 colony 
however, required heterozygote breeding (homozygote male COX-2-/- mice was bred with 
female heterozygote COX-2+/- mice), since homozygote female COX-2-/- mice are infertile 
(Morham et al., 1995). The possible genotypes of offspring from these breeding pairs were 
therefore either wild type (WT) (COX-1+/+ COX-2+/+), COX-2+/- (heterozygotes) or COX-2-/- 
(homozygotes); and mice were genotyped at breeding (Figure 2.1). The colonies I have used 
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in my thesis (WT, COX-1-/- and COX-2-/- mice) have been backcrossed on a regular basis, into 
their background C57BL/6J (Harlan, UK).  
Genotyping procedure 
The DNA from ear clips was extracted by using Dneasy Tissue Kit (Qiagen, 69056). In brief, 
the DNA from the ear clip samples was obtained by first digesting the tissue with (Qiagen 
proteinase K), followed by lysis (Qiagen lysis buffer and ethanol), multiple washing steps 
(Qiagen wash buffer) in mini-spin columns and then DNA bound to columns was eluded 
(using Qiagen elution buffer), ready for 3-primer polymerase chain reaction (PCR). The PCR 
protocol was developed according to (Ballou et al., 2000; Reddy et al., 1999). Extracted DNA 
was pipetted into tubes (GE healthcare, 27-9559-01) containing illustra PuReTaq Ready-To 
Go PCR beads with 3 primers (Invitrogen) for each gene. The PCR program on a Techgene 
PCR machine was set to: 5 minutes at 94:C (denaturing), 32-38 cycles (COX-1 PCR) and 35 
cycles (COX-2 PCR) of 15 seconds at 94:C (denaturing), followed by 15 seconds 60:C (COX-1 
PCR) and 15 seconds 55:C (COX-2 PCR) (annealing), 1 minutes 72:C (extension), 5-10 
minutes 72:C (final extension), finished off at 4:C. Amplified DNA samples were then either 
stored in the freezer (-20:C) or run through electrophoresis on the same day.  
 
The COX-1 primer for the WT allele was 5’ AGGAGATGGCTGCTGAGTTGG (which yielded a 
fragment of 601bp to represent COX-1+/+). The COX-1 null allele (with the neomycin insert) 
was identified with a primer for 5’ GCAGCCTCTGTTCCACATACAC (which yielded a fragment 
of 646bp to represent COX-1-/-). The reverse primer for both COX-1 WT (COX-1+/+) and 
mutant allele (COX-1-/-) was 3’ AATCTGACTTTCTGAGTTGCC and yielded two fragments of 
601bp and 646 respectively to represent COX-1+/- (Figure 2.1) (Ballou et al., 2000; Reddy et 
al., 1999).  
 
The COX-2 primer for the WT allele was 5’ ACACACTCTATCACTGGCACC (which yielded a 
fragment of 760bp to represent COX-2+/+). The COX-2 null allele (with the neomycin insert) 
was identified with a primer for 5’ ACGCGTCACCTTAATATGCG (which yielded a fragment of 
905bp to represent COX-2-/-). The reverse primer for both COX-2 WT (COX-2+/+) and mutant 
allele (COX-2-/-) was 3’ ATCCCTTCACTAAATGCCCTC and yielded two fragments of 760bp and 
905bp respectively to represent COX-2+/- (Figure 2.1) (Reddy et al., 1999).   
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Figure 2.1 PCR blot of extracted DNA from genotyping of our mouse colony  
 
Figure 2.1 PCR blot of extracted DNA from genotyping of our mouse colony. (1) DNA from wild type (WT) 
mice ear clips from COX-1
+/+
 at 601bp (~600bp), and COX-2
+/+
 760bp (~700bp) (2) DNA from COX-1
-/- 
at 646bp 
(~700bp) and COX-2
-/- 
at 905 (~900bp) (3) DNA bands from COX-1
+/-
 with two bands at 601bp and 646bp 
(~600bp and 700bp) and 760bp and 905bp (~700bp and 900bp) for COX-1
+/-
.  
 
WT mice 
The WT control mice were generated by inter-crossing COX-1+/- and COX-2+/- mice, then 
crossing their COX-1+/+ and COX-2+/+ offspring in order to maintain a similar genetic 
background. However, for some studies, before viable colony offspring WTs were available, I 
performed some experiments (see individual figure legends) using standard C57BL/6J male 
mice (purchased from Harlan, UK) as controls.  
 
The strategies for targeting COX-1 and COX-2 gene disruption  
The following information is interpreted from the papers originally describing the strategies 
and practicalities of generating the genetically modified mice used in this thesis. I have 
included this amount of detail in my thesis as, although not my work, it is very relevant for 
the understanding of the results obtained in my PhD.  
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Strategic generation of COX-1-/-mice 
The strategy when creating the COX-1-/- mice was to target the Serine 530 (Ser-530) amino 
acid located in the active catalytic site of COX-1 (Langenbach et al., 1995). Ser-530 is located 
in a highly conserved area of the COX-1 gene, also known as the prostaglandin-
endoperoxide synthase 1 (Ptgs1) gene and has been identified as the acetylating site of 
aspirin. Aspirin interaction with COX-1 involves a bulky acetyl group that forms a covalent 
bond with the Ser-530 residue which interferes with arachidonic acid (substrate) binding 
and thereby renders the COX-1 enzyme inactive (DeWitt et al., 1990). The mouse Ptgs1 
complementary DNA (cDNA) sequence (DeWitt et al., 1990) (Figure 2.7) revealed that the 
codon for Ser-530 is located in exon 11, hence this became the target for the COX-1 
disruption (Langenbach et al., 1995). A 357bp probe synthesised from 129 mouse strain 
embryonic stem (ES) cell DNA (confirmed by southern blot to be specific for a single gene), 
was used to screen E14TG2a mouse ES cells for the 5’ end of exon 11 on the Ptgs1 gene. 
This was followed by the isolation of a clone of a fragment from the 3’ region of the Ptgs1 
gene of approximately 15kb (including exon 11) (Figure 2.2) (Langenbach et al., 1995). The 
15kb fragment clone was confirmed to be from the COX-1 (Ptgs1) isoform and not COX-2 
(Ptgs2), by a multistep process that included the use of specific primer pairs for sequences 
of exon 11 in Ptgs1 and established that 100bp of DNA from exon 11 matched the 
corresponding published sequence of Ptgs1 (Langenbach et al., 1995).   
Figure 2.2 Strategic disruption of the COX-1 (Ptgs1) gene 
 
Figure 2.2 Strategic disruption of the COX-1 (Ptgs1) gene. A ~15kb fragment of the 3’ region of the Ptgs1 
gene, showing the position of exon 11 (black box) which includes the codon for the acetylating target of aspirin 
(amino acid residue Ser-530). Black boxes represent intron 10 and exon 11 respectively. Restriction site 
associated DNA markers:  X (Xbal), H (Hindlll), Xh (Xhol), C (Clal), Bg (Bglll) and B (BamHI). Figure modified from 
(Langenbach et al., 1995). 
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The targeting vector construct included a 4.3kb Notl-Xhol fragment (Figure 2.3B, see N-Xh), 
a neomycin resistance gene (Neo) designed to replace ~ 1 kb of intron 10 and the first 44bp 
of exon 11 (Figure 2.3B, see Neo), a 2.3kb BamHI fragment (Figure 2.3B B+C) and a herpes 
simplex virus thymidine kinase insert (Figure 2.3B, see Tk) (Langenbach et al., 1995). This 
targeted pPNT plasmid vector was then linearized with Notl (Figure 2.3B, see N) and 
electroporated into trypsinised 129 derived E14TG2a ES cells (Langenbach et al., 1995).  
Figure 2.3 Disruption of the Ptgs1 gene by recombination with the vector construct 
 
Figure 2.3 Disruption of the Ptgs1 gene by recombination with the vector construct. (A) A ~15kb fragment of 
the 3’ region of the Ptgs1 gene. Black boxes represent intron 10 and exon 11 respectively. Restriction site 
associated DNA markers: X (Xbal), H (Hindlll), Xh (Xhol), C (Clal), Bg (Bglll) and B (BamHI). X indicates 
homologous recombination. (B) Linearized vector construct; a 4.3kb N (Notl) to Xh (Xhol) fragment, a neomycin 
resistance gene (Neo) inserted to replace ~1kb of intron 10 and the first 44bp of exon 11 and a 2.3kb BamHI 
fragment from C (Clal) to B (BamHI). Tk indicate a herpes simplex virus thymidine kinase insert. Wavy line 
indicates the plasmid part and N is the restricted associated DNA marker (Notl). (C) Successful homologous 
recombination of the vector construct into the targeted gene (from X to B) is Neo positive and Tk negative. 
Figure modified from (Langenbach et al., 1995).  
Positive selection was made by adding the antibiotic genecitin (G418) in order to harvest the 
vector targeted genes since the Neo gene insert is resistant to G418 (Langenbach et al., 
1995). Subsequently, the anti-viral drug ganciclovir (GANC) was added as a negative 
selection process, to provide a 10-fold enrichment of the correctly targeted genes compared 
to GANC alone (to discard of any herpes simplex Tk containing vectors indicating non-
homologous insertion of the vector construct into the genome) (Mansour et al., 1988) 
(Figure 2.4).  
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Figure 2.4 Positive/negative selection enrichment of ES cells with the targeted mutation  
 
Figure 2.4 Positive/negative selection enrichment of ES cells with the targeted mutation. Closed black boxes 
indicate exons. Open boxes denotes introns. (A) Gene targeting- the neomycin resistance gene (neo) in the 
vector construct will replace the target gene of interest (Gene X). Successful homologous recombination of the 
targeting vector with the genomic DNA results in the disruption of the targeted gene and loss of the herpes 
simplex virus thymidine kinase gene insert (HSV-tk). These cells will be resistant to both genecitin (G418) and 
the anti-viral drug ganciclovir (GANC) and would therefore pass through both the positive (G418) and negative 
(GANC) selection process. x-neo 
r 
HSV-tk 
-
(G418 
r
, GANC 
r 
 means negative for gene X (x-), contain the Neo 
resistance gene (neo
r
), the HSV-tk gene is not present (HSV-tk-) and the targeted gene would be G418 and 
GANC resistant (G148 
r
, GANC 
r
)  (B) Random integration or non-homologous integration of the vector 
construct through the ends of the linearised DNA allows for integration of both neo and HSV-tk inserts into the 
genome and therefore such cells would pass through the positive selection with G418 but would be discarded in 
the negative selection process since they are sensitive to GANC (GANC 
s
). All in all, this selection process favours 
higher yield for cells that contain the desired targeted mutation. Figure modified from (Mansour et al., 1988).  
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DNA from the remaining G418 and GANC resistant colonies (6 out of 96) were isolated and 
used for Southern blot analysis (Figure 2.5E) (Langenbach et al., 1995). Cells from two of the 
successfully vector targeted clones were then injected into C57BL/6 blastocysts (Figure 
2.5A).  
Figure 2.5 Original breeding setup for generating COX-1-/- mice 
 
Figure 2.5 Original breeding setup for generating COX-1
-/-
mice.  (A) Embryonic stem (ES) cells (from the 129 
strain) carrying the targeted vector clone were injected into C57BL/6 blastocysts. Four male chimeras were 
born. (B) + (C) One of them produced heterozygote 129/C57BL/6 offspring when bred to a female C57BL/6 
mouse. (D) These heterozygote siblings were then inbred to create wild type (WT), heterozygote and 
homozygote COX-1 genotypes. (E) Southern blot showing the Hind III digested wild type allele (5.2kb) and 
vector targeted allele (2.8kb) from tail clip DNA from COX-1 wild type (+/+), COX-1 heterozygote (+/-) and COX-
1 homozygote (-/-) mice. Southern blot from (Langenbach et al., 1995). 
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Details about the COX-1 antibodies used in this thesis 
Two different COX-1 antibodies (160109 and 160108, both from Cayman antibodies with no 
reported cross reactivity with COX-2) were used in the experiments presented in this thesis 
(Figure 2.6).  
 
Figure 2.6 Comparison of the two COX-1 antibodies used in this thesis 
 
 
Figure 2.6 Comparison of the two COX-1 antibodies used in this thesis. Two COX-1 antibodies were used in 
this thesis; rabbit polyclonal anti-murine COX-1 (Cayman 190109) and rabbit polyclonal anti-ovine COX-1 
(Cayman 160108). They both cover a relatively similar amino acid range; amino acid positions 274-288 
(LMRYPPGVPPERQMA) and 272-282 (LMHYPRGIPPQ) respectively. The murine COX-1 antibody was used to 
detect mouse and rat COX-1 and the ovine COX-1 antibody was used to detect human COX-1 in this thesis.       
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Truncated COX-1 protein in COX-1-/- mice 
If a truncated version of the disrupted COX-1 protein was made it would lack 120 amino 
acids from the carboxy-terminal (including Ser-530). Furthermore, any alternative splicing to 
eliminate the Neo gene would affect the reading frame due to elimination of 14 amino acids 
(Langenbach et al., 1995) (Figure 2.7).  
Figure 2.7 Nucleotide and amino acid sequence (cDNA) of murine COX-1 
 
Figure 2.7 Nucleotide and amino acid sequence (cDNA) of murine COX-1. cDNA coding from a mouse 3T3 cell 
line (DeWitt et al., 1990). Standard one letter symbols above the nucleotides indicate the corresponding amino 
acids and numbers above refers to the amino acid position. The large red boxes mark out the position of the 
antigen recognised by the Cayman murine COX-1 antibody (160109) (amino acid sequence 
LMRYPPGVPPERQMA). The small red box indicates the location of the Serine 530 (Ser-530), where aspirin 
irreversibly acetylates COX-1 by adding a bulky side chain which interferes with arachidonic acid (substrate) 
binding and COX-1 enzymatic activity. This was the target site for disrupting COX-1. The red line indicates the 
carboxy-terminal 120 amino acids that would be missing if a COX-1 protein was made in a mouse. Figure 
modified from (DeWitt et al., 1990). 
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It is important to note that the murine COX-1 antibody used in this thesis (Cayman 160109) 
recognises a COX-1 peptide-antigen constructed to a sequence before the targeted COX-1 
disruption and could therefore hypothetically pick up a truncated version of a COX-1 protein 
expressed in COX-1
-/- 
mice (Figure 2.7). Although a truncated version is most likely to be 
inactive since it would lack the carboxy-terminal end (including Ser-530), its presence could 
theoretically be detected in western blots and/or immunohistochemical experiments 
presented in this thesis. 
In the original paper describing the COX-1-/- mice, the authors analysed gene and protein 
expression in kidneys and colons to see if a truncated version of COX-1 could be detected by 
northern and western blotting. There was a detectable COX-1 messenger RNA (mRNA) 
message in the northern blot of 2.8kb in the WT (COX-1+/+) mice, this signal was reduced to 
about half in the COX-1+/- and absent in the COX-1-/- mice (Langenbach et al., 1995). 
Moreover, an antibody raised to a very similar antigen sequence (LMRYSPPGVPPERQMAC 
residues 274-289) as the polyclonal COX-1 antibody used in this thesis 
(LMRYSPPGVPPERQMA residues 274-288) did not detect measurable truncated protein in 
western blots (Langenbach et al., 1995; Morita et al., 1995). 
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Strategic generation of COX-2-/- mice 
The targeting strategy when creating the COX-2 deficient (COX-2-/-) mice was to disrupt the 
nucleotides encoding amino acids crucial for COX-2 activity (Tyr-371 and His-374) on exon 8 
with a Neo gene insert, a 104bp deletion and a truncated exon 10 (Figure 2.8) (Morham et 
al., 1995). Mouse COX-2, or prostaglandin-endoperoxidase synthase 2 (Ptgs2), was isolated 
from the mouse strain 129 derived ES cell line E14TG2a. A probe consisting of 408 bp 
specific to exon 10 on Ptgs2 (not present in the corresponding region of Ptgs1), was used to 
locate Ptgs2 as a λ bacteriophage clone containing a 16kb fragment of BamHI digested 
genomic DNA (Morham et al., 1995). To confirm the identity of the λ clone and to 
discriminate it from Ptgs1, a Ptgs2 cDNA (O'Banion et al., 1992) probe was used as well as 
specific primers to exon 1, 4, 7, 8 and 10 in Ptgs2 (Morham et al., 1995). This λ clone 
targeting construct, (containing a neo gene inserted between EcoRI (E) and BstXI (Bx) in 
exon 8, a 104 bp deletion in exon 8 (of the regions encoding for Tyr-371 and His-374) and a 
truncated version of exon 10), was used to disrupt the Ptgs2 gene in the ES cell line 
E14TG2a  (Figure 2.8A-C). 
11 out of 192 clones passed the positive/negative selection process (by G418 and GANC), 
and was thereby assumed to have undergone successful homologous recombination. These 
11 clones carrying the desired gene target were digested with Sacl for Southern blot 
analysis, which confirmed the presence of the 3.8kb targeted allele fragment (Figure 2.8D). 
Two of these successfully targeted E14TG2a ES cell lines were injected into C57BL/6 
blastocysts, which resulted in the birth of male chimeric mice that were then mated with 
C57BL/6 females. The targeted Ptgs2 allele was passed on to the 129/C57BL/6 offspring and 
these COX-2 heterozygote mice were subsequently inbred to give rise to WT (COX-2+/+), 
heterozygote (COX-2+/-) and homozygote (COX-2-/-) mutant mice (see breeding setup 
schematic for the COX-1-/- mice in Figure 2.5A-D).  
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Figure 2.8 Disruption of the Ptgs2 gene by recombination with the vector construct 
 
Figure 2.8 Disruption of the Ptgs2 gene by recombination with the vector construct. (A) The Ptgs2 gene locus. 
Black boxes represent exons 1-10. Restriction site associated DNA markers: Bg (Bglll), St (Styl), S (Sacl), E 
(EcoRI), Bx (BstXI). Double ended arrow indicates the 2.6kb Sacl fragment (between S and S) characteristic of 
the WT Ptgs2 gene. X indicates homologous recombination. (B) Linearised λ clone vector construct; ∆8 
represents neomycin resistance gene (Neo) inserted at exon 8 along with a 104bp deletion in the E to Bx region, 
eliminating nucleotides encoding the amino acid residues Tyr-371 and His-374, both essential for COX-2 
activity. ∆10 represents a truncated version of exon 10. A herpes simplex thymidine kinase (Tk) gene was 
inserted for the negative selection process of correctly targeted genes. Wavy line indicates the continued 
plasmid sequence. (C) Successful homologous recombination of the vector construct into the targeted gene 
with a Neo insert and 104bp deletion in exon 8 and truncated exon 10. The correctly inserted gene is Neo 
positive and Tk negative, and would therefore pass through both positive and negative selection processes.  
Double ended arrow indicate the 3.8kb Sacl fragment (between S and S) characteristic of the targeted Ptgs2 
gene. (D) Southern blot of mouse genomic DNA digested with Sacl illustrating that DNA from WT mice (
+/+
) has 
a single band at 2.6kb on Southern blot. Heterozygote COX-2 mice (
-/+
) has one allele with the targeted gene 
(band at 3.8kb) and one allele with the WT gene (at 2.6kb). Homozygote COX-2 mice (
-/-
) has a single band at 
2.6kb (both allele carries the targeted gene). ES denotes DNA from the parental ES cell line (E14TG2a). Figure 
modified from (Morham et al., 1995).  
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Details about the COX-2 antibody used in this thesis 
The COX-2 antibody that has been used throughout this thesis is a polyclonal antibody from 
Cayman antibodies (160126), raised in rabbit against a peptide corresponding to the amino 
acids 584-598 in murine COX-2 (Figure 2.9). This COX-2 antibody also cross reacts with 
human, rat and bovine COX-2, but has no reported cross reactivity with COX-1 in any of 
these species.  
 
Figure 2.9 Murine COX-2 antibody and the amino acid sequence of Ptgs2 
 
Figure 2.9 Murine COX-2 antibody and the amino acid sequence of Ptgs2. (A) The details about the antigen 
and cross-reactivity of the murine COX-2 antibody 160126 from Cayman. (B) One letter coded amino acid 
sequence for Ptgs2. Dark grey indicates exon 8 which was the target for the insertion to disrupt Ptgs2. The 
targeting strategy also included a 104 bp deletion in exon 8 to eliminate nucleotides coding for the two amino 
acids crucial for COX-2 activity (Tyr-371 and His-374 in exon 8, marked in red). The amino acid sequence 
(SHSRLDDINPTVLIK, position 584-598,) coding for the antigen recognised by the polyclonal COX-2 antibody 
(Cayman 160126) used in this thesis is indicated by underlined bold black letters. Gly-469 - Leu 604 in exon 10 
(highlighted in light grey) was truncated in the targeted gene which would affect the sequence recognised by 
the COX-2 antibody.      
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Truncated COX-2 protein in COX-2-/- mice  
A truncated version of the disrupted COX-2 protein would have a missing section at exon 10,  
(including the amino acid sequence for the antigen recognised by the COX-2 antibody used 
in this thesis, Figure 2.9). Furthermore, earlier reports from these COX-2-/- mice indicate that 
these mice completely lack normal induction of Ptgs2 mRNA, protein and PGE2 synthesis in 
macrophages upon stimulation with LPS, measured by Northern blot, Western blot and 
competitive radioimmunoassay (RIA) (Morham et al., 1995). 
COX-1 and COX-2 protein phenotypes in WT, COX-1-/- and COX-2-/- mice                                               
Information described above from the literature would suggest that the mice used in my 
PhD have confirmed phenotypes. However, members of our group (Mr William Wright and 
Ms Ivana Vojnovic) have performed western blotting validation experiments using 
fibroblasts isolated from lungs of the WT, COX-1-/- , COX-2-/- mice from our colony (Figure 
2.10).  
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Figure 2.10 Western blots of COX-1 and COX-2 protein from lung fibroblasts isolated from 
our colony WT, COX-1-/- and COX-2-/- mice 
 
Figure 2.10 Western blots of COX-1 and COX-2 protein from lung fibroblasts isolated from our colony WT, 
COX-1
-/-
 and COX-2
-/-
 mice. Western blots showing (A) COX-1 and (B) COX-2 protein in lung fibroblasts from 
WT, COX-1
-/-
 and COX-2
-/- 
mice. Lung fibroblasts grown out from pieces of lung incubated in vitro were isolated 
and either left untreated (-) or treated with interferon γ (IFNγ, 10ng/ml) and LPS (serotype 0111:B4, 1μg/ml) to 
induce COX-2. The positive control was J774 macrophages treated with LPS and the strong bands underneath 
sample bands is β-actin. The weak band of COX-1 in the COX-2
-/-
 mice treated with IFNγ and LPS may be due to 
an error in protein loading since the β-actin band underneath is also greatly reduced. 
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Fibroblasts from WT mice and COX-2-/- mice, treated with or without interferon γ (IFNγ)+ 
LPS, gave clear bands on the Western blot corresponding to the expected size of COX-1 
protein (~70kda in size) (Figure 2.10A). These bands were absent in fibroblasts from COX-1-/- 
mice (Figure 2.10A).  In the COX-2 Western blot, there were clear bands at the expected size 
for COX-2 protein (~72kda), in fibroblasts from WT and COX-1-/- mice treated with IFNγ+ LPS, 
but this COX-2 band was absent in fibroblasts from COX-2-/- mice (Figure 2.10B).  The faint 
band of COX-2 in the untreated COX-1-/- mice is likely to represent COX-2 induced during 
fibroblast proliferation, consistent with COX-2 being induced by growth factors present 
during proliferation (Figure 2.10B).  
 
Reported phenotype of the COX-1-/- mice  
The COX-1-/- females were reported to have normal fertility and implantation but to have 
delayed parturition leading to a prolonged gestation (by 2-3 days compared to WT mice), 
which negatively influenced the pups survival rate (Gross et al., 1998). Langenbach et al 
reported that despite a 99% reduction in constitutive prostaglandins, the COX-1-/- mice 
developed normally, appeared healthy and had no significant pathology when they 
performed necropsy and microscopic examinations of heart, lung, liver, spleen and 
gastrointestinal and reproductive tracts (n=3 COX-1-/- male and n=3 COX-1-/- female mice).  
 
However, after closer examination of the kidneys they discovered that 3 out of 6 kidneys 
from the COX-1-/- mice had small foci of basophilic, immature tubules, which did not occur in 
the WT mice (Langenbach et al., 1995). 
 
In addition, in a standard ear swelling assay, where swelling of the ear was measured in 
response to topical application of inflammatory agents, the COX-1-/- mice had a 30% reduced 
inflammatory response to arachidonic acid compared to the WT mice, whereas there was 
no difference following exposure to tetradecanoyl phorbol acetate (TPA) (Morham et al., 
1995). This was thought to show that constitutive COX-1 contributes to oedema and 
inflammation induced by arachidonic acid, whereas TPA induced inflammation was 
mediated by induction of COX-2 (Morham et al., 1995).  
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Furthermore, as expected, platelets from COX-1-/- mice aggregated more slowly and were 
less responsive to arachidonic acid in vitro than platelets from WT mice (Morham et al., 
1995). Another phenotypic characteristic reported of these COX-1-/- mice is that they had no 
spontaneous stomach ulcers and their gastric mucosa appeared normal (although gastric 
pH, which is regulated by COX-1, was reduced) (Loftin et al., 2002).   
Reported phenotype of the COX-2-/- mice  
The COX-2-/- female mice were reported to be infertile due to defects in ovulation and 
implantation (Lim et al., 1997). Meanwhile, the COX-2+/- female mice had normal fertility. 
This was the reason why we needed to use heterozygote females in our breeding colonies. 
The most striking phenotypic characteristic reported about the COX-2-/- mice is their renal 
abnormalities, with severe developmental renal defects (Morham et al., 1995). In mice, the 
development of the kidneys continues postnatal, and COX-2 seems to play a pivotal role 
during this critical time (Figure 2.11) (Kömhoff et al., 2000). Adult COX-2-/- mice also have 
disrupted salt sensing which has consequences on renin-angiotensin system activation (Yang 
et al., 2000). COX-2 is normally induced in the macula densa and thick ascending limb in 
mice, by reductions in salt levels. COX-2 therefore appears to be essential for renal 
homeostasis including salt retention, volume and blood pressure regulation (Yang et al., 
2000). 
 
Figure 2.11 Histology of kidneys from 21 days old WT versus COX-2-/- mice 
 
Figure 2.11 Histology of kidneys from 21 days old WT versus COX-2
-/-
 mice. Section of a kidney from a 21 days 
old (A) WT (C57BL/6J) mouse and (B) COX-2
-/-
 mouse, stained with hematoxylin. Figure modified from (Kömhoff 
et al., 2000).  
 
A summary of the main phenotypic characteristics reported in the literature for the COX-1-/- 
and the COX-2-/- mice originally used to generate our colonies is provided in table 2.12.   
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Table 2.12 Phenotypic characteristics of COX-1-/- and COX-2-/- mice 
 
Physiology/pathology COX-1−/− mice COX-2−/− mice References 
Constitutive prostaglandin 
synthesis 
Decreased Normal 
(Langenbach et al., 1995; Morham et al., 
1995) 
Inducible prostaglandin 
synthesis 
Normal Decreased 
(Langenbach et al., 1995; Morham et al., 
1995) 
Ovulation 
Implantation 
Parturition 
Normal 
Normal 
Delayed 
Impaired 
Impaired 
Unknown 
(Gross et al., 1998; Lim et al., 1997) 
Neonatal mortality Normal Increased 
(Dinchuk et al., 1995; Langenbach et al., 
1995; Loftin et al., 2001; Morham et al., 
1995) 
Adult mortality Normal Increased (Morham et al., 1995) 
Patent ductus arteriosus Normal Increased  (Loftin et al., 2001) 
Postnatal kidney development Normal Impaired 
(Dinchuk et al., 1995; Kömhoff et al., 2000; 
Langenbach et al., 1995; Loftin et al., 2001; 
Morham et al., 1995) 
Spontaneous gastric ulceration Normal Normal 
(Langenbach et al., 1995; Morham et al., 
1995) 
Peritonitis incidence Normal Increased 
(Langenbach et al., 1995; Morham et al., 
1995) 
Induced acute colitis Increased Increased (Morteau et al., 2000) 
Platelet aggregation Impaired Normal 
(Langenbach et al., 1995; Morham et al., 
1995) 
Wound Healing Unknown Impaired (Langenbach et al., 1999) 
Febrile response Normal Decreased (Li et al., 2001; Li et al., 1999) 
Influenza A viral infection Increased Decreased (Carey et al., 2005) 
Inflammation                            
(AA induced Ear inflammation model, air 
pouch model and allergen induced 
pulmonary inflammation model) 
Altered Altered 
(Gavett et al., 1999; Langenbach et al., 1999; 
Langenbach et al., 1995) 
Collagen Induced Arthritis Normal Decreased (Myers et al., 2000) 
Abdominal Aortic Aneurysms                               
(Chronic angiotensin II infusion model) 
Unknown Decreased (Gitlin et al., 2007) 
Lipid deposition in the aorta 
following an atherogenic diet 
Unknown Increased (Narasimha et al., 2007) 
Table 2.12 Phenotypic characteristics of COX-1
-/-
 and COX-2
-/-
 mice. Table modified from (Loftin et al., 2002).  
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In summary, despite greatly decreased constitutive prostaglandin synthesis, the COX-1-/- 
mice were generally healthy without signs of spontaneous stomach ulcers (but with a more 
acidic gastric environment and heightened responsiveness to acutely induced colitis), had 
altered inflammatory response to influenza or bacterial infection, had normal fertility but 
delayed parturition (leading to smaller litter sizes) and impaired platelet aggregation 
responses (Langenbach et al., 1995).   
 
The COX-2-/- mice had normal levels of constitutive prostaglandins, but altered induced 
levels. Furthermore, the female homozygote knockout mice were infertile, many pups have 
premature closure of the patent ductus arteriosus and post natal renal abnormalities that 
deteriorated with age and led to an increased neonatal and adult mortality rate. The COX-2-
/- mice neither had any spontaneous gastric lesions but had increased incidence of 
peritonitis and acutely induced colitis. Moreover, wound healing was impaired, the febrile, 
influenza and inflammatory response was decreased and the immune response to collagen 
induced arthritis was reduced. Upon challenge with an atherogenic diet, there was more 
lipid deposition in the aorta and increased systemic markers of inflammation in the COX-2-/- 
mice.  
 
Mice lacking both COX-1 and COX-2 (double knockout COX-1-/- COX-2-/- mice), die from a 
patent ductus arteriosus within 12 hours of birth (Loftin et al., 2001), hence, this prevent 
study of the consequences of a lack of both COX isoforms.  
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Breeding and phenotypic data from our WT, COX-1-/- and COX-2-/- colonies 
The average litter sizes for mice used in this thesis were: WT (6.4 ± 0.3), COX-1-/- (4.7± 0.4) 
and COX-2-/- (7.3 ± 0.3); the COX-1-/- litter size was significantly smaller than the WT litter 
size (One-Way ANOVA with Dunnett’s post-test, p<0.05 was considered significant). This is 
consistent with what was reported by Langenbach et al 1995 where the delayed parturition 
in the COX-1-/- mice, is likely to lead to smaller litter sizes. The genotypic ratio from the 
heterozygote COX-2 breeding was 39% COX-2-/- versus 61% COX-2+/- in the last 678 mice 
bred. Genotyping protocols were thoroughly adhered to and for some experiments; sample 
tissue was saved in order to double-check the genotype of the animals in a particular study. 
Blood chemistry 
Whole blood cell counts and serum chemistries were analysed by a commercial veterinary 
diagnostics service (IDEXX Laboratories, UK) for the following parameters: number of red 
blood cells, white cells, neutrophils, lymphocytes, monocytes, eosinophils and platelets and 
haemoglobin content, haematocrit, mean corpuscular size of the red blood cells, 
concentration of haemoglobin, albumin, globulin, urea, creatinine, alanine transferase, 
alkaline phosphatase, aspartate transaminase and creatine phosphokinase.  
 
The most prominent result were that the COX-2-/- mice had microcytic anaemia (smaller red 
blood cells based on their mean corpuscular volume). This type of anaemia in patients is 
normally associated either with iron deficiency caused by poor absorption of iron from the 
diet or loss of iron via for instance intestinal blood loss from ulcers. Another example of this 
type of anaemia can occur in patients on chronic dialysis with chronic renal insufficiencies.  
 
Elevated plasma urea was a further significant difference in the COX-2-/- mice. Urea is made 
in the liver as a breakdown product of protein and is filtered and to some extent reabsorbed 
by the kidneys before the remainder is excreted in the urine. Elevated plasma urea 
concentration can be a marker of impaired kidney function but can also occur due to 
increased protein consumption and/or metabolism or due to dehydration.  
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There was also a trend for the COX-2-/- mice to have an increased number of platelets in 
their blood (WT; 1551 ± 107 x10ˆ9/L versus COX-2-/-; 2045 ± 335 x10ˆ9/L, n=6-7) although 
this did not reach statistical significance (One-Way ANOVA with Dunnett’s post-test, p<0.05 
was considered significant).   
 
Resin casts of the arterial tree in WT, COX-1-/- and COX-2-/- mice 
It is known that COX-2 immunoreactivity is expressed in highly specialised cells of the renal 
vasculature and as outlined earlier; COX-2 gene deletion results in profound renal 
remodeling and loss of kidney functions (Kömhoff et al., 2000; Morham et al., 1995; Yang et 
al., 2000). In pilot studies, performed in collaboration with Dr Antony Hunt at the 
Bioengineering department at Imperial College, I made resin casts of the arterial tree in WT, 
COX-1-/- and COX-2-/- mice (Figure 2.13A). The kidneys in the casts from the WT mice 
appeared enriched in small interlobular arteries, whereas the kidneys from the COX-2-/- 
mice (but also to a lesser extent in the COX-1-/- mice) appeared pruned in comparison 
(Figure 2.13B). This observation is in agreement with the general phenotype of the COX-2-/- 
mice with their reported renal abnormalities (Kömhoff et al., 2000; Morham et al., 1995; 
Yang et al., 2000).  
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Figure 2.13 Resin casts of the arterial tree from WT versus COX-1-/- and COX-2-/- mice 
 
Figure 2.13 Whole mouse resin casts of the arterial tree from WT versus COX-1
-/-
 and COX-2
-/-
 mice. 
Representative images from resin casts of the arterial tree in n=4 male, young adult (3 month old) WT 
(C57BL/6J, bred in-house), COX-1
-/-
 and COX-2
-/- 
mice. (A) General outline of the arterial tree in WT, COX-1
-/-
 and 
COX-2
-/-
 mice. (B) Photos of kidneys in the resin casts from the WT, COX-1
-/-
 and COX-2
-/-
 mice. In brief, mice 
were injected with 1000units/ml heparin (i.v. through the tail vein) followed by immediate CO2 asphyxiation. 
The mice were then injected with a red resin mixture through the left ventricle of the heart at a pressure of 95-
100mgHg, which was then allowed to set and left overnight. The resin cast of the arterial tree was then 
separated from the rest of the carcass by maceration/corrosion using potassium hydroxide (30% KOH).  After 3 
days maceration, the arterial cast was washed gently and allowed to dry.  
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ApoE-/- mice 
In my thesis I have used tissue from a mouse model of atherosclerosis. These models are 
not ideal since their lipid profile differs from that in man. Another short coming with mouse 
models of atherosclerosis is that despite the clear formation of atherosclerotic plaques, 
spontaneous plaque rupture (with the clinical manifestations of heart attack and stroke) 
have not been demonstrated (Daugherty, 2002).  Nevertheless, these models are useful and 
have been used by countless groups to help understand human disease.  The model I used 
in this thesis was the Apo lipoprotein deficient (ApoE-/-) mouse model of atherosclerosis and 
these mice were a gift from Professor Shu Ye at the William Harvey Research Institute. They 
were originally purchased from Jackson labs (ApoEtm1Unc strain, from a C57BL/6J 
background). The ApoE-/- mice colony was managed by one of my colleagues Dr Nicholas 
Kirkby.  
 
These mice have increased total plasma cholesterol levels (hypercholesterolemia), due to 
their deficiency in ApoE, which is essential for normal cholesterol metabolism. ApoE is 
normally present at the surface of high density lipoprotein (HDL) and very low density 
lipoprotein (VLDL) particles where it modulates interactions with low density lipoprotein 
(LDL) receptors (Daugherty, 2002). Consequently, ApoE-/- mice develop fatty streaks in the 
aortic arch at around 3 month age which progress with age. In these mice, development of 
fatty streaks is accelerated when they are fed an atherogenic high cholesterol diet. The 
lesions found in these mice are enriched with so called foam cells which are lipid laden 
macrophages, and with time the lesions progress to contain necrotic cores and fibrous caps 
(Daugherty, 2002). In addition to the ApoE disruption, other genetically dependent factors 
such as strain background influence the disease progression and ApoE-/- mice on a C57BL/6J 
background are particularly susceptible to atherosclerosis (Daugherty, 2002).  
 
In this thesis I have performed experiments in both normal chow fed ApoE-/- mice as well as 
ApoE-/- mice that have been fed an atherogenic diet, in order to consider a model of early 
atherogenesis as well as more advanced and established atherosclerosis respectively. 
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Normal chow fed ApoE-/- mice as a model of early atherogenesis  
The normal chow fed ApoE-/- mice are still reported to have markedly elevated plasma 
cholesterol (hypercholesterolemia) and have pre-atherosclerotic lesions or fatty streaks in 
their proximal aorta from 3 month of age and these lesions progress with age (even without 
an atherogenic diet) (Zhang et al., 1992). These animals also have increased markers of 
vascular inflammation with monocyte adhesion to intact endothelium in 2 month old ApoE-/- 
mice on a normal diet (Daugherty, 2002).  
 
High cholesterol chow fed ApoE-/- mice as a model of accelerated atherosclerosis  
At 12 weeks of age some of the ApoE-/- mice were put on an atherogenic high fat and high 
cholesterol diet (21% fat, 1.25% cholesterol, cholate-free; Research Diets, D12108) for 10 
weeks in order to accelerate the rate of atherosclerotic plaque formation. This diet 
dramatically increased serum cholesterol. Aortas were then stained with Sudan staining to 
confirm characteristic distribution of atherosclerotic plaques in branch points and 
curvatures in aortas from ApoE-/- mice fed an atherogenic diet (Figure 2.14). 
 
Figure 2.14 Distribution of atherosclerotic plaques in ApoE-/- mice  
 
Figure 2.14 Distribution of atherosclerotic plaques in ApoE
-/-
 mice. (A) Atherosclerotic lesions (in white, 
indicated by black arrows) in an 8 month old ApoE
-/- 
mouse fed a chow diet, showing that ApoE
-/- 
mice 
spontaneously develop plaques with time (even on a normal chow diet). 1 = greater curvature, 2 = lesser 
curvature of the mouse aortic arch. Picture from (Catanozi et al., 2009). (B) Atherosclerotic lesions in an ApoE
-/- 
mouse fed an atherogenic diet. (C) Sudan stained plaques (red) in an opened aortic arch from an ApoE
-/- 
mouse 
fed an atherogenic diet. 1 = greater curvature, 2 = lesser curvature of the mouse aortic arch. B + C 
representative pictures taken by my colleague Dr Nickolas Kirkby, of the aorta and aortic arch of one of the 
ApoE
-/-
 mice fed an atherogenic diet used in my PhD.  
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Rats 
In collaboration with Dr Alexander Lyon (Cardiologist, Imperial College), I was able to use 
tissue from male Sprague Dawley rats surgically treated to model post-infarction chronic 
heart failure (Lyon et al., 2011; Lyon et al., 2009). Our collaborator Dr Alexander Lyon 
performed the surgery, maintenance and husbandry of the rats. All animal surgical 
procedures and perioperative management were carried out in accordance with the United 
Kingdom Home Office Guide on the Operation of the Animals (Scientific Procedures) Act 
1986. 
 
Rat post-infarction chronic heart failure model 
 
In brief, male Sprague Dawley rats (250-300g, 2-3 month old) were anaesthetized and the 
left proximal coronary artery was ligated 1mm below the left atrial appendage, 
encompassing both the proximal left anterior descending artery and first diagonal coronary 
arteries, giving a large infarct size (~30% left ventricular myocardium) to induce chronic 
myocardial infarction. Animals were allowed to recover and were followed for 
approximately 4 months after the procedure, where markers of heart failure manifest.  
 The transmural infarct covered more than 30% of the left ventricular circumference 
(compared to rats with sham ligation) when examined after 4 months (Figure 2.15A) 
(Lyon et al., 2009).   
 Pressure-volume (PV) loop analysis in the left ventricle was performed after 4 
months using a microconductance catheter via an apical approach under anesthesia 
(1.5% isoflurane) and steady state data was recorded after 15 minutes stabilisation. 
PV loops from rats with chronic heart failure demonstrated increased ventricular 
volumes and increased diastolic blood pressure compared to sham controls (Figure 
2.15B) (Lyon et al., 2009).  
 Heart hypertrophy (as a marker of heart failure) was estimated by correcting heart 
weight for tibia length (heart weight (g) / Tibia length (mm), rather than body weight 
given the variety of complex and opposing changes that influence body weight in 
chronic heart failure. The heart weight/ tibia length ratio was significantly increased 
in the rats with chronic heart failure used for the experiments in this thesis, which 
validates that these rats had the characteristic heart failure hypertrophy of the 
viable left ventricle (Figure 2.15C) (Lyon et al., 2009).  
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 Contractile function was also significantly impaired in the rats with the chronic 
infarction, consistent with the chronic heart failure phenotype (Lyon et al., 2009). 
 
Figure 2.15 Markers of post-myocardial infarction induced chronic heart failure in rats 
 
Figure 2.15 Markers of post-myocardial infarction induced chronic heart failure in rats. After 4 month post 
infarction markers of heart failure manifest: (A) Midventricular sections of sham operated and a chronically 
infarcted rat heart stained with Masson’s trichrome stain. Black scale bar represent 2mm. (B) Representative 
steady state pressure-volume (PV) loops from in vivo measurements from sham operated and chronically 
infarcted rats. Arrows indicate end-diastolic blood pressure. (C) Heart hypertrophy (as a marker of chronic 
heart failure) was estimated by correcting heart weight for tibia length (heart weight (g) / Tibia length (mm)) 
from aged matched control versus rats with chronic heart failure used in the experiments presented in this 
thesis. Data (supplied by Dr Lyon) is the mean ± S.E.M. from n=5 rats (6-7 months old) and was analysed using 
paired Student’s t-test and *p<0.05 taken as significant.   
 
Aged matched controls versus sham operated controls 
In initial experiments performed by Dr Lyon, when the heart failure model was set up, sham 
operated animals were used as control, but after confirming that there were no significant 
differences between sham ligated and aged matched control rats (personal communication, 
Dr Lyon), the latter were used as controls in the experiments presented in this thesis. 
Considering that the time of sacrifice is so remote in time (at least 4 months after) from the 
infarct surgery, it is less likely for spillover of ‘operation effects’ per se on the vasculature. 
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Human pulmonary artery 
During the course of my PhD I had the opportunity to image COX-1 and COX-2 in a human 
blood vessel (pulmonary artery). Whilst this could only be done as a pilot study, I have 
included the results in my thesis in order to serve as validation for my data using rodent 
vascular tissue. The human pulmonary artery was from lungs obtained from an American 
tissue bank (International Institute for Advancement of Medicine), with confirmed consent 
from the donor) and used under appropriate ethical approval held by Professor Belvisi 
(Imperial College) which our group is also named on (ethics number 09/H0708/72). The 
donor was 67 year old Caucasian female with 49 pack year smoking history (1 pack a day for 
49 years) and a known medical history of chronic obstructive pulmonary disease (COPD), 
essential hypertension and diabetes mellitus. Cause of death was spontaneous intracerebral 
haemorrhage. Brain stem death was declared at 6pm 15th March 2011 (US Mountain Time 
Zone, MT). Patient was maintained on artificial ventilation with her heart beating 
spontaneously until cross-clamp and lung removal the next evening (11pm, 16th March 
2011). Time from cross-clamp to dissection in our lab (cold ischemia time) was 
approximately 36 hours. 
 
After transport to the UK, the lungs arrived in our lab on the 18th of March. The aortic arch 
and the pulmonary artery was dissected and placed in 2% formaldehyde for 20 minutes (in 
room temperature) before it was moved to a vial with phosphate buffered saline (PBS). The 
aortic arch was cut open and pinned out on wax in order to take photos of the intima 
(Figure 6.1 in the General Discussion Chapter 6). Whereas the pulmonary artery was cleared 
of fat and connective tissue and cut into small ~1-2mm rings and placed in a well with 200μl 
of PBS in a 96-well plate for incubations with reagents and antibodies (Figure 2.18). 
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Experimental models 
En face confocal imaging of the endothelium in the mouse aortic arch model 
En face confocal imaging of the mouse aortic arch was adapted from previously published 
techniques (Hajra et al., 2000; Iiyama et al., 1999; Zakkar et al., 2008; Zakkar et al., 2009). 
This model was developed following the observation that atherosclerotic plaques formed in 
defined regions of the aortic arch in LDL receptor knockout mice (LDLR-/- mice) fed a high 
cholesterol diet. It was shown, that the aortic arch provided a robust model encompassing 
both a low probability region for lesion development (greater curvature) and a high 
probability region for atherosclerotic plaque formation (lesser curvature) (Figure 2.16) 
(Iiyama et al., 1999).  
 
Figure 2.16 Mapping the mouse aortic arch for high and low probability regions of 
atherosclerosis development  
 
Figure 2.16 Mapping the mouse aortic arch for high and low probability regions of atherosclerosis 
development. (A) A schematic of the proximal ascending aortic arch with marked dissection points A+B 
indicate aortic valves C is the cut of point after brachiocephalic artery branch. (B) The mouse aortic arch shown 
opened (flattened) with A+B+C as anatomical landmarks. LP = the Low Probability region, where lipid content 
(visualised using oil red O stain) was absent (0%) indicating that this area was clear of atherosclerotic plaques, 
in n=8 LDLR
-/-
 mice fed a semi purified high cholesterol diet for 4 weeks (the same was true after 20 weeks). HP 
= the High Probability region, where oil red O stain was abundant (100%) indicating that this area had 
atherosclerotic plaques, in n=8 LDLR
-/-
 mice fed a semi purified high cholesterol diet for 4 weeks. (C) Map % of 
mice with oil red o stain in the aortic arch. HP is shown in black where 100% (8 out of 8) LDLR
-/-
 mice had oil red 
o stain and LP shown in white where 0% (0 out of 8) LDLR
-/- 
mice had oil red o stain. Figure modified from 
(Iiyama et al., 1999).  
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Hajra et al also reported that the endothelium lining the lesser curvature of the aortic arch 
was ‘primed for activation’ with elevated levels of nuclear NF-κB and cell adhesion 
molecules (Hajra et al., 2000). As introduced in Chapter 1, hemodynamic shear stress 
profiles affect the endothelial cell morphology and susceptibility to inflammation and 
atherosclerosis in curvatures and branch points of the vasculature. In general terms, the 
laminar, unidirectional and high shear stress experienced by the endothelium in the greater 
curvature typically corresponds to a ‘resting’ endothelial phenotype which is similar to other 
straight segments of the vasculature such as the descending aorta and/or the thoracic aorta.      
 
The two regions of high versus low susceptibility of atherosclerosis in the aortic arch have a 
somewhat confusing and inconsistently used, but still interchangeable nomenclature. 
Therefore, in order to help clarify the terminology used to refer to different regions of the 
aortic arch throughout the thesis; please see table 2.17. I will refer to the two regions as the 
greater and the lesser curvature of the aortic arch.  
 
Table 2.17 Interchangeable terms to describe the greater and the lesser curvature of the 
mouse aortic arch 
Commonly used descriptors for the 
‘greater curvature’ of the aortic arch 
Commonly used descriptors for the 
‘lesser curvature’ of the arch 
References 
 Greater curvature 
 Outer curvature 
 Low probability region (LP) 
 Athero-resistant region 
 Athero-protected region 
 Protected region 
 Lesser curvature 
 Inner curvature 
 High probability region (HP) 
 Athero-prone region 
 Athero-susceptible region 
 Susceptible region 
 (Iiyama et al., 1999) 
 (Davies, 2009) 
 (Hajra et al., 2000) 
 (Kinderlerer et al., 2008) 
 (Warboys et al., 2011) 
 (Zakkar et al., 2009) 
Figure 2.17 Interchangeable terms to describe the greater and the lesser curvature of the mouse aortic arch.  
 
General outline of procedure for the mouse aortic arch 
In this thesis, mice were either left untreated or injected i.p. with 4mg/kg LPS for 4 hours, 
(serotype 0111:B4, L4391, Sigma) or 4mg/kg or 10mg/kg LPS for 30 minutes or 4.5 hours 
(serotype, 055:B5, L16529, Sigma), see individual figure legends, before CO2 asphyxiation. 
The thoracic cavity was opened up and the aortic arch was then immediately subject to 
either systemic transcardial perfusion fixation or ex vivo semi perfusion fixation as described 
below. 
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Systemic transcardial perfusion fixation procedure 
Following CO2 asphyxiation, the thoracic cavity was immediately opened up and a needle 
(connected to a 20 ml syringe) was inserted through the left ventricle of the heart and the 
mouse was systemically perfused with 20ml of phosphate buffered saline (PBS, Sigma 
D8537) (at room temperature) to flush out all the blood from the aortic arch. Subsequently, 
the perfusion procedure was repeated with 20ml of 2% formaldehyde (histological fixative 
from 10% buffered formalin solution that naturally contain ~4% formaldehyde, diluted 1:2 
with PBS to create a ~2% solution, Sigma HT501320) to cross link (fix) the proteins in the 
tissue and thereby stop decay and autolysis. Formaldehyde fixation is based on crosslinking 
the aldehydes and the proteins creating a gel that should retain the cellular constituents 
and in vivo appearance for accurate histopathologic evaluation.  
 
The manual systemic perfusion was always performed using the same syringe and needle 
size and at a ‘manually sustained’ constant pressure, for around 20 seconds per syringe (20 
seconds PBS perfusion and 20 seconds formaldehyde perfusion). After ~ 5 minutes of 
fixation (at room temperature), the heart (including the aortic arch and the thymus 
protecting the arch), was dissected off in one piece, by holding the trachea and cutting 
along the back bone of the chest, avoiding stretching of the aortic arch and put into a vial 
with PBS. The proximal aortic arch was then carefully dissected off the heart/thymus 
complex at the start of the aortic root and carefully cleared off connective tissue, before 
transferring the arch as an intact tube to a well with 200μl PBS in a 96-well plate for 
incubations with reagents and antibodies (Table 2.18-2.20).  
 
Ex vivo semi-perfusion fixation procedure 
When the experiment was part of an animal share that did not allow for systemic 
transcardial perfusion fixation, the ex vivo semi-perfusion fixation procedure was performed 
as outlined. Following CO2 asphyxiation, and shortly after death, the heart (including aortic 
arch and thymus) was quickly dissected out and flushed through with 2% formaldehyde 
using a needle inserted through the heart and placed in a vial with 2% formaldehyde for 10 
minutes, then put into a vial with PBS (at room temperature). The proximal aortic arch was 
then cut from the heart (by the start of the aortic root) and carefully cleared off connective 
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tissue, before transferring the arch as an intact tube to a well with 200μl PBS in a 96-well 
plate for incubations with reagents and antibodies (Table 2.18-2.20).  
 
It is important to note that no discernible difference was seen in endothelial or other cell 
morphology in the aortic arch of mice prepared by either fixation procedure. Nevertheless 
the nature of the fixation procedure used (systemic transcardial perfusion versus ex vivo 
semi-perfusion) in each data set is given in the methods section of individual results 
chapters as well as indicated in the figure legends.  
 
General outline of staining protocol 
1. Joint permeabilisation and blocking step (0.1-0.5% Triton X and 20% normal goat 
serum in PBS) in room temperature (RT) for a few hours or overnight (O/N). 
2. 2-3, 5 minutes washes with 200μl of PBS. (Carefully avoiding contact of the tissue 
with the pipette tip, which can damage the tissue) 
3. Primary antibody incubation step (shorter incubations were made in PBS at RT and 
longer incubations were made in the fridge (4°C) O/N or for ~24 hours). 
4. 2-3, 5 minutes washes with 200μl of PBS. 
5. Secondary antibody raised against the species that the primary antibody was raised 
in and conjugated to an Alexa Fluor 568 or 594 fluorophore (this was always a much 
shorter step than the primary, around 2hours RT in PBS) During this step and 
onwards, the 96’ well plate was kept in the dark (covered in tinfoil or kept in a 
cupboard) since fluorophores are light sensitive. 
6. 2-3, 5 minutes washes with 200μl of PBS. 
7. Primary antibody against the endothelial cell marker CD31, directly conjugated to 
Alexa Fluor 488. Incubated for a few hours RT or O/N or 24-48hours in the fridge. 
8. 2-3, 5 minutes washes with 200μl of PBS. 
9. 4’, 6’-diamidino-2-phenylindole (DAPI) nuclear stain (5 minutes incubation in RT in 
distilled water (dH20) since it falls out of solution in PBS). 
10. 2-3, 5 minutes washes with 200μl of (dH20). 
Once a staining protocol proved successful (according to positive and negative controls in 
the pilot study), the protocol was strictly adhered to for the remaining duration of the study.  
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Table 2.18 Immunohistochemistry protocols for COX immunoreactivity 
Protocol                                               
Permeabilisation and blocking:                                      
PBS with (0.5% or 0.1% Triton X and 20% 
normal goat serum)                           
Mouse tissue: 0.5% Triton X                               
Rat and human tissue: 0.1% Triton X 
Incubation                                  
Mouse Tissue: (O/N in RT)                             
Rat tissue: (2h RT)                                          
Human tissue: (O/N in RT) 
Reagents                                                     
PBS (Sigma, D8537x6)                               
Triton X-100, (Sigma T8787)                     
Normal goat serum (Santa Cruz, SC-2043 
or Vector labs S-1000)  
COX-1 and 2 blocking peptide                  
Mouse tissue: 1:50 dilution in PBS                  
Rat tissue: 1:200 dilution in PBS 
Human Tissue: 1:250 dilution in PBS                                                                       
                                                          
Incubate blocking peptide and 
primary antibody 1:1 for 1h RT,  
add mix to the designated wells for 
incubation as primary 
Blocking peptides: from Cayman                       
to block antibody/protein complex                                   
COX-2 murine block (360106)                   
COX-1 murine block (360109)                               
COX-1 ovine+ human block (360108)  
Primary antibody staining:                    
Mouse tissue: 1:50 dilution in PBS                  
Rat tissue: 1:200 dilution in PBS 
Human Tissue: 1:250 dilution in PBS                               
Mouse tissue:                                    
(160109, 160126) 4h RT                     
Rat Tissue:                                            
(160109, 160126) 2h RT                                               
Human Tissue:                                    
(160108 and 160126) O/N 4°C 
Polyclonal antibodies:                                       
raised in rabbit from Cayman:                                         
COX-1 anti-mouse and rat (160109)                                               
COX-1 anti-ovine + human (160108)                                 
COX-2 rabbit anti-mouse, rat, and 
human (160126) 
Secondary antibody staining:                     
Mouse tissue: 1:100 dilution in PBS                 
Rat tissue: 1:100 dilution in PBS               
Human tissue: 1:500 dilution in PBS 
                                                            
Mouse tissue (2h) RT                           
Rat Tissue (1h RT)                        
Human Tissue (2h RT) 
Secondary antibody:                            
Invitrogen Alexa Fluor 594 conjugated 
goat anti-rabbit (A-11012) 
CD31 primary antibody staining:   
Mouse Tissue (1:100 in PBS) 
Rat tissue (no CD31 step) 
Human tissue (1:50 in PBS) 
 
                                                               
Mouse tissue (O/N at 4°C) 
Rat Tissue (no CD31 step) 
Human Tissue                                
(O/N 4°C with primary step) 
CD31 primary antibody:                                       
Mouse tissue: Alexa Fluor 488 
conjugated anti-mouse CD31 
(Biolegend,102514)                                               
Human tissue: Alexa Fluor 488 
conjugated murine anti-human CD31 
(AbD Serotec MCA1738F)  
DAPI nuclear stain                            
25μg/ml in dH20 
Mouse + rat tissue: 5 min RT                       
Human Tissue: 15 min RT 
DAPI from Invitrogen (DI106) 
Mounting                                                             
One drop during mounting, top up with 
more before glass slide, mount and coat 
edges with nail varnish 
                                                                      
O/N RT under ~7lb pressure               
(3 boxes of gloves) 
Hardset mounting medium                      
(Vector Labs, Vectashield H-1400)                            
Cover slips, electrostatic (SC-24976) 
Glass slides, electrostatic (SC-24975) 
Table 2.18 Immunohistochemistry protocols for COX immunoreactivity.  
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Table 2.19 Immunohistochemistry protocol for NF-κB immunoreactivity in mice 
Protocol                                               
Permeabilisation and blocking:                                      
PBS with (0.5% Triton X and                            
20% normal goat serum)                           
Incubation                                               
O/N in RT                             
Reagents                                                     
PBS (Sigma, D8537x6)                               
Triton X-100, (Sigma T8787)                   
Normal goat serum                                     
(Santa Cruz, SC-2043) 
Primary antibody staining:                    
1:500 dilution in PBS               
                                                             
24h at 4°C 
Polyclonal antibody:                                       
anti-p65/NF-κB antibody raised in rabbit  
(Santa Cruz, SC-372)                                     
Secondary antibody staining:                     
1:1000 dilution in PBS               
                                                            
2h RT                           
Secondary antibody:                            
Alexa Fluor 568 conjugated goat anti-
rabbit (Invitrogen, A11026) 
CD31 primary antibody staining:                
1:100 in PBS 
                                                               
Mouse tissue (O/N at 4°C) 
CD31 primary antibody:                                       
Alexa Fluor 488 conjugated anti-mouse 
CD31 (Biolegend,102514)                                                
DAPI nuclear stain                            
25μg/ml in dH20 
                                                                                           
5 min RT  
DAPI from Invitrogen (DI106)
Mounting                                                             
One drop during mounting, top up with 
more before glass slide, mount and coat 
edges with nail varnish 
                                                                      
O/N RT under ~7lb pressure               
(3 boxes of gloves) 
Hardset mounting medium                      
(Vector Labs, Vectashield H-1400)                            
Cover slips, electrostatic (SC-24976) 
Glass slides, electrostatic (SC-24975) 
Table 2.19 Immunohistochemistry protocols for NF-κB immunoreactivity in mice.  
Chapter 2 General Methods 
108 
 
Table 2.20 Immunohistochemistry protocol for CD41 immunoreactivity in mice 
Protocol                                                         
Permeabilisation and blocking:                                      
PBS with (0.1% Triton X and                            
20% normal goat serum)                           
Incubation                                               
2h RT                             
Reagents                                                                    
PBS (Sigma, D8537x6)                               
Triton X-100, (Sigma T8787)                 
Normal goat serum (Vector labs S-1000) 
Primary antibody staining:                    
1:50 dilution in PBS               
                                                             
O/N at 4°C 
Polyclonal antibody:                                       
rat anti-mouse (AbD serotec, MCA2245GA)                                     
Secondary antibody staining:                     
1:200 dilution in PBS               
                                                            
2h RT                           
Secondary antibody:                                         
Alexa Fluor 594 conjugated goat anti-rat 
(Invitrogen, A-11007) 
CD31 primary antibody staining:                
1:100 in PBS 
2h RT CD31 primary antibody:                                       
Alexa Fluor 488 conjugated rat anti-mouse 
CD31 (Biolegend,102514)                                                
DAPI nuclear stain                            
25μg/ml in dH20 
                                                                                           
5 min RT  
 DAPI from Invitrogen (DI106) 
Mounting                                                             
One drop during mounting, top up with 
more before glass slide, mount and coat 
edges with nail varnish 
                                                                      
2h RT under ~7lb pressure               
(3 boxes of gloves) 
Aortic arches: Hardset mounting medium 
(Vector Labs, H-1400)                                            
Blood smears: Aqueous mounting medium 
(Vector labs, Vectashield H-1000)                                       
Cover slips, electrostatic (SC-24976) Glass 
slides, electrostatic (SC-24975) 
Table 2.20 Immunohistochemistry protocols for CD41 immunoreactivity in mice.  
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Mounting of aortic tissue  
After the designated incubation time with antibodies (Table 2.18, 2.19 and 2.20) the mouse, 
rat or human tissue was mounted on a coverslip slide with a drop of hard set mounting 
medium and was subject to the following mounting procedure. The slide was visualised 
under a light dissection microscope and the mouse aortic arch was cut just before the 
brachiocephalic artery and cut open along the greater curvature, then carefully flipped over 
with the luminal surface facing down against the coverslip glass (Figure 2.21). The flipping 
and flattening procedure can cause a lot of damage to the endothelium, but trial and error 
showed that cutting the arch at an angle from the lesser curvature to the greater curvature, 
gives a more stable, butterfly-like shape that is less likely to curl up once mounted (Figure 
2.21).  
 
More mounting medium was then added to ensure even spread without air bubbles and a 
cover glass slide with clear nail varnish coated sides was slowly folded on top of the 
coverslip with the tissue, allowing the mounting medium to spread evenly. The labelled slide 
was then placed under 3 boxes of gloves (~7lb) and left at RT O/N to ensure that the tissues 
were sufficiently flattened.  
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Figure 2.21 Photos and schematics illustrating enface mounting of the mouse aortic arch 
 
Figure 2.21 Photos and schematics illustrating enface mounting of the mouse aortic arch. (A) Picture of the 
proximal ascending aortic arch from a wild type (C57BL/6J) mouse. Red dotted line indicates cutting points 
along the greater curvature (1) and at an angle from the lesser curvature (2) to the greater curvature (1) of the 
aortic arch. (B) Drawing showing the butterfly shaped aortic arch once cut open and flattened. (C) Schematic of 
a flattened aortic arch on a glass slide, where the luminal surface (aortic arch endothelium) is towards the 
lower glass slide. The coverslip was always mounted (with clear nail varnish) close to the title of the slide to 
ensure that the slide would lay flat on top of the inverted Leica confocal microscope stage. In the confocal 
imaging, there is a 90° shift to the right of the actual orientation of the aortic arch on the glass slide (D) to (E).     
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Confocal microscopy  
Confocal microscopy; defined as ‘having the same focus’, means that the final image has the 
same focus as the point of focus in the specimen. The main advantage of confocal 
microscopy (developed by Marvin Minsky in the 1950’s), compared to conventional wide-
field fluorescence microscopy is that out-of-focus signal can be eliminated by the use of 
point illumination and a confocal pinhole in front of the microscope photo-detector or 
camera.  
 
A conventional microscope is limited by how deep into the tissue that the light source can 
penetrate, whereas confocal microscopy has an increased optical resolution, which permits 
imaging one layer of tissue (depth) at a time. Due to the confocal pinhole (which only allows 
entry of in-focus signal), the overall brightness (amount of light) coming from the specimen 
is greatly reduced. To compensate for this, powerful lasers are used (instead of conventional 
mercury lamps) to produce very bright light at a particular wavelength to excite the 
fluorophore stained specimen. The fluorescent signal emitted from the specimen is then 
detected by a highly sensitive photo-multiplier detector (PMT) (set at a specified 
wavelength range) to detect the reduced (but in-focus) signal through the pinhole. Another 
feature of the confocal microscope is images showing co-localisation of different 
fluorophores (collected from different PMT channels).  
 
In my thesis, I have used a Leica SP5 inverted confocal microscope, located at the Imperial 
Facility for Imaging by Light Microscopy (FILM) facility in Sir Alexander Fleming Building at 
the South Kensington campus. This microscope is equipped with a diode laser for excitation 
at 405nm (and a UV light for visualisation in the microscope eye piece), an argon laser for 
excitation at 488nm and a helium neon laser for excitation at 543 nm.  
 
Confocal settings 
Once the confocal settings had been optimised for the fluorescently labelled primary 
antibody of interest (during the pilot run of each study), they were kept identical and strictly 
adhered to for the remainder of the study so that fluorescence levels could be compared 
between experimental runs. This is imperative since, as shown in Figure 2.23, changes in 
settings such as the gain can greatly alter fluorescence values.  
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Since relative COX-1 and COX-2 immunoreactivity was compared head to head, in the same 
experiments, on the same experimental runs, their experimental procedure (including 
staining protocols) and confocal settings were kept the same, so that levels of 
immunoreactivity from the two isoforms could be compared relative to one another.  
 
All the confocal images presented in this thesis were taken using an oil based 40x1.25 
objective (giving a field of view of 387.5x387.5µm) and these following settings were also 
kept the same: argon laser was set at 15% under the configurations tab, pinhole was set at 1 
(airy unit, AU equivalent of 67.9μm) for all channels and the line frequency was kept at 400 
Hz (higher value means higher time resolution). Invitrogen spectra viewer was used to 
decide on suitable spectra wavelengths to detect nuclear stain DAPI, endothelial marker 
CD31 (directly conjugated to Alexa Fluor 488) and Alexa Fluor 594 or 568 conjugated protein 
of interest (Figure 2.22).  
 
Figure 2.22 Invitrogen spectra viewer showing fluorophore emission wavelengths for DAPI, 
Alexa Fluor 488 and Alexa Fluor 594/568 
 
Figure 2.22 Invitrogen spectra viewer showing fluorophore emission wavelengths for DAPI, Alexa Fluor 488 
and Alexa Fluor 594/568. Fluorophore emission for DAPI (blue), CD31 as Alexa Fluor 488 (green) and Alexa 
Fluor conjugated to primary antibody of interest (red) for (A) Alexa Fluor 594 and (B) Alexa Fluor 568.  
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The gain (brightness enhancement) setting was optimised for each fluorophore channel 
with the aim to avoid saturation, but to be far above the ‘zero’ level. The zero level was 
adjusted by the offset (amount of dark background) to ensure that all labeled tissue was 
detectable. The positive control (the sample expected to be the brightest) was imaged first 
to estimate a gain level with a clear positive signal, yet below saturation. Then the 
secondary control (background, expected to be the darkest) slide was imaged to see how 
the gain setting chosen for the positive control fits with the background level of signal, with 
the overall aim to choose a gain setting which covers a wide range between 0 and 100% 
signal (Figure 2.23).     
 
Figure 2.23 Effects on the different gain settings on the mean fluorescence (signal)  
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Figure 2.23 Effects on the different gain settings on the mean fluorescence (signal). (A) Representative 
images of COX-1 immunoreactivity and background (secondary control) below, at 800, 850 and 900 Gain (G). 
(B) Quantified mean fluorescence at 800, 850 and 900Gain for COX-1 (positive signal) and background n=1.    
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Specific confocal settings for each experiment are indicated in table 2.24.  
 
Table 2.24 Confocal settings 
Study Lasers Format 
Chapter 3 (3month old)                 
Male WT mice                                
Endothelial morphology  study 
 
DAPI:  50% UV 405 laser                     
Detection (420-480nm)                   
CD31: 30% Argon 488 laser                 
Detection: (500-550nm)                   
Image Size: 203.95x203.95μm 
2048x2048 pixels                                            
1.9 zoom, Line average 2                                                                                                                 
DAPI (PMT1) channel:                             
Gain: 550 Offset: -2%                             
CD31 (PMT2) channel:                         
Gain: 880 Offset: -2%                  
Chapter 3 (3month old)                
Male WT mice                                       
Chapter 4 (3month old)  
Female mice,                            
Chapter 4 (12month old)                
Male WT mice                                                                        
COX-1/COX-2 
immunoreactivity studies 
DAPI:  15% UV 405 laser                     
Detection (405-458nm)                   
CD31: 15% Argon 488 laser                 
Detection: (493-544nm)                  
COX-1/COX-2 (Alexa Fluor 594): 
50% Helium Neon 543 laser             
Detection: (590-700nm) 
Size: 387.5x387.5μm 2048x2048 pixels                                           
No zoom, Line accumulation 4                                              
COX-1/COX-2 (PMT4) channel:                          
Gain: 780  Offset: -0.6%                                                          
DAPI/CD31 (PMT1 and2) channels:              
Gain and offset settings varied since 
these channels were not quantified and 
could therefore be adjusted if needed 
Chapter 3 (3month old) mice                    
WT, COX-1
-/- 
,COX-2
-/- 
mice              
Chapter 4 (12month old) mice      
WT, COX-1
-/- 
,COX-2
-/- 
mice   
COX-1/COX-2 
Immunoreactivity and 
blocking peptides studies              
DAPI:  50% UV 405 laser                     
Detection (420-480nm)                   
CD31: 30% Argon 488 laser                 
Detection: (500-550nm)                  
COX-1/COX-2 (Alexa Fluor 594): 
50% Helium Neon 543 laser             
Detection: (590-700nm) 
Size: 387.5x387.5μm 1024x1024 pixels                                              
No zoom, Frame average 2 or 3                                                                                                                                                      
COX-1/COX-2 (PMT4) channel:                          
Chapter 4: Gain: 700 Offset: -1.1%      
Chapter 3: Gain: 850 Offset: -1.1%                   
Frame average 3                                                                                          
DAPI/CD31 (PMT1 and2) channels:              
Gain and offset settings varied 
Chapter 3 Human tissue               
COX-1/COX-2 
immunoreactivity study 
 
DAPI:  50% UV 405 laser                     
Detection (420-480nm)                   
CD31: 30% Argon 488 laser                 
Detection: (500-550nm)                  
COX-1/COX-2 (Alexa Fluor 594): 
50% Helium Neon 543 laser             
Detection: (590-700nm) 
Size: 387.5x387.5μm 1024x1024 pixels                                               
No zoom, Line average 2                                                                                                                 
COX-1/COX-2 (PMT4) channel:                          
Gain: 850 Offset: -1.0%                                                                                                  
DAPI/CD31 (PMT1 and2) channels:              
Gain and offset settings varied 
Table 2.24 Confocal settings (continues on the next page).  
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Table 2.24 (continued) Confocal settings 
Study Lasers Format 
Chapter 4 Rat tissue                                        
Heart failure study in rat             
COX-1/COX-2 
immunoreactivity study 
DAPI: 50% UV 405 laser                     
Detection (420-480nm)                   
COX-1/COX-2 (Alexa Fluor 594): 
50% Helium Neon 543 laser             
Detection: (590-700nm) 
Image size: 387.5x387.5μm            
1024x1024 pixels                                            
No zoom, Frame average 2                                                                                                            
COX-1/COX-2 (PMT4) channel:                          
Gain: 900, Offset: -1.0%                                                   
DAPI (PMT1) channel:                                          
Gain and offset settings varied 
Chapter 4 ApoE
-/-
 mice                                       
Lipid fed and normal chow fed             
COX-1/COX-2 
immunoreactivity study 
DAPI: 50% UV 405 laser                     
Detection (420-480nm)                   
COX-1/COX-2 (Alexa Fluor 594): 
50% Helium Neon 543 laser             
Detection: (590-700nm) 
Size: 387.5x387.5μm 1024x1024 pixels              
No zoom, Frame average 2                                                                                                            
COX-1/COX-2 (PMT4) channel:                          
Gain: 850, Offset: -1.0%                                                   
DAPI (PMT1) channel:                                          
Gain and offset settings varied 
Chapter 5 (3month old)  mice                 
WT, COX-1
-/-
, COX-2
-/-
 mice              
NF-κB immunoreactivity study 
DAPI:  15% UV 405 laser                     
Detection (405-458nm)                   
CD31: 15% Argon 488 laser                 
Detection: (493-544nm)                       
NF-κB/p65  (Alexa Fluor 568): 
50% Helium Neon 543 laser             
Detection: (585-680nm) 
Size: 387.5x387.5μm 1024x1024 pixels              
No zoom, Line accumulation 8                                                                                                                 
NF-κB/p65 (PMT4) channel:                          
Gain: 900 Offset: -0.6%                                                                                                  
DAPI/CD31 (PMT1 and2) channels:              
Gain and offset settings varied 
Chapter 5 (3month old) mice               
WT, COX-1
-/-
, COX-2
-/-
 and 
normal chow fed                 
ApoE
-/-
 mice                                     
CD41 positive platelets study                                          
Endothelial morphology study 
(DAPI/CD31 settings constant)  
DAPI:  50% UV 405 laser                     
Detection (420-480nm)                   
CD31: 30% Argon 488 laser                 
Detection: (500-550nm)                  
CD41  (Alexa Fluor 594):                    
50% Helium Neon 543 laser             
Detection: (585-680nm) 
Size: 387.5x387.5μm 2048x2048 pixels              
No zoom, Line average 2                                                                                                                 
CD41 (PMT4) channel:                          
Gain: 700 Offset: -1.0%                                                                                                  
DAPI (PMT1) channel:                             
Gain: 550 Offset: -2%                             
CD31 (PMT2) channel:                         
Gain: 880 Offset: -2%                  
Table 2.24 Confocal settings.  
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Confocal settings during z-profiling  
Z-profiles were created by changing the confocal mode from XYZ to XZY setting to enable z-
profiling through the entire depth of the tissue (at 7.8 zoom), 50x50μm image size and with 
a line average 8 to (sharpen the image to make up for a more blurry optical resolution in the 
XZY than in XYZ mode). 
 
Confocal settings during ‘tiling’ 
Tile composite of 4x4 pictures was created using the automated tile function in the Leica 
application suite (LAS) confocal program with the same confocal settings as the study the 
tile was made in (i.e. study of COX-1/COX-2 immunoreactivity in 3 month old and 12 month 
old mice, Chapter 3 and 4), but with a lower pixel quality (512x512 pixels).  
 
Image selection 
As described below, images were selected blinded from target protein by observing only 
DAPI and CD31 staining down the eyepiece of the confocal microscope, with the red 
channel showing (COX-1, COX-2, DC41 or NF-κB) immunoreactivity switched off. 2-3 images 
were taken from separate areas from each region (greater and lesser curvature) of each 
slide/aortic arch. The area was selected based on anatomy (greater curvature on the edge 
and lesser curvature running along the middle section of the tissue) and using the 
characteristic differences in endothelial cell morphology, with nuclear density being the 
most striking one, as a guild.  
 
As described fully in Chapter 3, the endothelial nuclei in the greater curvature are more 
evenly spaced out compared to the more crammed in and randomly orientated and often 
overlapping endothelial nuclei in the lesser curvature. Clear differences in endothelial cell 
alignment (best visible by CD31 immunoreactivity) can also easily be distinguished between 
the two regions. CD31 was also important as a marker of intact endothelium as damage 
(inflicted during the mounting process). Therefore, when selecting areas to image, areas 
with clear (experimental handling inflicted) damage were avoided and an area with flat, 
intact endothelium was imaged (where possible). Thus, the captured image was selected 
based on endothelial integrity visualised under the blue (DAPI) and green (CD31) channels 
on the microscope (not the red channel showing protein of interest). The red channel with 
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the relevant red staining (i.e. COX, NF-κB or CD41) was not seen until the area to image had 
been chosen (based on endothelial integrity/morphology as defined above) and the picture 
was captured, for the first time showing the red channel on the screen.  
 
The aim with this procedure was to avoid bias in image selection. Furthermore, the tiling 
procedure also ensured that when a large area was captured (by an automated tiling 
function on the mobile microscope stage) it was confirmed that the individual images 
displayed a fair representation of results in the whole tissue.   
 
General quantification procedure 
Since the aim was to image the aortic arch (which is a curved tube structure that has been 
forced flat), the endothelium was not always flat in the full view of the image 
(387.5x387.5µm), resulting in some images with roughly half of the area in focus with the 
other half out of focus. In order to avoid out of focus artefacts during the quantification 
process, a Region Of Interest (ROI) box of ~ half the total image area was manually moved to 
the area in focus using Leica Application Suite Advanced Fluorescence Lite software program 
(LAS AF, no licence, Leica Microsystems). During this image handling process, the red PMT4 
channel with the protein of interest (i.e. COX-1 or COX-2 or NF-κB or CD41) was switched off 
from view to avoid bias and to allow the ROI to be selected only based on the area being in 
focus with clear DAPI in blue and CD31 endothelial outline in green, and the mean 
fluorescence immunoreactivity from this particular area was noted down (Figure 2.25). The 
mean fluorescence was quantified for each image, which represents the total fluorescence 
divided by the area (either the total area or the area selected for analysis by an ROI box). 
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Figure 2.25 Examples of selecting an area in focus for quantification 
 
Figure 2.25 Examples of selecting an area in focus for quantification. Half the area of the picture was selected 
for quantification (of red) based on blue and green in focus, using a region of interest (ROI) box (in green).  
Original picture size: 2048x2048 pixels (4194304 pixels) (387.5x387.5µm) Green region of interest (ROI) box 
picture size:  2068892 pixels (193µm by 378µm). The red immunoreactivity in this selected area was quantified 
as mean fluorescence. (A) Representative image where almost the full image is in focus. The green box was 
placed in an area with intact endothelium in focus. (B) One of the worst examples of an image where almost 
half of the image is completely out of focus (which would negatively and inaccurately affect the mean 
fluorescence). The green ROI box was moved to the endothelial area in focus for quantification.   
 
Subtraction of secondary control (background) mean fluorescence 
The average background mean fluorescence from each area of the ‘secondary control slide’ 
(tissue stained only with secondary control antibodies) was subtracted from each image 
before the data was presented in graphs. It was established early in my PhD that there was 
no discernable difference in secondary control fluorescence values obtained from either 
region of the arch or indeed from adjacent tissue of the descending aorta. Thus, as my 
studies progressed I used aortic arch or descending aorta interchangeably as tissue for 
secondary control baseline data. The secondary control background immunoreactivity was 
in general very low and diffuse/ non-specific looking. 
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Data analysis- definition of n-values for the aortic arch imaging studies 
Within the mouse aortic arch definable morphology for the lesser and greater curvature 
regions allows for multiple sampling from the same animal. Thus, n-values were defined (in 
the first instance) as separate sections/images of a particular region of the arch with n=2-3 
data points being gathered from arches of each mouse and with tissue from at least 4 
separate animals used for each study. In the pilot study using human tissue, 3 separate 
images were taken from segments of pulmonary artery from 1 human. In the imaging 
studies of the rat tissue, the endothelial cell morphology was more homogenous (due to the 
straighter and more uniform sections) and therefore, n-values were defined as data from 
individual animals where values of 2-3 images per animal were averaged.  
 
Quantification of NF-κB immunoreactivity in endothelium of aortic arches from WT, COX-1-/- 
and COX-2-/- mice 
In order to calculate ‘non-specific binding’ of the secondary antibody and resultant non-NF-
κB associated immunofluorescence, control incubations were performed, using descending 
aorta from WT mice. Non-specific binding was found to be very low and did not vary much 
between experiments, nor did it differ significantly in tissue from WT and COX-1-/- or COX-2-/- 
mice. Specific NF-κB immunoreactivity was calculated after the values for non-specific 
binding were subtracted. It should be noted that, due to a technical error, accurate 
secondary antibody staining data could not be achieved for one of my experimental runs in 
this study.  
 
For this experiment, background values were assumed from the mean of the full data set 
(the other experimental runs). Importantly, inclusion of this data set was not critical to the 
conclusions of the study.  
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Endothelial NF-κB immunoreactivity was objectively analysed using Velocity 5 (licensed 
imaging software) in the following way: 
 
1) Total levels of NF-κB immunoreactivity; total NF-κB fluorescence minus the total 
fluorescence in the secondary control (non-specific binding) of the cropped areas. 
2) Nuclear NF-κB immunoreactivity; nuclear bodies, imaged as ‘independent’ DAPI 
positive objects were quantified in the same cropped images (225x225µm). At least 
50 separate nuclei were analyzed from each image. Using Velocity 5 software the 
amount of nuclear NF-κB immunoreactivity, captured as ‘red’ co-localized with ‘blue’ 
within the selected nuclei, was calculated. An average amount of NF-κB 
immunoreactivity per nuclei imaged was then calculated for each image and referred 
to as ‘Nuclear NF-κB immunoreactivity (average nuclear fluorescence)’.  
 
Quantification of non-nucleated CD41 positive platelet-like bodies in the mouse aortic arch- 
manual blind scoring procedure 
CD41 was used as a platelet marker to stain platelets adhered to the endothelium in aortic 
arches from WT, COX-1-/- , COX-2-/- and ApoE-/- mice. 2 images (387.5x387.5µm) were taken 
from each area (greater and lesser curvature), from each aortic arch. Unlike CD31, CD41 is 
only expressed on platelets, (not the endothelium or other nucleated cells), hence clear and 
distinct platelet-like bodies could be identified using CD41 as a marker and were easily 
quantified by blind manual scoring. In order to fully validate the blind scoring approach, all 
images were scored by me and my colleague, Ms Claire Potter, and the two sets of results 
from our manual blind scoring were averaged.  
 
Images were manipulated using the LAS AF software program to zoom in the full sized 
(387.5x387.5µm) images (with all of the channels zoomed in simultaneously), to identify 
DAPI negative, CD31 positive, CD41 positive distinct platelet-like bodies.  
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Quantification of non-nucleated CD41 positive platelet-like bodies in the mouse aortic arch- 
automated quantification using Image J 
The quantification of the CD41 positive platelets were then repeated by a more automated 
method using Image J software. Before analysis, the scale was set to 5.283 pixels/μm. Full 
sized images (387.5x387.5µm) were thresholded using the ‘intermodes function’ and 
adjusted to around 70 (out of 255) on the thresholding scale of brightness and saturation. 
This was manually adjusted for each image (blinded to the identity of the animal), to a 
threshold level that included the full area of any CD41 positive signal present in the image, 
but excluded unspecific background noise. At this setting: ‘intermodes function’ (at 70 out of 
255), the secondary control images were zero for all measurements. The total number of 
CD41 positive platelets present in each image was then quantified based on the sum of 
these thresholded CD41 positive objects that exceeded a size of 1µm2. The average size in 
diameter of these more or less round objects was estimated based on the formula for the 
area of a circle= π x radius2, where the average area (µm2) was divided with π (π=3.14), and 
the square root of this result was multiplied with 2 to get an estimate of the diameter of the 
circle like (roundish) CD41 positive platelets in the aortic arches and in the blood smears.      
 
Quantification of non-nucleated CD41 positive platelet-like bodies in blood smears 
The total number and total area taken up by CD41 positive platelets in blood smears from 
WT, COX-1-/- , COX-2-/- and ApoE-/- mice was estimated from images taken from a consistent 
location on the blood smear slides. These images were thresholded using the default criteria 
(Image J) and the selected CD41 positive platelets (1μm in size to infinity) were included in 
the analysis.  
 
Quantification of nuclear density and CD31 immunoreactivity in the greater and lesser 
curvature of the mouse aortic arch 
Nuclear area and CD31 immunoreactivity was quantified from two different data sets, in 
two different studies presented in Chapter 3 and in Chapter 5 of this thesis.  
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Nuclear density and CD31 immunoreactivity in aortic arches from WT mice (Chapter 3) 
This study was performed using images that had been taken with a 1.9 zoom on the 
confocal microscope to ensure a full area of intact endothelium in focus. In order to 
estimate the nuclear density in the endothelial layer and in the smooth muscle layer of 
these images, they were processed using Image J Software. Before analysis, the system was 
calibrated to the known distance in pixels (physical length divided by the pixel size) to set 
the scale to how many pixels there are in 1µm of the image (i.e. 5.015 pixels/μm). Images 
were then thresholded using the automated Huang criteria function (in Image J), to allow 
consistent and non-biased determination of a suitable threshold level for each image. The 
analysis was defined as 25 to infinity and the total area (of DAPI positive, thresholded nuclei, 
larger than 25 pixels) was analysed.   
 
Nuclear density and CD31 immunoreactivity in aortic arches from WT, COX-1-/-, COX-2-/- and 
chow fed ApoE-/- mice (Chapter 5) 
The images from this study came from the CD41 study and were taken without any zoom on 
the confocal microscope (full size: 387.5x387.5µm). The images were processed using Image 
J software. Before analysis, the scale was set to 5.283 pixels/μm. CD31 immunoreactivity 
was quantified as mean fluorescence in images that were cropped using Image J software 
(from 387.5x387.5µm in size to 200x200µm) using a saved ROI box (200x200µm, 1059x1059 
pixels) that was dragged to an area in focus selected based on endothelial integrity (in an 
area devoid of damage from handling). This area was then earmarked for cropping and 
quantification of the DAPI stained nuclei. The DAPI stained nuclei in the cropped ROI image 
were thresholded using the ‘default’ criteria in the thresholding function (thresholded 
images show the thresholded DAPI positive objects in red) and the DAPI positive nuclear 
density (or total area size in µm), was calculated based on the total sum of the thresholded 
objects (exceeding a size of 2µm2). The average number of DAPI positive nuclei and average 
size of these nuclei was estimated based on the same data as the total sum was calculated 
from and any object with an area less than 2 µm2 was excluded from the analysis.  
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Measurement of COX activity in vascular tissue (bioassay protocols) 
 
The ‘equilibrated study’ protocol of COX bioactivity, measured by prostacyclin release 
detected as the breakdown product 6-keto PGF1α using radioimmunoassay (RIA)  
Aortic arches or thoracic aortic segments from WT, COX-1-/- or COX-2-/- mice were dissected 
out in PBS, cleaned of connective tissues and fat, cut into rings (~2mm length) and placed in 
plastic wells of a 96-well plate. They were then left to equilibrate in 200µl of Dulbecco's 
Modified Eagle Medium (DMEM) for 1 hour at 37°C. The medium was then replaced with 
fresh pre-warmed DMEM or DMEM plus 100μM of the COX-1/COX-2 inhibitor NSAID 
diclofenac (100µM) for 30 minutes at 37°C. After equilibration, 50µl of sample was removed 
from each well as baseline measure of prostacyclin release. The calcium ionophore, 
(A23187, 50μM) was then added to activate PLA2 in order to facilitate maximal prostacyclin 
release and the incubations continued for a further 30 minutes. At the end of this time, 
samples were collected. All samples were stored frozen and -80oC until measurements of 
the stable prostacyclin breakdown product 6-ketoPGF1α could be made (all the samples 
were analysed together on completion of the study).  
 
The ‘Acute study’ protocol of COX bioactivity measured by prostacyclin release using Enzyme 
Immunoassay (EIA) 
Aortic arches or thoracic aortic segments from WT, COX-1-/- or COX-2-/- mice were dissected 
out, quickly cleaned of connective tissues and fat and cut into rings (~2mm length). These 
rings were immediately (<5 minutes from time out of the animal) added to wells containing 
calcium ionophore, (A23187, 50μM in 200μl of DMEM for 30 minutes at 37°C) to activate 
PLA2 in order to facilitate maximal prostacyclin release. At the end of this time, samples 
were collected and stored in -80oC until measurements of the stable prostacyclin 
breakdown product 6-ketoPGF1α. 
 
In early experiments 6-ketoPGF1α release was measured using the group’s in-house radio 
immunoassay (RIA; see individual figure legends) by Ms Ivana Vojnovic at William Harvey 
Research Institute. However, for subsequent experiments 6-ketoPGF1α was measured using 
commercial Enzyme Immunoassay (EIA) kits. In some experiments thromboxane A2 was also 
measured (as the breakdown product thromboxane B2) again using EIA. 
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Enzyme Immunoassay (EIA) measurement of prostacyclin release detected as the breakdown 
product 6-keto PGF1α and thromboxane release detected as TXB2  
The EIA kits from Cayman Chemical to detect 6-keto PGF1α (Cayman 515211) and TXB2  
(Cayman 159031) are competitive EIAs. In brief, the basic principle of the assay is based on 
competition for a limited number of 6-keto PGF1α specific rabbit antibody binding sites, 
between free 6-keto PGF1α or TXB2 (sample) and Acetylcholinesterase (AChE) conjugated 6-
keto PGF1α or TXB2 (provided in the kits as tracers). The applied concentration of tracer will 
be constant whereas the free 6-keto PGF1α or TXB2 will vary between samples, which means 
that the higher concentration of free 6-keto PGF1α or TXB2 in the sample, the less tracer will 
be able to bind. This is measured by the extent of colour change upon development with 
Ellman’s Reagent (which is the substrate for the AChE) and this enzymatic reaction results in 
a product that with a distinct yellow colour (which absorbs strongly at 412 nm) that can be 
determined spectrophotometrically by a plate reader. The more yellow (at 412nm) the 
samples are, the less free 6-keto PGF1α or TXB2 do they contain and vice versa. The IC50 
(50%B/B0) of the 6-keto PGF1α EIA is 40pg/ml and the detection limit is 6pg/ml (80%B/B0) 
(Figure 2.26A). The IC50 (50%B/B0) of the TXB2 EIA is 57pg/ml and the detection limit is 
11pg/ml (80%B/B0) (Figure 2.26B).  
 
Figure 2.26 Representative standard curves from the 6-ketoPGF1α and TXB2 EIA assays 
 
Figure 2.26 Representative standard curves from the 6-ketoPGF1α and TXB2 EIA assays. %B/B0 
(%Bound/Maximum Bound) is the ratio of the absorbance of a standard (or sample) well (%B) to the maximum 
amount of tracer that the antibody can bind in the absence of standard (or sample). (A) Standard curve for 
prostacyclin breakdown product 6-ketoPGF1α in the EIA assay (Cayman Chemical, 515211). (B) Standard curve 
for thromboxane breakdown product TXB2 in the EIA assay (Cayman Chemical, 159031).  
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PGE2 measured by Homogeneous Time-Resolved Fluorescence (HTRF) assay   
Supernatants from the ‘equilibrated’ protocol from the rat heart failure study were also 
assayed for PGE2 (as a measure of COX-2 induction after the overnight incubation with LPS). 
These measurements were done by Homogeneous Time-Resolved Fluorescence (HTRF) 
assay (Cisbo) and performed with the help of my colleague Dr Nicholas Kirkby at the William 
Harvey Research Institute (see standard curve in Figure 2.27). HTRF is a combination of 
Fluorescence Resonance Energy Transfer (FRET) and Time-Resolved Fluorescence (TRF). 
FRET is based on a donor and an acceptor fluorophore and upon excitation, the donor 
transfers energy to the acceptor, (provided that the acceptor is within a given proximity to 
the donor), and once this energy reach the donor, light of a certain wavelength is emitted. 
HTRF combines FRET with TRF in order to reduce background fluorescence by the use of 
fluorophores with long half-lives (compared to the short lived background fluorescence). 
The excitation was set to 320nm and emission at 620nm (control, non-bound PGE2) and 
665nm (increased signal at this wavelength if energy is transferred). The long-lived and 
stable donor fluorophore was Europium cryptate and the acceptor fluorophore was d2. High 
levels of PGE2 correspond to a low signal and the results are normalised to a control and are 
presented as arbitrary units (Figure 2.27).    
 
Figure 2.27 A representative standard curve from the PGE2 HTRF assay 
 
Figure 2.27 A representative standard curve from the PGE2 HTRF assay. Delta F (%) reflects the signal to 
background for the assay calculated using HTRF ratios. Due to less energy transfer, higher levels of PGE2 
correspond to lower levels of Delta F (%). Delta F (%) corresponds to arbitrary units and negative values can 
occur due to normalisation.   
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Statistics  
Results are expressed as the mean ± Standard error of the mean (S.E.M). Statistical analysis 
was performed with Graph Pad Prism 5 statistical software, using statistical tests as 
indicated in individual figure legends. Differences at a probability value of <0.05 was taken 
as significant and denoted by * and p>0.05 was considered non-significant and denoted by 
ns. For within group analysis of difference in immunoreactivity between the two regions 
(images from the greater versus lesser curvature of the aortic arch); a paired two-tailed t-
test was employed according to the statistical test reported in publications using the same 
model (Hajra et al., 2000; Iiyama et al., 1999).  
For between group analyses an unpaired two tailed t-test was employed if there were only 
two groups. When there were more than two groups, (i.e. WT versus COX-1-/- or COX-2-/- 
mice) a One-Way ANalysis Of Variance (ANOVA) was performed with post-tests where 
relevant (either Bonferroni or Dunnett’s post test).  
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Endothelial morphology in the aortic arch:  
Examination of the constitutive expression and activity  
of COX-1 and COX-2 in healthy endothelium 
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Rationale behind Chapter 3 
Endothelial cells line the luminal surface of all blood vessels. Their morphology is regulated 
by, and associated with, different types of physical factors including shear stress and cyclic 
strain. In areas of unidirectional laminar flow endothelial cells appear aligned whereas in 
areas of complex or turbulent flow they appear to have a cobblestone appearance (Hajra et 
al., 2000; Potter et al., 2011). The aortic arch is thought to experience both types of shear 
stress patterns; with the endothelium in the greater curvature exposed to unidirectional 
shear stress, whereas the endothelium lining the lesser curvature is exposed to 
multidirectional, oscillatory shear stress (Hajra et al., 2000; Suo et al., 2007). Importantly, 
endothelial cells lining the lesser curvature are particularly susceptible to activation and the 
underlying wall is prone to low grade chronic inflammation and atherosclerosis, whilst the 
endothelium of the greater curvature is protected (Iiyama et al., 1999; Jongstra-Bilen et al., 
2006; Zakkar et al., 2009). This phenomenon has given rise to the hypothesis that the nature 
of shear stress that endothelial cells are exposed to predefines their physiological and 
pathophysiological phenotype. However, a detailed analysis of the morphology of the 
endothelium across these two regions and including the interface portion of the aortic arch 
and the underlying smooth muscle layer has not previously been conducted.  
 
It is well established that vascular endothelium is enriched in COX and makes prostacyclin as 
a consequence of COX and prostacyclin synthase co-expression. However, COX isoform 
expression has routinely been studied in cultured endothelial cells grown under static 
conditions in vitro. These cells may not be representative of endothelial phenotypes present 
in vivo. Furthermore, COX-2 expression has been shown to be regulated by shear stress 
applied to cells in vitro (Topper et al., 1996). Thus, it would seem that the best way to 
understand COX expression in endothelial cells would be to look at vascular endothelium on 
vessels in situ. However, the relative distribution of COX-1 versus COX-2 immunoreactivity in 
endothelial cells of different flow-derived phenotypes in situ is not known. Moreover, the 
relative contribution of each isoform to prostacyclin production by different blood vessels 
has not been addressed.  
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Thus, in this chapter I have used en face confocal microscopy to image the endothelial 
intracellular junction marker CD31 as well as COX-1 and COX-2 in the endothelium and 
underlying smooth muscle across the greater and the lesser curvature of the aortic arch 
from mice or in endothelium of the human pulmonary artery. For some experiments 
animals were treated with LPS in vivo to intentionally increase COX-2 levels in the 
vasculature. Finally, I have taken aortic arch and thoracic aortic tissue from WT, COX-1-/- and 
COX-2-/- to measure prostacyclin release under different experimental conditions.                        
The research questions and aims of this chapter can be summarised as follows: 
 
How is the morphology of the endothelium and the underlying smooth muscle defined in 
the gross area of the mouse aortic arch? 
 Study CD31 positive intracellular junctions and DAPI positive nuclear density in both 
endothelial and smooth muscle layers in different regions of the aortic arch and 
examine the depth of the endothelial layer through z-profiling. 
Which COX isoform predominates in vascular endothelium and how does this relate to 
endothelial cell morphology? 
 Investigate the normal distribution of COX-1 and COX-2 in endothelial cells lining the 
atherosclerosis-protected greater curvature and the atherosclerosis-prone lesser 
curvature of the mouse aortic arch from young (3 month old) healthy male WT mice, 
using immunohistochemistry and enface confocal microscopy.  
 Repeat protocol in a pilot study using human pulmonary artery.  
 Perform validation experiments: 
 Positive control (in vivo injection i.p. with endotoxin/LPS to upregulate COX-2). 
 Negative control (background immunofluorescence from secondary control). 
 Specificity of COX antibodies by the use of specific blocking peptides.  
 Examine COX-1 and COX-2 immunoreactivity in COX-1 and COX-2-/- mice.  
Which COX isoform drives endothelial prostacyclin production in healthy blood vessels? 
 Establish the functional relevance of COX-1 versus COX-2 in the aorta in terms of 
prostacyclin releasing capacity by using tissue from young (3 month old) healthy WT 
versus COX-1-/- and COX-2-/- mice.  
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Methods 
Animals 
WT, COX-1-/- and COX-2-/- mice were bred, maintained and genotyped as described in the 
General Methods Chapter 2. For this chapter, animals were male and female (but 
predominantly male) and used at 10-12 weeks (3 month) of age (considered as young adult 
mice). In some experiments mice were injected with LPS (E.coli serotype 0111:B4, 4mg/kg 
i.p. for 4 hours) or (E.coli serotype 055:B5, 10mg/kg i.p. for 4.5 hours) see individual figure 
legends. All WT mice were from the C57BL/6J strain; some WT were purchased from Harlan, 
UK, whilst colony WT were bred in-house with a shared background to match the COX-1-/- 
and COX-2-/- mice (backcrossed to C57BL/6J, Harlan, UK, more than 7 times) see General 
Methods Chapter 2. Purchased WT mice will be referred to as ‘C57BL/6J Harlan, UK’ and the 
other COX colony WT controls will be referred to as ‘C57BL/6J bred in-house’. Animals were 
killed by CO2 asphyxiation and aortic arches were dissected out and fixed with 2% 
formaldehyde according to the ‘ex vivo semi-perfusion fixation procedure’ or the 
‘transcardial perfusion fixation procedure’ and staining protocols described in the General 
Methods Chapter 2 and as specified in the figure legends.  
 
Human tissue 
This chapter includes data from a pilot study of COX immunoreactivity in human pulmonary 
artery endothelium (from one donor). The pulmonary artery was dissected out from lungs 
from an American tissue bank (International Institute for Advancement of Medicine) with 
confirmed consent from the donor and under the Royal Brompton hospital ethics 
regulations (ethics number 09/H0708/72). The donor was a 67 year old female Caucasian 
who died from a cerebrovascular accident (intracerebral haemorrhage). For more details 
about the past medical history of this donor and staining protocols for this tissue, see 
General Methods Chapter 2.  
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En Face imaging of arch lumen 
In this chapter I have imaged CD31, COX-1 and COX-2 using antibodies and the stain DAPI to 
visualise nuclei as described in the General Methods Chapter 2 (Table 2.18). In order to 
investigate the relative COX-1 and COX-2 isoform expression in the endothelium, tissues 
were subject to the same staining protocol, with or without the addition of blocking 
peptides to the antigen that the COX primary antibodies were raised against and imaged 
head to head by confocal microscopy (Leica SP5 inverted confocal microscope, 40x oil 
objective), with the same confocal settings maintained throughout the study. 
Immunoreactivity was quantified as mean fluorescence using LAS AF software and Image J 
software was used to calculate nuclei area as described in General Methods Chapter 2. 
Measurement of COX activity 
COX activity was measured in two protocols; the first ‘equilibrated study’ included a lengthy 
equilibration step. For validation purposes, the study was repeated without the 
equilibration step, referred to as the ‘acute study’. In both cases, aortic arch or thoracic 
aortic rings were removed from animals and incubated in vitro with the calcium ionophore, 
A23187 (50 μM) with or without diclofenac (100 μM), for 30 minutes. Prostacyclin release 
from the tissue was measured as the stable breakdown product 6-keto PGF1α by RIA or EIA 
as described in the General Methods Chapter 2.  
 
Analysis and statistics 
Data is presented as the mean ± S.E.M and was analysed using Graph Pad Prism 5 using 
statistical tests described in the figure legends. A p value of <0.05 was taken as significant 
and denoted by * and p>0.05 was considered non-significant and denoted by ns.   
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Results 
Morphology of the luminal surface of the mouse aortic arch 
The morphology of endothelial cells lining the luminal surface of the greater and the lesser 
curvature of the aortic arch were found to be clearly different, with ‘aligned’ versus 
‘cobblestone’ morphology enriched in the greater curvature and lesser curvature 
respectively (Figure 3.1C+D). The greater curvature was enriched in endothelial cells with 
elongated nuclei that were evenly spread out and appeared aligned with the unidirectional 
laminar shear stress (Figure 3.1E). In contrast, the nuclei of the endothelial cells lining the 
lesser curvature had a polygonal shape and were randomly orientated with cobblestone 
morphology (Figure 3.1F). Figure 3.1D show that endothelial cells in the ‘interface region’ 
are of mixed morphology. Endothelial cells from all regions of the aortic arch stained 
positive for the endothelial marker CD31 (Figure 3.1C+D+E+F, shown in green).  
 
DAPI positive nuclear density 
A key and striking observation of this tiled image of the luminal surface of the arch is how 
‘nuclear dense’ the cells of the lesser curvature appear (shown on the tile as blue DAPI 
staining, Figure 3.1C+G). Indeed, quantification of these images showed a graded increase in 
the total area of DAPI positive nuclei from the greater curvature to the lesser curvature 
(Figure 3.1 D+E). The increased nuclear density in the lesser curvature was also evident in 
images from a separate study (Figure 3.2A+B I, III and IV) and in the quantified pooled data 
(Figure 3.3A).  
 
CD31 immunoreactivity 
CD31 immunoreactivity however, declined proportionally (in comparison to DAPI staining) 
across the tile from the greater to the lesser curvature region (Figure 3.1D+H). This 
observation was again evident in images from a separate study (Figure 3.2A+B II) and in the 
quantified pooled data (Figure 3.4A). The expression pattern of the CD31 immunoreactivity 
appeared more abundantly expressed throughout the cytoplasm of the endothelial cells in 
the greater curvature and more localised to intracellular junctions in the lesser curvature 
(Figure 3.1C+D+E+F and 3.2A+B).  
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Images of the endothelial cell layer z-plane and the directly underlying vascular smooth 
muscle layer z-plane in the greater and lesser curvature of the mouse aortic arch 
In separate experiments, images were taken from defined Z-planes (confocal microscopy 
movement through the tissue) in the greater and lesser curvature of the aortic ach (Figure 
3.2). The first (manually adjusted) z-plane captured images and fluorescence data from the 
superficial endothelial layer (visually confirmed by characteristic endothelial like CD31 
immunoreactivity and DAPI stained nuclei) (Figure 3.2).  The second z-plane (deeper down 
through the tissue) captured images and fluorescence data from the directly underlying 
smooth muscle layer (visually confirmed by the absent CD31 immunoreactivity and by 
smooth muscle like DAPI stained nuclei) (Figure 3.2).  
 
As seen in the tiled image (Figure 3.1), the endothelial layer showed positive CD31 staining 
and the typical aligned versus cobblestone morphology in the greater versus lesser 
curvature regions (Figure 3.2A+B I+II+III). CD31 immunoreactivity was to a large extent lost 
in the Z-plane of the vascular smooth muscle (Figure 3.2A+B and Figure 3.4B), but DAPI 
nuclear staining of the smooth muscle cells was clearly visible (Figure 3.2A+B). DAPI stained 
smooth muscle nuclei in the greater curvature appeared aligned, whereas DAPI stained 
smooth muscle nuclei in the lesser curvature displayed multi directional alignment similar to 
the overlying endothelial layer (Figure 3.2A+B I, III and IV).  However, in contrast to the 
endothelial layer, the total area of nuclear staining (nuclear density) in the smooth muscle 
layer was not significantly different in the lesser curvature versus the greater curvature 
(Figure 3.3B).  
 
Measurement of endothelial cell layer depth  
Z-plane images were taken to measure the depth/thickness of the endothelial layer at the 
lesser and greater curvature regions of the aortic arch (Figure 3.5). There was a trend for the 
CD31 positive endothelial layer to be deeper in the greater curvature than in the lesser 
curvature region of the aortic arch but this did not reach statistical significance (Figure 
3.5C). 
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COX-1 and COX-2 immunoreactivity in the endothelium of the aortic arch in untreated and 
LPS treated conditions 
COX-1 immunoreactivity in the endothelial layer was readily detectable, obvious in every 
cell and expressed in similar levels in the greater and lesser curvature regions (Figure 3.6). 
The intracellular staining pattern of the COX-1 immunoreactivity appeared diffused 
cytoplasmic and intense perinuclear (Figure 3.6E). By contrast, COX-2 immunoreactivity in 
the endothelial layer was comparatively very low (Figure 3.7). Where it was detected, COX-2 
immunoreactivity appeared as punctate staining (Figure 3.7E). Pooled immunoreactivity 
data confirmed that COX-1 immunoreactivity predominates over COX-2 immunoreactivity in 
both regions of the aortic arch (Figure 3.8A+B+C).  
 
In tissue of untreated mice, the COX-2 immunoreactivity was very low, but modestly 
enriched in the lesser curvature of the aortic arch (Figure 3.9A+C+D). As expected, COX-2 
expression was increased by LPS treatment in vivo (4mg/kg i.p. for 4 hours), which reached 
statistical significance in endothelial cells of the lesser curvature region of the arch (Figure 
3.9B+C+D). The LPS induced COX-2 immunoreactivity was also significantly higher in the 
lesser curvature of the arch (Figure 3.9B+C+D). COX-1 immunoreactivity was highly 
abundant in every area of the endothelium of the aortic arch and there was no significant 
difference between the greater and the lesser curvature in untreated animals (Figure 
3.10A+C+D). However, even though COX-1 is not an ‘inducible’ gene in the same way that 
COX-2 is, it was surprising to note that COX-1 immunoreactivity was also increased in the 
endothelium of the lesser curvature region of the arch from mice treated with LPS (4mg/kg 
i.p. for 4 hours) (Figure 3.10B+C+D). This COX-1 immunoreactivity was in contrast to 
untreated conditions, significantly higher in the lesser curvature.  
 
COX-1 and COX-2 immunoreactivity in the endothelial versus smooth muscle layer 
In another study, I imaged COX-1 and COX-2 again in the endothelial layer of the mid arch 
and descending aorta of the aortic arch in tissue from untreated animals, before changing 
the focus of the z-plane to the directly underlying smooth muscle layer, where I imaged 
COX-1 and COX-2 again (Figure 3.11). It was clear that COX immunoreactivity (in particular 
COX-1 immunoreactivity) was highly enriched in the endothelial layer with much less 
expression in the underlying vascular smooth muscle layer (Figure 3.11A-C).  
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Pilot study of COX-1 and COX-2 immunoreactivity in human pulmonary artery endothelium  
Using the same protocol I had developed for mouse tissue I was able to fix, mount and 
image endothelium in situ from sections of a human pulmonary artery (Figure 3.12). 
Endothelial cells of the human vessel stained positive for CD31 and appeared aligned in 
their morphology (Figure 3.12A). COX-1 immunoreactivity was abundant in almost every 
CD31 positive endothelial cell in 3 separate images (Figure 3.12 C). COX-2 immunoreactivity 
was also detected, but as with the mouse tissue, it was much lower in intensity than seen 
for COX-1 (Figure 3.12 C+D), but was confirmed to be specific as it was reduced by the 
addition of COX-2 blocking peptide with only low levels of punctate immunoreactivity 
remaining (Figure 3.12D+E).  
 
Overall, this pilot study showed a similar pattern in the human vessel as in the mouse 
vessels regarding abundant COX-1 immunoreactivity compared to sparse COX-2 
immunoreactivity (Figure 3.12F). This human pulmonary artery tissue was also shown to 
release prostacyclin upon stimulation with the NOD-1 agonist C12-iE DAP or LPS in a 
bioassay performed by my colleague Dr Timothy Gatheral (basal: 15.0 ±3.7 ng/ml, 
stimulated with C12-iE DAP: 127.7 ± 61.2 ng/ml or stimulated with LPS 55.1± 25.3 ng/ml). 
 
Validation studies for COX-1 and COX-2 immunoreactivity; non-specific background and 
blocking peptides for COX-1 and COX-2  
The COX-1 and COX-2 antibodies used in this thesis are well validated (General Methods, 
Chapter 2). However, it was important to conduct validation experiments to be able to 
interpret our data with confidence. Background immunofluorescence was low or 
undetectable, and did not differ between regions of the arch/aorta or in experiments with 
or without LPS (4mg/kg i.p. for 4 hours), in parallel incubations where only secondary 
antibody was used (‘secondary controls’) (Figure 3.13A+B+C).  
 
Please note that for data shown with primary antibodies ‘secondary control’ 
immunofluorescence values obtained in parallel incubations were subtracted before the 
data was pooled and presented in graphs of immunoreactivity. In separate experiments, 
specific blocking peptides to the precise epitope (antigenic determinant) of COX-1 used to 
raise our antibodies, greatly reduced immunoreactivity to COX-1 in endothelium of 
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untreated WT mice or those treated with LPS (10mg/kg i.p. for 4.5 hours), (Figure 3.14). 
Similarly, blocking peptides to COX-2 inhibited COX-2 immunoreactivity in the endothelium 
of mice treated with LPS (Figure 3.15). For these experiments, the greater curvature was 
compared to the descending aorta from the same animal since these areas display similar 
endothelial phenotypes affected by laminar unidirectional shear stress.  
 
COX-1 and COX-2 immunoreactivity in endothelium of the aortic arch from mice with COX-1 
or COX-2 gene deletion  
In my thesis I have used colonies of mice where COX-1 or COX-2 genes have been disrupted. 
These modifications result in mice with no function of COX-1 or COX-2 enzyme activity 
respectively, but may (theoretically) transcribe truncated, yet inactive, forms of the protein 
(Langenbach et al., 1995; Morham et al., 1995) (See General Methods Chapter 2).   
 
COX-1 immunoreactivity in COX-1-/- mice 
The antibodies used for COX-1 were raised to a sequence in the middle of the COX-1 gene, 
prior to the target site for the genetic disruption (General Methods, Chapter 2), and 
therefore this region would potentially be preserved if a truncated COX-1 protein was 
synthesised and survived. This may explain why COX-1 immunoreactivity was detectable in 
aortic endothelium of COX1-/- mice (Figure 3.16 A+B), but when quantified the levels were 
reduced compared to WT mice (Figure 3.16 C). This COX-1 immunoreactivity was blocked by 
the addition of COX-1 blocking peptide (Figure 3.17 A+B). 
 
COX-2 immunoreactivity in COX-2-/- mice 
The COX-2 antibody was raised to a sequence at the end of the COX-2 gene (in exon 10), 
which was truncated in the targeted gene (General Methods, Chapter 2). Hence, if a 
truncated COX-2 protein was synthesised, the antibody used in this thesis is unlikely to 
recognise it. Figure 3.18 shows that the COX-2 immunoreactivity in tissue from LPS treated 
COX-2-/- mice were significantly reduced and lacked the COX-2 staining pattern seen in the 
WT and the COX-1-/- mice (Figure 3.18A+B+C).  
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COX-1 immunoreactivity in COX-2-/- mice and COX-2 immunoreactivity in COX-1-/-mice 
I was able to establish that COX genes were not induced in compensation for each other in 
specific knockout animals. Thus, COX-1 immunoreactivity was not altered in endothelium of 
COX-2-/- mice (Figure 3.16 D) and COX-2 immunoreactivity was not altered in the 
endothelium of COX-1-/- mice (Figure 3.18 A+B+D) compared to the levels detected in WT 
mice.  
 
Effect of COX-1 and COX-2 gene deletion of prostacyclin release from aortic arches and 
thoracic aorta  
The immunohistochemical experiments presented so far suggest that COX-1 predominates 
over COX-2 in the endothelium of freshly fixed blood vessels. However, immunoreactivity 
does not necessary reflect biological activity. In order to further understand the relative role 
of COX-1 and COX-2 in prostacyclin release from large healthy blood vessels, bioassay 
experiments were performed. These experiments were performed in two ways. In the first 
set of experiments, vascular tissue was washed and allowed to equilibrate before being 
stimulated to release prostacyclin (Figure 3.19; ‘equilibrated study’). However, it has been 
debated that COX-2 protein may be very unstable with rapid offset kinetics from its shear-
induced gene expression (Funk et al., 2007; Grosser et al., 2006), and considering that the 
blood vessels (in the equilibrated study, Figure 3.19) were equilibrated outside the animal 
for 1.5 hours in total before being stimulated in vitro, this may have affected the results. 
Therefore, for validation purposes, the protocol was repeated a second time where vascular 
tissue was immediately (<5 minutes) placed in media containing the calcium ionophore 
stimuli, (A23187) and the resultant prostacyclin release was measured after 30 minutes 
(Figure 3.20; ‘acute study’).  
 
(Figure 3.19); ‘equilibrated study’ 
After equilibration, segments of thoracic aorta from WT mice released detectable levels of 
prostacyclin when stimulated with 50μM of the calcium ionophore A23187 (Figure 3.19B). 
This was completely inhibited by the COX-1 and COX-2 inhibitor (NSAID) diclofenac (Figure 
3.19B). By contrast thoracic aorta from COX-1-/- mice released minimal levels of prostacyclin 
in the presence or absence of A23187 (Figure 3.19B). Thoracic aorta from COX-2-/- mice 
however, released detectable levels of prostacyclin that were not different to those 
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measured from tissue of WT animals (Figure 3.19B). In order to directly compare our 
prostacyclin release with the COX immunohistochemical data presented in this thesis, 
prostacyclin release experiments were repeated using aortic arch tissue in place of thoracic 
aorta (Figure 3.19A). As seen in aortic segments, prostacyclin was released by aortic arches 
stimulated with A23187 from WT and COX-2-/- mice, but only very low levels were released 
from tissue of COX-1-/- mice (Figure 3.19A).  
 
(Figure 3.20 and 3.21); ‘acute study’ 
Similar results were obtained when the study was repeated and aortic arch and thoracic 
aortic tissue was immediately stimulated in the ‘acute study’, without the postmortem delay 
in the ‘equilibrated study’ (Figure 3.20A+B). Using this protocol I performed a pilot study 
(n=2) to investigate (i) how COX deletion affected thromboxane release by blood vessels 
and (ii) what effect LPS treatment in vivo had on a prostacyclin and thromboxane release. 
LPS treatment had no discernable effect on the ability of aortic tissue from any genotype of 
mouse to release prostacyclin or thromboxane (Figure 3.21). As expected, thromboxane 
release was very low in aortic tissue, and again, as with prostacyclin, the levels of release 
were not affected by LPS. It was interesting to note that the low levels of thromboxane 
release detected were reduced in tissue from COX-1-/-, but not COX-2-/- mice (Figure 3.21). 
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Figures 
Figure 3.1 Tile composite of 4x4 images showing the morphology of the luminal surface of 
the proximal aortic arch of a WT mouse 
 
Figure 3.1 continues on the next page. 
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Figure 3.1 (Continued) Tile composite of 4x4 images showing the morphology of the luminal 
surface of the proximal aortic arch of a WT mouse 
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Figure 3.1 Tile composite of 4x4 images showing the morphology of the luminal surface of the aortic arch of 
a mouse. An aortic arch fixed according to the ex vivo semi-perfusion fixation procedure was dissected from a 
young (3 month old) female WT mouse (C57BL/6J, bred in-house) (A) Red dotted line, mark dissection cutting 
points. (B) A schematic of the mounted (opened and flattened) aortic arch, marking the location of the lesser 
and the greater curvature as well as the position of the tile composite (4x4 images, coordinates 1.1-4.4). (C) 
The entire tile of 4x4 images was captured using the automated tiling function on a Leica SP5 inverted confocal 
microscope. Nuclei visualised with DAPI (blue) and endothelial cells outlined with the endothelial cell marker 
CD31 (green). (D) Selected images from the tile, (coordinate 3.1 to 3.4) showing typical shear responsive 
phenotypic differences in endothelial cell morphology in the greater curvature, interface region and the lesser 
curvature respectively. Zoomed in images from (E) greater curvature: coordinate 3.1 and (F) lesser curvature: 
coordinate 3.4. (G) Total DAPI stained nuclear area (μm
2
) in each of the selected images in (D) (3.1-3.4). (H) 
CD31 immunoreactivity measured in each of the selected images in (D) (3.1-3.4) (Image size 387.5x387.5μm).
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Figure 3.2 Images of the endothelial layer z-plane and the directly underlying vascular 
smooth muscle layer z-plane in the greater and the lesser curvature of the mouse aortic arch 
 
Figure 3.2 Images of the endothelial layer z-plane and the directly underlying vascular smooth muscle layer 
z-plane in the greater and lesser curvature of the mouse aortic arch. Morphology of the endothelial layer and 
directly underlying smooth muscle layer of the (A) greater curvature and (B) lesser curvature regions of the 
aortic arch, fixed according to the transcardial perfusion fixation procedure. Pictures taken with a 40x objective 
and 1.9 zoom (image size 203.95x203.95μm). Images are representative from n=4 young (3 month old) male 
WT mice (C57BL/6J, bred in-house). (I) DAPI stained nuclei in the endothelial and underlying smooth muscle 
layers of both regions (blue). (II) CD31 immunoreactivity in both layers of both regions (green). (III) CD31 and 
DAPI images are merged with blue and green both visible. (IV) DAPI positive nuclei in the endothelial and the 
smooth muscle layers were highlighted by thresholding using the Huang criteria in Image J, and these defined 
DAPI positive ‘objects’ (endothelial and smooth muscle cell nuclei) (red) were selected for quantification of total 
nuclear area in the endothelial and smooth muscle layers of the greater and lesser curvature of the aortic arch.  
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Figure 3.3 Quantified total nuclear area of DAPI stained nuclei in the endothelial and smooth 
muscle cell layers in the greater and the lesser curvature of the mouse aortic arch 
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Figure 3.3 Quantified total nuclear area of DAPI stained nuclei in the endothelial and smooth muscle cell 
layers in the greater and the lesser curvature of the mouse aortic arch. Total Area (μm
2
) of DAPI stained 
nuclei in the (A) endothelial layer and in the (B) smooth muscle layer of the greater curvature (white columns) 
and lesser curvature (black columns) regions of the mouse aortic arch fixed according to the transcardial 
perfusion fixation procedure. Data was analysed from confocal pictures taken with a 40x objective and 1.9 
zoom (image size 203.95x203.95μm), see representative images (Figure 3.2). One picture was taken from each 
area and nuclei were selected for quantification by thresholding using the Huang criteria in Image J (Figure 
3.2A+B IV). Data is presented as the mean ± S.E.M from n=4 young (3 month old) male WT mice (C57BL/6J, 
bred in-house) and was analysed using paired Student’s t-test and p<0.05 taken as significant and denoted by * 
and p>0.05 was considered non-significant and denoted by ns.  
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Figure 3.4 Quantified CD31 immunoreactivity in the endothelial and smooth muscle cell 
layers of the greater and the lesser curvature of the mouse aortic arch 
CD31 immunoreactivity
in the endothelial layer
0
20
40
60
80 Greater Curvature
(Protected region aortic arch)
Lesser Curvature
(Susceptible region aortic arch)
*
M
ea
n
 F
lu
o
re
sc
en
ce
CD31 immunoreactivity
in the smooth muscle layer
0
20
40
60
80 Greater Curvature
(Protected region aortic arch)
Lesser Curvature
(Susceptible region aortic arch)
*
M
ea
n
 F
lu
o
re
sc
en
ce
A
B
 
Figure 3.4 Quantified CD31 immunoreactivity in the endothelial and smooth muscle cell layers of the greater 
and the lesser curvature of the mouse aortic arch. CD31 immunoreactivity in the (A) endothelial or (B) smooth 
muscle layer of the greater curvature (white columns) and lesser curvature (black columns) regions of the 
mouse aortic arch fixed according to the transcardial perfusion fixation procedure. Data was analysed from 
confocal pictures taken with a 40x objective and 1.9 zoom (image size 203.95x203.95μm), see representative 
images (Figure 3.2A+B II). One picture was taken from each area and CD31 immunoreactivity was quantified as 
mean fluorescence. Data is the mean ± S.E.M from n=4 young (3 month old) male WT mice (C57BL/6J, bred in-
house) and was analysed using paired Student’s t-test and p<0.05 taken as significant and denoted by *.  
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Figure 3.5 Z-profiling of the depth of the endothelial cell layer at the greater curvature and the 
lesser curvature of the mouse aortic arch 
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Figure 3.5 Z-profiling of the depth of the endothelial cell layer at the greater curvature and the lesser 
curvature of the mouse aortic arch. (A) View of luminal surface of the endothelium (40x objective at 7.75 
zoom) with the position of the z-profile shown as a red line. (B) Transverse z-profile image of the endothelium 
(identified by CD31 immunoreactivity in green) and DAPI stained nuclei in blue. The green channel (CD31) has 
been enhanced for viewing purposes, to the same extent in both A and B. (C) Pooled data of the depth of the 
endothelial (CD31 positive) cell layer. Data is the mean ± S.E.M for n=4 young (3 month old) male WT mice 
(C57BL/6J, bred in-house) and was analysed using paired Student’s t-test and p>0.05 taken as non-significant 
and denoted by ns. 
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Figure 3.6 Tile composite of 4x4 images showing COX-1 immunoreactivity in the greater and 
the lesser curvature of the aortic arch from a young adult male WT mouse 
 
Figure 3.6 Tile composite of 4x4 images showing COX-1 immunoreactivity in the greater and the lesser 
curvature of the aortic arch from a young adult WT mouse. An aortic arch fixed according to the transcardial 
perfusion fixation procedure, dissected from a 3 month old (young adult) male WT mouse (C57BL/6J, Harlan, 
UK). (A) Red dotted line, mark dissection cutting points. (B) A schematic of the mounted (opened and flattened) 
aortic arch, marking the location of the greater and the lesser curvature as well as the position of the tile 
composite (4x4 images, coordinates 1.1-4.4). (C) The entire tile of 4x4 images. DAPI stained nuclei (blue) and 
COX-1 immunoreactivity (red). (D) Representative images from the lesser and the greater curvature (coordinate 
3.1 and 4.3). (E) Zoomed in images showing intracellular localisation of COX-1 immunoreactivity. 
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Figure 3.7 Tile composite of 4x4 images showing COX-2 immunoreactivity in the greater and 
the lesser curvature of the aortic arch from a young adult male WT mouse 
 
Figure 3.7 Tile composite of 4x4 images showing COX-2 immunoreactivity in the greater and the lesser 
curvature of the aortic arch from a young adult WT mouse An aortic arch fixed according to the transcardial 
perfusion fixation procedure, dissected from a 3 month old (young adult) male WT mouse (C57BL/6J, Harlan, 
UK). (A) Red dotted line, mark dissection cutting points. (B) A schematic of the mounted (opened and flattened) 
aortic arch, marking the location of the greater and the lesser curvature as well as the position of the tile 
composite (4x4 images, coordinates 1.1-4.4). (C) The entire tile of 4x4 images. DAPI stained nuclei (blue) and 
COX-1 immunoreactivity (red). (D) Representative images from the lesser and the greater curvature (coordinate 
3.4 and 3.2). (E) Zoomed in images showing intracellular localisation of COX-2 immunoreactivity. 
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Figure 3.8 Quantified COX-1 versus COX-2 immunoreactivity in the greater and the lesser 
curvature of the mouse aortic arch from young adult male WT mice 
 
Figure 3.8 continues on the next page. 
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Figure 3.8 (Continued) Quantified COX-1 versus COX-2 immunoreactivity in the greater and 
the lesser curvature of the mouse aortic arch from young adult male WT mice 
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Figure 3.8 Quantified COX-1 versus COX-2 immunoreactivity in the greater and the lesser curvature of the 
mouse aortic arch from young adult male WT mice. Representative cropped images (200x200μm) of COX-1 
immunoreactivity (A) and COX-2 immunoreactivity (B) (red), from the greater and the lesser curvature of the 
mouse aortic arch fixed according to the transcardial perfusion fixation procedure. Nuclei visualised with DAPI 
(blue) and endothelial cells outlined with CD31 (green). (C) Pooled data comparing COX-1 and COX-2 
immunoreactivity from 6 head to head experiments. 3 unique images were captured from the greater 
curvature and the lesser curvature respectively. COX immunoreactivity was quantified as mean fluorescence 
and secondary control background immunoreactivity from each region has been subtracted from each image. 
Data is the mean ± S.E.M of n=14-18 images from separate regions of tissue from n=6 young adult (3 month 
old) male WT mice (C57BL/6J, Harlan, UK).  Data was analysed using one-way ANOVA with Bonferroni’s multi 
comparison post-test and *p<0.05 was taken as significant and denoted by*. 
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Figure 3.9 COX-2 immunoreactivity in the greater and the lesser curvature of aortic arches 
from untreated versus LPS treated young adult male WT mice  
 
Figure 3.9 continues on the next page. 
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Figure 3.9 (Continued) COX-2 immunoreactivity in the greater and the lesser curvature of 
aortic arches from untreated versus LPS treated young adult male WT mice 
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Figure 3.9 COX-2 immunoreactivity in the greater and the lesser curvature of aortic arches from untreated 
versus LPS treated young adult male WT mice.  Representative cropped images (200x200μm) of COX-2 
immunoreactivity (in red) from (A) untreated and (B) LPS injected (E.coli serotype 0111:B4, 4mg/kg i.p. for 4 
hours) WT mice. Aortic arches were fixed according to the transcardial perfusion fixation procedure. Nuclei 
visualised with DAPI (blue) and endothelial cells outlined with CD31 (green). (C) Zoomed in images (40x40μm) 
of COX-2 staining pattern in untreated and LPS treated WT mice. (D) Pooled data of COX-2 immunoreactivity in 
the greater and the lesser curvature in n=6 aortic arches from untreated (-) and LPS treated (+) WT mice 
(secondary control background was subtracted from each image before analysis). Data is the mean ± S.E.M of 
n=18 (3 separate images were taken per region) from n=6 young adult (3 month old), WT mice (C57BL/6J, 
Harlan, UK). Within group analysis was performed using paired Student’s t-test and when significant denoted 
by #. Between groups analysis was analysed using one-way ANOVA with Bonferroni’s multi comparison post-
test and when significant denoted by *. P<0.05 taken as significant and denoted by * or # and p>0.05 was 
taken as non-significant and denoted by ns.  
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Figure 3.10 COX-1 immunoreactivity in the greater and the lesser curvature of aortic arches 
from untreated versus LPS treated young adult male WT mice 
 
Figure 3.10 continues on the next page. 
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Figure 3.10 (Continued) COX-1 immunoreactivity in the greater and the lesser curvature of 
aortic arches from untreated versus LPS treated young adult male WT mice 
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Figure 3.10 COX-1 immunoreactivity in the greater and the lesser curvature of aortic arches from untreated 
versus LPS treated young adult male WT mice.  Representative cropped images (200x200μm) of COX-1 
immunoreactivity (red) from (A) untreated and (B) LPS injected (E.coli serotype 0111:B4, 4mg/kg i.p. for 4 
hours) WT mice. Aortic arches were fixed according to the transcardial perfusion fixation procedure. Nuclei 
visualised with DAPI (blue) and endothelial cells outlined with CD31 (green). (C) Zoomed in images (40x40μm) 
of COX-1 staining pattern in untreated and LPS treated WT mice. (D)  Pooled data of COX-1 immunoreactivity in 
the greater and the lesser curvature in n=6 aortic arches from untreated (-) and LPS treated (+) WT mice 
(secondary control background was subtracted from each image before analysis). Data is the mean ± S.E.M of 
n=14-18 (3 separate images were taken per region) from n=6 young adult (3 month old), WT mice (C57BL/6J, 
Harlan, UK). Within group analysis was performed using paired Student’s t-test. Between groups analysis was 
analysed using one-way ANOVA with Bonferroni’s multi comparison post-test. P<0.05 taken as significant and 
denoted by * and p>0.05 was taken as non-significant and denoted by ns.  
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Figure 3.11 COX-1 and COX-2 immunoreactivity in the endothelial layer versus the smooth 
muscle cell layer  
 
Figure 3.11 continues on the next page. 
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Figure 3.11 (Continued) COX-1 and COX-2 immunoreactivity in the endothelial layer versus 
the smooth muscle cell layer  
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Figure 3.11 COX-1 and COX-2 immunoreactivity in the endothelial layer versus the smooth muscle cell layer. 
Representative cropped images (200x200μm) of (A) COX-1 immunoreactivity and (B) COX-2 immunoreactivity 
(red), in the endothelial layer and in the directly underlying smooth muscle layer in the mid arch (COX-2) and 
descending aorta (COX-1) of a mouse aortic arch fixed according to the transcardial perfusion fixation 
procedure. Nuclei visualised with DAPI (blue) and endothelial cells outlined with CD31 (green). (C) COX 
immunoreactivity quantified as mean fluorescence. Data is the mean ± S.E.M of n=4 images from n=4 WT mice 
(2 male and 2 female, 3 month old, young adult, C57BL/6J mice, bred in-house). Data was analysed using one-
way ANOVA with Bonferroni’s multi comparison post-test. P<0.05 taken as significant and denoted by * and 
p>0.05 was taken as non-significant and denoted by ns.  
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Figure 3.12 Pilot study of COX-1 and COX-2 immunoreactivity in human pulmonary artery 
endothelium (from one human donor) 
 
Figure 3.12 continues on the next page. 
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Figure 3.12 (Continued) Pilot study of COX-1 and COX-2 immunoreactivity in human 
pulmonary artery endothelium (from one human donor) 
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Figure 3.12 Pilot study of COX-1 and COX-2 immunoreactivity in human pulmonary artery endothelium (from 
one human donor). (A) A full field picture (387.5x387.5μm) of CD31 positive (green) endothelium from a 
human pulmonary artery. Nuclei visualised by DAPI (blue). (B)  3 representative cropped images (200x200μm) 
showing background immunoreactivity (red) from the secondary antibody used (goat anti-rabbit Alexa Fluor 
594). (C) 3 separate pictures showing human endothelial COX-1 immunoreactivity (red), from the same human 
donor, using the anti-human COX-1 anti-serum (Cayman 160108).  (D) 3 separate pictures showing human 
endothelial COX-2 immunoreactivity from the same human donor, using the same COX-2 antibody as previously 
(Cayman 160126 which also recognises human COX-2) (red).  (E) COX-2 blocking peptide (the precise epitope 
which the Cayman 160126 COX-2 antibody was raised against) was added to test the specificity of the COX-2 
immunoreactivity. (F) Quantified COX-1 and COX-2 immunoreactivity (with or without COX-2 blocking peptide), 
as mean fluorescence from n=3 separate images from n=1 human donor (See details about donor in General 
Methods Chapter 2). Secondary control background was subtracted from each image before analysis.      
 
 
 
 
Chapter 3 Results 
158 
 
Figure 3.13 Summary of non-specific background immunoreactivity from the secondary 
control Goat anti rabbit Alexa Fluor 594 
 
Figure 3.13 continues on the next page. 
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Figure 3.13 (Continued) Summary of non-specific background immunoreactivity from the 
secondary control Goat anti rabbit Alexa Fluor 594 
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Figure 3.13 Summary of non-specific background immunoreactivity from Alexa Fluor 594. Secondary 
antibody Goat anti-rabbit Alexa Fluor 594 (Invitrogen A-11012) used to detect the COX-1 and COX-2 primary 
antibodies (raised in rabbit). Representative cropped images (200x200μm) of non-specific background 
immunoreactivity in the greater and lesser curvature of the aortic arch from (A) untreated and (B) LPS treated 
(E.coli serotype 0111:B4, 4mg/kg i.p. for 4hrs) 3 month old (young adult) male WT mice (C57BL/6J, Harlan, UK) 
Aortic arches were fixed according to the transcardial perfusion fixation procedure. (C) Background 
immunoreactivity quantified as mean fluorescence from the greater and lesser curvature and the descending 
aorta, from untreated (-) and LPS treated (+) mice. Data is the mean ± S.E.M of n=12 (2 separate images were 
taken per region from n=6 mice), except for the descending aorta where it was based on n=2 (2 separate 
images from n=1 mouse). Data was analysed using one-way ANOVA with Bonferroni’s multi comparison post-
test. P>0.05 was taken as non-significant and denoted by ns. 
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Figure 3.14 Use of blocking peptide to test the specificity of the COX-1 immunoreactivity 
 
Figure 3.14 continues on the next page. 
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Figure 3.14 (Continued) Use of blocking peptide to test the specificity of the COX-1 
immunoreactivity 
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Figure 3.14 Use of blocking peptide to test the specificity of the COX-1 immunoreactivity. Representative 
cropped images (200x200μm) of COX-1 immunoreactivity (red) in the greater curvature of aortic arches from 
(A) untreated and (B) LPS treated (E.coli serotype 055:B5, 10mg/kg i.p. for 4.5 hours) WT mice. Aortic arches 
(including the descending aorta) were fixed according to the ex vivo semi-perfusion fixation procedure. The 
descending aorta from the same animal was incubated with COX-1 blocking peptide (the precise epitope which 
the Cayman 160109 murine COX-1 antibody was raised against). Nuclei visualised with DAPI (blue) and 
endothelial cells outlined with CD31 (green). (C) COX-1 immunoreactivity quantified as mean fluorescence, data 
is the mean ± S.E.M from n=4-8 pictures, 1-2 separate images from n=4 young adult (3 month old), male WT 
mice (C57BL/6J bred in-house). Secondary control background was subtracted from each image before analysis. 
Data was analysed using unpaired Student’s t-test and p<0.05 taken as significant and denoted by *. 
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Figure 3.15 Use of blocking peptide to test the specificity of the COX-2 immunoreactivity  
 
 
Figure 3.15 continues on the next page. 
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Figure 3.15 (Continued) Use of blocking peptide to test the specificity of the COX-2 
immunoreactivity 
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Figure 3.15 Use of blocking peptide to test the specificity of the COX-2 immunoreactivity. Representative 
cropped images (200x200μm) of COX-2 immunoreactivity (red) in the greater curvature of aortic arches from 
(A) untreated and (B) LPS treated (E.coli serotype 055:B5, 10mg/kg i.p. for 4.5 hours) WT mice. Aortic arches 
(including the descending aorta) were fixed according to the ex vivo semi-perfusion fixation procedure. The 
descending aorta from the same animal was incubated with COX-2 blocking peptide (the precise epitope which 
the Cayman 160126 murine COX-2 antibody was raised against). Nuclei visualised with DAPI (blue) and 
endothelial cells outlined with CD31 (green). (C) COX-2 immunoreactivity quantified as mean fluorescence, data 
is the mean ± S.E.M from n=4-8 pictures, 1-2 separate images from n=4 young adult (3 month old), male WT 
mice (C57BL/6J bred in-house). Secondary control background was subtracted from each image before analysis. 
Data was analysed using unpaired Student’s t-test and p<0.05 taken as significant and denoted by *. 
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Figure 3.16 COX-1 immunoreactivity in the greater and the lesser curvature of aortic arches 
from young adult male WT, COX-1-/- and COX-2-/-mice  
 
 
Figure 3.16 continues on the next page. 
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Figure 3.16 (Continued) COX-1 immunoreactivity in the greater and the lesser curvature of 
aortic arches from young adult male WT, COX-1-/- and COX-2-/-mice 
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Figure 3.16 COX-1 immunoreactivity in the greater and the lesser curvature of aortic arches from young 
adult male WT, COX-1
-/-
 and COX-2
-/-
mice. Representative cropped images (200x200μm) of COX-1 
immunoreactivity (red) in aortic arches from untreated WT, COX-1
-/-
 and COX-2
-/-
 mice in (A) the greater 
curvature and (B) the lesser curvature. The aortic arches were fixed according to the ex vivo semi-perfusion 
fixation procedure. COX-1 immunoreactivity in the Greater Curvature (GC) and Lesser Curvature (LC) was 
quantified in untreated (C) WT versus COX-1
-/-
 mice and (D) WT versus COX-2
-/-
 as mean fluorescence. Data is 
the mean ± S.E.M from n=6-8 pictures, 2 separate images from each region from n=4 young adult (3 month 
old), male WT (C57BL/6J, bred in-house), COX-1
-/-
 and COX-2
-/-
 mice. Secondary control background was 
subtracted from each image before analysis. Data was analysed using unpaired Student’s t-test and p<0.05 
taken as significant and denoted by * and p>0.05 was taken as non-significant and denoted by ns. 
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Figure 3.17 COX-1 immunoreactivity in COX-1-/- with or without blocking peptide 
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Figure 3.17 COX-1 immunoreactivity in COX-1
-/-
 with or without blocking peptide. (A) Representative cropped 
image (200x200μm) of COX-1 immunoreactivity (red) in the greater curvature of an aortic arch from an 
untreated COX-1
-/-
 mice and the descending aorta from the same animal after incubation with COX-1 blocking 
peptide (the precise epitope which the Cayman 160109 murine COX-1 antibody was raised against). Aortic 
arches (including the descending aorta) were fixed according to the ex vivo semi-perfusion fixation procedure. 
(B) COX-1 immunoreactivity quantified as mean fluorescence. Data is the mean ± S.E.M from n=8 pictures, 2 
separate images from n=4 young adult (3 month old), male COX-1
-/-
 mice. Secondary control background was 
subtracted from each image before analysis. Data was analysed using unpaired Student’s t-test and p<0.05 
taken as significant and denoted by *. 
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Figure 3.18 COX-2 immunoreactivity in the greater and the lesser curvature of aortic arches 
from LPS treated young adult male WT, COX-1-/- and COX-2-/-mice  
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Figure 3.18 COX-2 immunoreactivity in the greater curvature of aortic arches from LPS treated young adult 
male WT, COX-1
-/- 
and COX-2
-/-
mice. Representative cropped images (200x200μm) of COX-2 immunoreactivity 
(red) in aortic arches from untreated WT, COX-1
-/-
 and COX-2
-/-
 mice in (A) the greater curvature and (B) the 
lesser curvature in LPS treated conditions (E.coli serotype 055:B5, 10mg/kg i.p. for 4.5 hours). The aortic arches 
were fixed according to the ex vivo semi-perfusion fixation procedure. COX-2 immunoreactivity in the Greater 
Curvature (GC) and Lesser Curvature (LC) was quantified as mean fluorescence in LPS treated (C) WT versus 
COX-2
-/-
 mice and (D) WT versus COX-1
-/-
 mice . Data is the mean ± S.E.M from n=8 pictures, 2 separate images 
from each region from n=4 young adult (3 month old), male WT (C57BL/6J, bred in-house), COX-1
-/-
 and COX-2
-/-
 
mice. Secondary control background was subtracted from each image before analysis. Data was analysed using 
unpaired Student’s t-test and p<0.05 taken as significant and denoted by * and p>0.05 was taken as non-
significant and denoted by ns. 
Chapter 3 Results 
168 
 
Figure 3.19 ‘Equilibrated study’; stimulated prostacyclin release from aortic arches and 
thoracic aorta from young adult WT, COX-1-/- and COX-2-/- mice 
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Figure 3.19 ‘Equilibrated study’; stimulated prostacyclin release from aortic arches and thoracic aorta from 
young adult WT, COX-1
-/-
 and COX-2
-/-
 mice. Prostacyclin release after 1.5 hours equilibration (-) , and after 30 
minutes calcium ionophore (A23187, 50μM) stimulation (+), from aortic arches (A) and thoracic aorta (B) from 
young adult (3 month old), male and female WT (C57BL/6J, bred in-house), COX-1
-/- 
and COX-2
-/- 
mice, 
measured as the prostacyclin stable breakdown product 6-ketoPGF1α by RIA. 100 μM diclofenac was added to 
the wells of some thoracic aorta segments during the equilibration phase (1.5 hours) and for the stimulation 
phase (30 minutes). Data is the mean ± S.E.M from n=6-7 animals. Within group analysis was performed using 
unpaired Student’s t-test and p<0.05 taken as significant and denoted by #. Between groups analysis was 
performed using one-way ANOVA with Bonferroni’s multi comparison post-test, p<0.05 was taken as significant 
and denoted by * and p>0.05 was taken as non-significant and denoted by ns.  
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Figure 3.20 ‘Acute study’; stimulated prostacyclin release from aortic arches and thoracic 
aorta from young adult WT, COX-1-/- and COX-2-/- mice 
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Figure 3.20 ‘Acute study’; stimulated prostacyclin release from aortic arches and thoracic aorta from young 
adult WT, COX-1
-/-
 and COX-2
-/-
 mice. Prostacyclin release after 30 minutes calcium ionophore (A23187, 50μM) 
stimulation (+), from aortic arches (A) and thoracic aorta (B) from young adult (3 month old), male and female 
WT (C57BL/6J, bred in-house) COX-1
-/- 
and COX-2
-/- 
mice, measured as the prostacyclin stable breakdown 
product 6-ketoPGF1α by EIA. 100 μM diclofenac was added to the wells of some thoracic aorta segments during 
the stimulation phase (30 minutes). Data is the mean ± S.E.M from n=4 animals. Within group analysis was 
performed using unpaired Student’s t-test and p<0.05 taken as significant and denoted by #. Between groups 
analysis was performed using one-way ANOVA with Bonferroni’s multi comparison post-test, p<0.05 was taken 
as significant and denoted by*. 
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Figure 3.21 ‘Equilibrated study’; Pilot study (n=2) of stimulated prostacyclin and 
thromboxane release from aortic arches and thoracic aorta from untreated and LPS treated 
young adult WT, COX-1-/- and COX-2-/- mice 
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Figure 3.21 ‘Equilibrated study’; pilot study (n=2) of stimulated prostacyclin release from aortic arches and 
thoracic aorta from young adult WT, COX-1
-/-
 and COX-2
-/- 
mice. Stimulated prostacyclin (A) and thromboxane 
(B) release after 1.5 hours equilibration plus 30 minutes calcium ionophore (A23187, 50μM) stimulation, from 
thoracic aorta from young adult (3 month old), untreated and LPS treated (E.coli serotype 055:B5, 10mg/kg i.p. 
for 4.5 hours) male WT (C57BL/6J, bred in-house), COX-1
-/- 
and COX-2
-/- 
mice. Prostacyclin release was 
measured as the stable breakdown product 6-ketoPGF1α and thromboxane release was measured as the stable 
breakdown product TXB2 by EIA. Data is the mean ± S.E.M from n=2 animals.  
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Summary of Chapter 3 
Below is a summary of the results from this chapter and how they relate to the research 
questions that I set out to study: 
 
How is the morphology of the endothelium and the underlying smooth muscle defined in 
the gross area of the mouse aortic arch? 
Using tissue from young healthy mice, without cardiovascular disease, I have in this chapter 
characterized morphological phenotypes of endothelial cells enriched in areas of the aortic 
arch that correlates with different types of shear stress (Suo et al., 2007). Cells in the greater 
curvature displayed characteristic elongated nuclei and were evenly spread out and aligned. 
In contrast, endothelial cells lining the lesser curvature had polygonally shaped nuclei and 
were randomly orientated in a more cobblestone fashion. The endothelial cells lining the 
‘interface region’ (situated between the greater and the lesser curvature displayed a mixed 
morphology.  
 
There was a distinct difference in nuclear density and of the endothelial cell marker, CD31 
immunoreactivity, between the two regions of the arch. Nuclear density of the endothelial 
cells increased progressively from the greater curvature via the interface region to the lesser 
curvature whereas the opposite was shown for the CD31 immunoreactivity which declined 
in parallel. The pattern of the CD31 immunoreactivity also differed between the two 
regions, where the CD31 appeared more evenly expressed throughout the cytoplasm in the 
cells of the greater curvature it was more localised at the intracellular junctions in cells in 
the lesser curvature. There depth of the CD31 positive endothelial cell layer was not 
significantly different between the two regions.  
 
The smooth muscle cell nuclei (directly underneath the endothelial cell layer) appeared to 
be more aligned in the greater curvature and randomly oriented in the lesser curvature, 
although the nuclear density was not different between the regions.  
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Which COX isoform predominates in vascular endothelium in situ and how does this relate 
to endothelial cell morphology? 
 
This en face model was used to study relative COX expression in different areas of 
endothelium of the aortic arch, in order to examine how different shear stress profiles 
(laminar shear stress in the greater curvature and oscillatory shear stress in the lesser 
curvature), may affect constitutive COX expression and activity in young healthy mice.  
 
 Tile composites covering a large area of aortic arch endothelium showed that COX-1 
immunoreactivity was highly abundant with an intense perinuclear staining pattern in 
every endothelial cells lining both the atherosclerosis protected (greater curvature) 
and the atherosclerosis prone (lesser curvature) regions of the mouse aortic arch and 
thereby in each shear responsive endothelial phenotype represented in this vascular 
structure.  
 There was no significant difference in COX-1 immunoreactivity in endothelial cells of 
the two regions in untreated mice. COX-1 immunoreactivity was, however increased in 
the endothelium of the lesser curvature region in mice treated with LPS.  
 COX-1 immunoreactivity was enriched in the endothelial layer compared to the 
smooth muscle layer. 
 COX-2 immunoreactivity in the endothelium of the aortic arch was overall very sparse 
and displayed a punctate staining pattern. However, COX-2 appeared to be modestly 
enriched in the atherosclerosis prone, lesser curvature of the mouse aortic arch 
compared to any other region of the arch. 
 Similarly, preliminarily pilot data using human pulmonary artery showed that, COX-1 
immunoreactivity was abundant and COX-2 immunoreactivity was sparse in the 
endothelium of this human vessel. 
 Whilst COX-2 was low in endothelium of healthy, control mice, it was, as expected, 
induced when animals were treated with LPS and this COX2 induction was also 
significantly higher in the lesser curvature compared to the greater curvature. 
 Specificity of COX primary antibodies was validated using respective blocking peptides. 
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 Some COX-1 immunoreactivity was detected in endothelium of COX-1-/- mice which 
was reduced with the COX-1 blocking peptide, suggesting a truncated COX-1 protein 
persists in these mice.  
 Levels of COX-1 immunoreactivity were not altered in COX-2-/- mice compared to WT 
mice.  
 COX-2 immunoreactivity in LPS treated COX-2-/- mice was significantly reduced 
compared to WT mice.  
 Counterpart COX isoforms were not up-regulated in endothelium of the COX-/- mice.  
 
Which COX isoform drives endothelial prostacyclin production in healthy blood vessels? 
 
 Prostacyclin ‘basal’ release was very low in unstimulated tissues.  
 Calcium ionophore stimulated prostacyclin release in thoracic and aortic arch tissue 
from WT and COX-2-/- mice. Thromboxane release was low under all conditions and 
in tissue from each type of mouse. 
 This bioassay protocol was validated using the COX-1 and COX-2 inhibitor (NSAID) 
diclofenac, which completely inhibited the stimulated prostacyclin release.  
 Prostacyclin release was very low or absent in thoracic aorta or aortic arch tissue 
from COX-1-/- mice even after stimulation with calcium ionophore.  
 Similar results were obtained using a second protocol, without the equilibration 
step, ‘acute’ protocol, where prostacyclin release from either thoracic aorta or aortic 
arch was abundant it tissue from WT and COX-2-/- mice, but abolished in tissue from 
COX-1-/- mice.  
 This pattern of COX-1 bioactivity remained the same in tissue from mice treated with 
LPS.  
 
These experiments indicate that the enzyme responsible for prostacyclin production in 
aortic tissue from young healthy mice is mainly COX-1. The implications of these 
observations are discussed in detail in my General Discussion chapter (Chapter 6). 
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Chapter 4 
 
 
 
Effect of age, gender and heart disease on expression and 
activity of COX isoforms in the aortic endothelium 
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Rationale behind Chapter 4 
The results from the previous chapter indicate that COX-1 immunoreactivity predominates 
in the endothelium of both the atherosclerosis protected (greater curvature) and 
inflammation and atherosclerosis susceptible (lesser curvature) regions of the aortic arch 
from healthy young adult male mice and that COX-1 enzyme activity accounts for the 
majority of the prostacyclin production in blood vessels from these mice.  COX-1 therefore 
seems to be the main constitutively expressed endothelial COX isoform, responsible for 
prostacyclin production in healthy tissues. 
It is however important to consider that COX activity and isoform expression may differ 
between males and females (Akarasereenont et al., 2000; Egan et al., 2004). Furthermore, 
cardiovascular homeostasis and risk of disease is known to be influenced by the sex of the 
animal. In humans, for example women are somewhat protected from heart attack and 
stroke up until the age of menopause (Kannel et al., 1976). This chapter therefore includes 
experiments where I examined COX immunoreactivity in tissue from healthy female mice 
and sub analysed data for COX bioactivity between male versus female mice.  
There is also literature that suggests that COX-2 in the endothelium is increased as we age 
and/or with endothelial dysfunction associated with chronic cardiovascular conditions 
(Heymes et al., 2000; Wu et al., 1998). This is a relevant argument considering that the 
target patient group for chronic dosing of NSAIDs and COX-2 selective inhibitors are often 
elderly patients with arthritis. It has been shown that the negative effect of age on 
endothelial function in mice is apparent by 12 months (Gendron et al., 2007). I therefore 
compared results in tissue from young (3 month old) as well as mature (12 month old) mice 
to see if there is any age related change in endothelial COX-1 and COX-2 expression and 
prostacyclin production.  
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Finally, in order to understand how gross cardiovascular disease/inflammation may affect 
the relative expression and activity of COX isoforms in the endothelium I studied vascular 
tissue from animal models of (i) heart failure and (ii) atherosclerosis.  
 
In summary, I have in this chapter specifically compared the role of COX-1 and COX-2 in 
blood vessels from young adult versus mature adult mice, in male versus female mice, in 
tissue from control rats versus rats with chronic heart failure and in WT mice versus ApoE-/- 
mice fed either normal chow or an atherogenic diet. 
The aims and research questions of this chapter can be summarised as follows: 
 
Which COX isoform(s) predominate in vascular endothelium in female mice and in mature 
adult (12 month old) WT mice? 
 Examine COX-1 and COX-2 immunoreactivity in endothelial cells lining the 
atherosclerosis-protected greater curvature and the atherosclerosis-prone lesser 
curvature of the mouse aortic arch from young adult (3 month old) female WT mice 
and from mature adult (12 month old) WT mice.   
 
Which COX isoform drives endothelial prostacyclin production in female mice and in 
mature adult (12 month old) WT mice? 
 Establish the functional relevance of COX-1 versus COX-2 in the aorta in terms of 
prostacyclin releasing capacity by using tissue from young (3 month old) and mature 
adult (12 month old) male versus female, WT versus COX-1-/- and COX-2-/- mice.  
 
Does the relative expression pattern of endothelial COX-1 and COX-2 or prostanoid profile 
released from vessels change following cardiovascular disease (rat model of chronic heart 
failure or mouse model of atherosclerosis)? 
 Repeat the COX en face immunohistochemistry protocol and stimulated prostanoid 
release in rats with chronic heart failure and in mice with early markers of 
atherogenesis and vascular inflammation (in ApoE-/- mice fed a normal chow diet) and 
with established atherosclerotic plaques (in ApoE-/- mice fed an atherogenic diet).  
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Methods 
Animals 
WT, COX-1-/- and COX-2-/- mice 
WT, COX-1-/- and COX-2-/- mice were bred, maintained and genotyped as described in the 
General Methods Chapter 2. For this chapter, animals were male and female and used at 
two age groups; young adult (3-4 month old) and mature adult (11-16 months old) mice.  All 
WT mice were from the C57BL/6J strain; some WT were purchased from Harlan, UK, whilst 
other WT were bred in-house with a shared background to match the COX-1-/- and COX-2-/- 
mice (backcrossed to C57BL/6J, Harlan, UK, more than 7 times) see General Methods 
Chapter 2. Purchased WT mice will be referred to as ‘C57BL/6J, Harlan, UK’ and the other 
COX colony WT controls will be referred to as ‘C57BL/6J, bred in-house’. Mice were killed by 
CO2 asphyxiation and aortic arches were dissected out and fixed with 2% formaldehyde 
according to the ‘ex vivo semi-perfusion fixation procedure’ or the ‘transcardial perfusion 
fixation procedure’ and staining protocols described in the General Methods Chapter 2 
(Table 2.18). COX and CD31 immunoreactivity was measured in the endothelium of the 
aortic arch as described in Chapter 3 and as detailed in the General Methods Chapter 2. COX 
activity was also measured in tissue from WT and COX-1-/- and COX-2-/- mice according to 
the ‘equilibrated study’ or ‘acute study’ protocol as described in Chapter 3 and as detailed in 
the General Methods Chapter 2. Stimulated prostacyclin release data from Chapter 3 (Figure 
3.19 and Figure 3.20) including the ‘equilibrated study’ and the ‘acute study’ protocol were 
included for post-hoc analysis of male versus female prostacyclin release from aortic arches 
and thoracic aorta.  
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ApoE-/- mice 
In this thesis I have performed experiments in both normal chow fed ApoE-/- mice 
(ApoEtm1Unc from a C57BL/6J background) as well as ApoE-/- mice that have been fed an 
atherogenic diet, in order to consider a model of early atherogenesis as well as more 
advanced and established atherosclerosis respectively (for more details see General 
methods Chapter 2).  
 
Normal chow fed ApoE-/- mice as a model of early atherogenesis  
The normal chow fed ApoE-/- mice and WT controls (C57BL/6J, bred in-house) were killed by 
CO2 asphyxiation and aortic arches were dissected out and fixed with 2% formaldehyde 
according to the ‘transcardial perfusion fixation procedure’ and staining protocols for COX 
immunoreactivity as described in the General Methods Chapter 2 (Table 2.18).  
 
High cholesterol chow fed ApoE-/- mice as a model of accelerated atherosclerosis  
These ApoE-/- mice were fed an atherogenic high fat and high cholesterol diet (21% fat, 
1.25% cholesterol, cholate-free; Research Diets, D12108) starting from 12 weeks of age for 
10 weeks in order to accelerate the rate of atherosclerotic plaque formation. 
 
For illustrative purposes and as a pilot study, I was able to image and quantify some of these 
functional changes in the aortic arch of a high cholesterol chow fed ApoE-/- mouse which 
had gone on to develop profound atherosclerosis (due to the high fat feeding). This first 
high cholesterol chow fed ApoE-/- mouse (female) was perfused according to the 
‘transcardial perfusion fixation procedure’ whereas due to an animal share, the remaining 
n=4 male and female high cholesterol chow fed ApoE-/- mice were perfused according to the 
‘ex vivo semi-perfusion fixation procedure’.  
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Heart failure model; Rats 
In this chapter I have examined COX activity and expression in a heart failure model in rats. 
The full details of the model are given in the General Methods Chapter 2. The surgery, 
maintenance and husbandry of the rats were performed by our collaborator Dr Alexander 
Lyon (Imperial College). In brief, male Sprague Dawley rats (250-300g, 2-3 month old) were 
anaesthetized and the left proximal coronary artery was ligated 1mm below the left atrial 
appendage, encompassing both the proximal left anterior descending artery and first 
diagonal coronary arteries, giving a large infarct size (~30% left ventricular myocardium) to 
induce chronic myocardial infarction. Animals were allowed to recover and were followed 
for approximately 4 months after the procedure, where markers of heart failure manifest.  
These are described in detail in the General Methods Chapter 2. For this study, rats with 
established chronic heart failure rats or age-matched controls (male Sprague Dawley rats) 
were anaesthetised with isoflurane (5% induction and 3% maintenance) and buprenorphine 
(opioid for pain relief, 0.05ml of 1mg/ml) was administered subcutaneously. Unfractionated 
heparin (100-200 units) was injected intravenously prior to dissection. The aortic arch 
(including carotid artery branches) and the thoracic aorta was removed immediately after 
death and placed in PBS.  The thoracic aorta was prepared for the ‘equilibrated study’ 
protocol of stimulated prostanoid release, whilst the aortic arch fixed in 2% 
paraformaldehyde for 20 minutes before the start of the COX immunoreactivity staining 
protocol according to details in the General Methods Chapter 2.  
 
For antibody validation purposes, segments of an abdominal aorta (from a control rat, n=1) 
were incubated overnight in 37°C +/- LPS (E.coli serotype 0111:B4, 10μg/ml) in order to 
serve as a positive control for COX-2 induction. These segments were then subject to the 
‘equilibrated study’ protocol of stimulated prostanoid release, whilst the aortic arch fixed in 
2% paraformaldehyde for 20 minutes before the start of the COX immunoreactivity staining 
protocol according to details in the General Methods Chapter 2 (Table 2.18).  
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En Face imaging of the arch lumen 
In this chapter I have imaged CD31, COX-1 and COX-2 using antibodies and the stain DAPI to 
visualise nuclei as described in the General Methods Chapter 2 (Table 2.18). Mean 
fluorescence was quantified using LAS AF software. COX-1 and COX-2 immunoreactivity was 
measured in the endothelium of the aortic arch, the descending thoracic aorta, the carotid 
branches (brachiocephalic artery, left common carotid artery and the left subclavian artery) 
according to protocols described in the General Methods Chapter 2. 
 
Measurement of COX activity 
COX activity was measured in the male versus female mice, mature adult mice and rats with 
or without chronic heart failure, after equilibration (according to the ‘equilibrated study’ 
protocol, see Chapter 2), in thoracic aortic tissue stimulated with calcium ionophore 
(A23187, 50 μM) for 30 minutes. COX activity was indexed by measuring levels of 
prostacyclin (as the stable breakdown product 6-ketoPGF1α; by EIA assay from Cayman 
Chemical), PGE2 by HTRF assay (Cisbo), or TXA2 (measured as the stable breakdown product 
TXB2; by EIA assay from Cayman Chemical).  
 
Analysis and statistics 
Data is presented as the mean ± S.E.M and was analysed using Graph Pad Prism 5 using 
statistical tests described in the figure legends. A p value of <0.05 was taken as significant 
and denoted by * and p>0.05 was considered non-significant and denoted by ns.   
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Results 
COX isoform expression and activity in endothelium of male versus female young adult mice 
Similar to the observations made in male mice in the previous chapter, I found that COX-1 
immunoreactivity predominated vastly over COX-2 immunoreactivity in female mice and the 
COX-2 immunoreactivity (although sparse) was significantly higher in the lesser curvature 
compared to the greater curvature (Figure 4.1A+B+C). In a sub-analysis of  data presented in 
the previous chapter, prostacyclin release from aortic arches or thoracic aortas from young 
adult (3 month old) female mice (n=2) was virtually absent in tissue from COX-1-/- mice and 
being unaffected by COX-2 gene deletion (Figure 4.2). This was true using both the 
‘equilibrated’ and the ‘acute’ bioassay protocols (Figure 4.2A+B+C+D). No discernible 
difference was seen in prostacyclin release from tissue of male versus female young adult (3 
month old) mice (Figure 4.2) or older mature adult (12 month old) mice (Figure 4.3). 
COX isoform expression in aortic arch endothelium from mature adult (12 month old) mice 
Mice reach sexual maturity at approximately 2 months. At 3-6 months mice are considered 
mature but still young with no particular signs of cardiovascular ageing. At 12 plus months 
mice are considered mature/middle aged with significant signs of vascular aging (Gendron 
et al., 2007). As was seen in the endothelium of the aortic arch of young adult (3 month old) 
mice, COX-1 was readily detected in tissue from mature adult (12 month old) mice in a 
similar perinuclear staining pattern as observed in young adult (3 month old) mice (Figure 
4.4C+D and Figure 4.6). Again, as was seen in tissue from young adult (3 month old) mice, 
COX-2 immunoreactivity was sparse in the endothelium of the aortic arch from mature adult 
(12 month old) mice and showed a similar punctate staining pattern (Figure 4.5C+D and 
Figure 4.6). Levels of mean fluorescence were comparable for COX-1 and COX-2 in tissue 
from young adult (3 month old) versus mature adult (12 month old) mice (Figure 4.6C)  
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COX activity in endothelium from mature adult (12 month old) mice 
In a pilot study at the beginning of my PhD, where we had WT mice and COX-1-/- mice, but 
not COX-2-/- mice, I was able to measure prostacyclin release from thoracic aorta from 
mature adult (12 month old) mice, using the same ‘equilibrated’ protocol I described in 
Chapter 3. In this early study I found that prostacyclin releasing capacity of aortic tissue was 
greatly reduced in tissue from COX-1-/- mice (Figure 4.7). Once we had enough animals from 
the COX-2-/- colony, I then repeated this entire experiment and compared the ability of 
thoracic aortic tissue from WT, COX-1-/- and COX-2-/- mature adult (12 month old) mice 
(Figure 4.8). Again, I found that prostacyclin release was virtually absent in aortic tissue 
from COX-1-/-, but not COX-2-/- mature adult (12 month old) mice (Figure 4.8). Figure 4.8 
confirms that, in this second data set, COX-1 again predominates over COX-2 in the aortic 
endothelium of 12 month aged mice and additionally shows no discernible compensatory 
effects on COX-1 or COX-2 expression in tissue from COX-1-/- and COX-2-/- mice (Figure 4.9). 
COX isoform expression in endothelium from aged matched control rats versus rats with 
chronic heart failure    
As with endothelium from mouse aortic tissue, COX-1 predominates over COX-2 
immunoreactivity in aortic arch endothelium from aged matched control rats and rats with 
established heart failure, and both the COX-1 and COX-2 immunoreactivity was blocked by 
the addition of COX-1 and COX-2 blocking peptides (Figure 4.10).  Similar observations were 
made in the carotid artery branches of the aortic arch (Figure 4.11). No significant effect of 
heart failure was seen on COX-1 or COX-2 immunoreactivity (Figure 4.10 and Figure 4.11).     
Validation studies for the COX immunoreactivity in rat endothelium     
There was no significant difference between the non-specific background immunoreactivity 
between aged matched control rats and rats with chronic heart failure (Figure 4.12). In 
order to be sure that the COX-2 antibody (Cayman 160126) was indeed able to detect COX-2 
in rat tissue, I performed a validation study where segments of abdominal aorta from an 
aged matched control rat were incubated with or without LPS overnight and COX-2 
immunoreactivity imaged. In these experiments, COX-2 immunoreactivity was easily 
detectable, increased by LPS and blocked by COX-2 blocking peptide (Figure 4.13).  
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COX prostanoid profile bioactivity in endothelium from aged matched control rats versus rats 
with chronic heart failure    
In line with COX immunoreactivity, COX activity, measured by prostacyclin, thromboxane 
and PGE2 release, was similar in tissue from aged matched control and heart failure animals 
(Figure 4.14A). In a post-hoc analysis of the rats with the highest myocardial infarction score 
(n=2 out of n=4 rats with heart failure), there was still no difference compared to n=2 aged 
matched controls in terms of COX immunoreactivity or prostanoid profile. As was seen with 
the mouse tissue, prostacyclin was the major COX product released from these vessels. 
Although, PGE2 release was as expected increased from the abdominal aorta that had been 
treated over night with LPS treated (Figure 4.14B).  
COX isoform expression in aortic endothelium from WT versus normal chow fed ApoE-/- mice 
As was found in tissue from WT mice; COX-1 immunoreactivity was highly abundant in 
endothelium from the descending aorta from ApoE-/- mice (when fed a normal chow diet), 
whereas COX-2 immunoreactivity in endothelium from the adjacent mid arch part of the 
aortic arch was very sparse (Figure 4.15). Furthermore, there was no significant difference in 
COX-1 or COX-2 immunoreactivity between the WT mice and ApoE-/- mice in both the 
endothelial and underlying smooth muscle layers of these tissues (Figure 4.16A+B).  
En face imaging of a large plaque like structure in the aortic arch from an ApoE-/- mouse fed 
an atherogenic diet 
I was able to repeat the en face imaging protocol In an ApoE-/- mouse fed an atherogenic 
diet, which upon micro dissection had distinct yellow/white plaque like structures inside the 
lesser curvature of the aortic arch, the mid arch and the proximal part of the descending 
aorta as well as dense and calcified aortic valves (Figure 4.17A).  
The superficial layer of the plaque had CD31 positive endothelium covering most of the 
plaque (although somewhat fainter in intensity and more localised to intracellular junctions 
compared to plaque free ‘normal looking’ adjacent areas of endothelium). There was also a 
strikingly higher nuclear density (visualised by the nuclear stain DAPI) (Figure 4.17C). Since 
DAPI does not distinguish between different cell types, other more specific markers would 
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be needed for closer examination of the cellular and non-cellular composite of this plaque 
like structure.   
COX isoform expression in aortic endothelium from ApoE-/- mice fed an atherogenic diet 
When the mid arch and the proximal descending aorta from the same ApoE-/- mouse (fed an 
atherogenic diet) was stained with COX-1 and COX-2, there was clear COX-1 and COX-2 
immunoreactivity enriched on top and inside the plaque (Figure 4.18 and 4.19). When this 
study was repeated in 4 other mice and the data from these mice were quantified, there 
was a trend for enriched COX-1 and COX-2 immunoreactivity in the plaque like structure, 
but this did not reach statistical significance (Figure 4.19C+D).  
It is relevant and important to note that in experiments performed by my colleague, Dr 
Nicholas Kirkby, prostacyclin release by COX-2 knock out ApoE-/- mice (double knockout 
mice; ApoE-/- COX-2-/-) show that, even in atherosclerotic enriched vascular tissue, COX-1 
drives gross prostacyclin production. 
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Figures 
Figure 4.1 COX-1 versus COX-2 immunoreactivity in the greater and the lesser curvature of 
the mouse aortic arch from young adult female WT mice 
 
Figure 4.1 continues on the next page. 
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Figure 4.1 (Continued) COX-1 versus COX-2 immunoreactivity in the greater and the lesser 
curvature of the mouse aortic arch from young adult female WT mice 
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Figure 4.1 COX-1 versus COX-2 immunoreactivity in the greater and the lesser curvature of the mouse aortic 
arch from young adult female WT mice. Representative cropped images (200x200μm) of (A) COX-1 
immunoreactivity and (B) COX-2 immunoreactivity (red), from the greater and the lesser curvature of the 
mouse aortic arch. Aortic arches were fixed according to the transcardial perfusion fixation procedure. Nuclei 
visualised with DAPI (blue) and endothelial cells outlined with CD31 (green). (C) Pooled data comparing COX-1 
and COX-2 immunoreactivity in n=4 female WT mice from head to head experiments (same experimental 
conditions, staining protocol and secondary antibody Alexa Fluor 594 was used to capture both COX-1 and 
COX-2 immunoreactivity). 3 unique images were captured from the greater curvature and the lesser curvature 
respectively, using identical confocal settings throughout the study. COX immunoreactivity was quantified as 
mean fluorescence. Secondary control background was subtracted from each image before analysis. Data is 
presented as the mean ± S.E.M of n=9-12 images from separate regions of tissue from n=4 WT mice young 
adult (3 month old), female mice (C57BL/6J, bred in-house). Within group analysis (greater curvature versus the 
lesser curvature) was performed using paired Student’s t-test and p<0.05 was taken as significant and denoted 
by #. Between groups analysis was analysed using one-way ANOVA with Bonferroni’s multi comparison post-
test and *p<0.05 was taken as significant and denoted by *. 
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Figure 4.2 ‘Equilibrated study’ and ‘Acute study’; stimulated prostacyclin release from aortic 
arches and thoracic aorta from young adult male versus female WT, COX-1-/- and COX-2-/- 
mice  
 
Figure 4.2 ‘Equilibrated study’ and ‘Acute study’; stimulated prostacyclin release from aortic arches and 
thoracic aorta from young adult male versus female WT, COX-1
-/-
 and COX-2
-/-
 mice.  
‘Equilibrated study’: Stimulated prostacyclin release measured from (A) aortic arches and (B) thoracic aorta 
after 1.5 hours equilibration and 30 minutes calcium ionophore (A23187, 50μM) stimulation, measured as the 
prostacyclin stable breakdown product 6-ketoPGF1α by RIA. Data is presented as the mean ± S.E.M from n=4-5 
male and n=2 female young adult (3 month old) WT (C57BL/6J, bred in-house), COX-1
-/- 
and COX-2
-/-
 mice.  
‘Acute study’: Stimulated prostacyclin release measured from (B) aortic arches and (C) thoracic aorta after 30 
minutes calcium ionophore (A23187, 50μM) stimulation, measured as the prostacyclin stable breakdown 
product 6-ketoPGF1α by EIA. Data is the mean ± S.E.M from n=2 male and n=2 female young adult (3 month 
old) WT (C57BL/6J, bred in-house), COX-1
-/- 
and COX-2
-/-
 mice.  
 Data represents post hoc analysis of prostacyclin release from male versus female mice from pooled data 
(presented in Figure 3.18 and 3.19 in Chapter 3).  
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Figure 4.3 ‘Equilibrated study’ stimulated prostacyclin release from thoracic aorta from 
mature adult, male versus female WT mice  
Prostacyclin release from thoracic aorta
males versus females
0
2
4
6
8
10
WT male (n=4)
WT female (n=2)
Ca2+ ionophore
 A23187
-    +      +          -     +     +
diclofenac -    -      +          -        -     +
[6
-k
et
o
 P
G
F 1

] 
(n
g/
m
l)
 
Figure 4.3 ‘Equilibrated study’ stimulated prostacyclin release from thoracic aorta from mature adult, male 
versus female WT mice. Stimulated prostacyclin release measured from thoracic aorta after (-) 1.5 hours 
equilibration and (+) after 30 minutes calcium ionophore (A23187, 50μM) stimulation, measured as the 
prostacyclin stable breakdown product 6-ketoPGF1α by EIA. 100 μM diclofenac was added to the wells of some 
thoracic aorta segments during the stimulation phase (30 minutes). Data is presented as the mean ± S.E.M 
from n=4 male and n=2 female mature adult (10-16 month old) WT mice (C57BL/6J, bred in-house). Data 
represents post hoc analysis of prostacyclin release from male versus female mice from pooled data (Figure 
4.8). 
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Figure 4.4 Tile composite of 4x4 images showing COX-1 immunoreactivity in the greater and 
the lesser and curvature of the aortic arch from a mature adult WT mouse 
 
Figure 4.4 Tile composite of 4x4 images showing COX-1 immunoreactivity in the lesser and greater curvature 
of the aortic arch from a mature mouse. Images from a perfusion fixed (according to the transcardial 
perfusion fixation procedure) aortic arch dissected from a mature adult (12 month old) male WT mouse 
(C57BL/6J, Harlan, UK). (A) Red dotted line, mark dissection cutting points. (B) A schematic of the mounted 
(opened and flattened) aortic arch, marking the location of the greater and the lesser curvature as well as the 
position of the tile composite (4x4 images, coordinates 1.1-4.4). (C) The entire tile of 4x4 images. DAPI stained 
nuclei (blue) and COX-1 immunoreactivity (red). (D) Zoomed in images (from coordinates 2.1 and 3.3) showing 
intracellular localisation of COX-1 immunoreactivity. 
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Figure 4.5 Tile composite of 4x4 images showing COX-2 immunoreactivity in the greater and 
the lesser curvature of the aortic arch from a mature adult WT mouse 
 
Figure 4.5 Tile composite of 4x4 images showing COX-2 immunoreactivity in the greater and the lesser 
curvature of the aortic arch from a mature mouse. Images from a perfusion fixed (according to the 
transcardial perfusion fixation procedure) aortic arch dissected from a mature adult (12 month old) male WT 
mouse (C57BL/6J, Harlan, UK). (A) Red dotted line, mark dissection cutting points. (B) A schematic of the 
mounted (opened and flattened) aortic arch, marking the location of the greater and the lesser curvature as 
well as the position of the tile composite (4x4 images, coordinates 1.1-4.4). (C) The entire tile of 4x4 images. 
DAPI stained nuclei (blue) and COX-2 immunoreactivity (red). (D) Zoomed in images (from coordinates 3.1 and 
3.4) showing intracellular localisation of COX-2 immunoreactivity.  
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Figure 4.6 Comparison of COX-1 and COX-2 immunoreactivity in aortic arches from male 
young adult (3 month old) versus mature adult (12 month old) WT mice 
 
Figure 4.6 continues on the next page. 
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Figure 4.6 (Continued) Comparison of COX-1 and COX-2 immunoreactivity in aortic arches 
from male young adult (3 month old) versus mature adult (12 month old) WT mice 
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Figure 4.6 Comparison of COX-1 and COX-2 immunoreactivity in aortic arches from male young adult (3 
month old) versus mature adult (12 month old) WT mice. (A) Part of tiles showing COX-1 and COX-2 
immunoreactivity in the greater and lesser curvature of aortic arches from young versus mature male WT mice. 
(B) Representative cropped images (200x200μm) showing COX-1/COX-2 immunoreactivity (red), in merged 
images with  DAPI stained nuclei (blue) and endothelial cell marker CD31 (green), in the greater and lesser 
curvature of aortic arches from young adult (3 month old) versus mature adult (12 month old) male WT mice 
(C57BL/6J, Harlan, UK). (C) Quantified COX immunoreactivity as mean fluorescence from the greater and lesser 
curvature of the aortic arch. Data is presented as the mean ± S.E.M from n=14-18 images from separate 
regions of tissue from n=6 young adult (3 month old), male WT mice (C57BL/6J, Harlan, UK) and n=8-11 images 
from n=4 mature adult (12 month old), male WT mice (C57BL/6J, Harlan, UK).  Secondary control background 
was subtracted from each image before analysis. Data was analysed using one-way ANOVA with Bonferroni’s 
multi comparison post-test and *p<0.05 was taken as significant and denoted by*. 
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Figure 4.7 ‘Equilibrated study’; stimulated prostacyclin release from thoracic aorta from 
male mature adult WT and COX-1-/- mice 
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Figure 4.7 ‘Equilibrated study’; stimulated prostacyclin release from thoracic aorta from male young adult 
WT and COX-1
-/-
 mice. Stimulated prostacyclin release after 1.5 hours equilibration and after 30 minutes 
calcium ionophore (A23187, 50μM) stimulation (+), from thoracic aorta from mature adult (12 month old), 
male WT and COX-1
-/- 
mice, measured as the prostacyclin stable breakdown product 6-ketoPGF1α by RIA. Data 
is presented as the mean ± S.E.M from n=4-5 animals and was analysed using unpaired Student’s t-test and 
p<0.05 taken as significant and denoted by*.  
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Figure 4.8 ‘Equilibrated study’; stimulated prostacyclin release from thoracic aorta from 
male and female mature adult WT, COX-1-/- and COX-2-/- mice 
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Figure 4.8 ‘Equilibrated study’; stimulated prostacyclin release from thoracic aorta from male and female 
mature adult WT, COX-1
-/-
 and COX-2
-/-
 mice. Prostacyclin release after 1.5 hours equilibration (-) , and after 
30 minutes calcium ionophore (A23187, 50μM) stimulation (+), from thoracic aorta from 12 month old, mature 
adult, male and female WT, COX-1
-/- 
and COX-2
-/- 
mice, measured as the prostacyclin stable breakdown product 
6-ketoPGF1α by EIA. 100 μM diclofenac was added to the wells of some thoracic aorta segments during the 
equilibration phase (1.5 hours) and for the stimulation phase (30 minutes). Data is presented as the mean ± 
S.E.M from n=6 animals. Within group analysis was performed using unpaired Student’s t-test and p<0.05 
taken as significant and denoted by #. Between groups analysis was performed using one-way ANOVA with 
Bonferroni’s multi comparison post-test, p<0.05 was taken as significant and denoted by *.  
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Figure 4.9 COX-1 and COX-2 immunoreactivity in the greater and the lesser curvature of 
aortic arches from mature adult WT, COX-1-/- and COX-2-/-mice 
 
Figure 4.9 COX-1 and COX-2 immunoreactivity in the greater and the lesser curvature of aortic arches from 
mature adult WT, COX-1
-/-
 and COX-2
-/-
mice. Representative cropped images (200x200μm) of COX-1 and COX-
2 immunoreactivity (red) in the greater and the lesser curvature of aortic arches from untreated WT, COX-1
-/-
 
and COX-2
-/- 
mice. All of the images have been treated the same in terms of alterations in brightness and 
contrast for clarity of viewing purposes (+40% brightness and +40% contrast).  
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Figure 4.10 COX-1 and COX-2 immunoreactivity in aortic arch endothelium from aged 
matched control rats versus rats with chronic heart failure 
 
Figure 4.10 continues on the next page. 
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Figure 4.10 (Continued) COX-1 and COX-2 immunoreactivity in aortic arch endothelium from 
aged matched control rats versus rats with chronic heart failure 
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Figure 4.10 COX-1 and COX-2 immunoreactivity in aortic arch endothelium from aged matched control rats 
versus rats with chronic heart failure. Representative cropped images (200x200μm) of COX-1 and COX-2 
immunoreactivity aortic arch segments from (A) aged matched control rats (6-7 months old) and (B) rats with 
chronic heart failure (6-7 month old). Nuclei was visualised by DAPI (blue) and merge (blue and red) represents 
both DAPI stained nuclei (blue) and COX-2 immunoreactivity (red). Some aortic arch segments were incubated 
with COX-1 or COX-2 blocking peptides (the precise epitopes which the Cayman COX-1 160109 or 160126 COX-2 
antibodies was raised against). (C) Quantified COX immunoreactivity as mean fluorescence from n=4 heart 
failure rats and n=5 aged matched control rats (average values from 2 pictures per aortic arch tissue imaged).  
Data is presented as the mean ± S.E.M and was analysed using one-way ANOVA with Bonferroni’s multi 
comparison post-test and p<0.05 was taken as significant and denoted by * and p>0.05 was taken as non-
significant and denoted by ns.  
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Figure 4.11 COX-1 and COX-2 immunoreactivity in the endothelium of the carotid artery 
branches of the aortic arch from aged matched control rats versus rats with chronic heart 
failure 
 
Figure 4.11 continues on the next page. 
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Figure 4.11 (Continued) COX-1 and COX-2 immunoreactivity in the endothelium of the 
carotid artery branches of the aortic arch from aged matched control rats versus rats with 
chronic heart failure 
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Figure 4.11 COX-1 and COX-2 immunoreactivity in the endothelium of the carotid artery branches of the 
aortic arch from aged matched control rats versus rats with chronic heart failure. Representative cropped 
images (200x200μm) of COX-1 and COX-2 immunoreactivity in carotid artery branches (brachiocephalic artery, 
left common carotid artery and left subclavian artery) from (A) aged matched control rats (6-7 months old) and 
(B) rats with chronic heart failure (6-7 months old). Some segments of the carotid artery branches of the aortic 
arch were incubated with COX-1 or COX-2 blocking peptides (the precise epitopes which the Cayman COX-1 
160109 or 160126 COX-2 antibodies was raised against). Nuclei was visualised by DAPI (blue) and merge (blue 
and red) represents both DAPI stained nuclei (blue) and COX-2 immunoreactivity (red).(C) Quantified COX 
immunoreactivity as mean fluorescence from n=2 heart failure rats and n=3 aged matched control rats 
(average values from 2 pictures per tissue imaged).  Data is presented as the mean ± S.E.M.  
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Figure 4.12 Non-specific background immunoreactivity from Alexa Fluor 594 secondary 
control in the endothelium of aortic arch tissue and carotid artery branches from aged 
matched control rats versus rats with chronic heart failure 
 
Figure 4.12 Non-specific background immunoreactivity from Alexa Fluor 594 secondary control in the 
endothelium of aortic arch tissue and carotid artery branches from aged matched control rats versus rats 
with chronic heart failure.  Representative cropped images (200x200μm) of background immunoreactivity 
(red) in (A) aortic arch tissue and (B) carotid artery branches (brachiocephalic artery, left common carotid 
artery and left subclavian artery) from aged matched control rats and rats with chronic heart failure (all rats 
were 6-7 month old). Nuclei was visualised by DAPI (blue) and merge (blue and red) represents both DAPI 
stained nuclei (blue) and background immunoreactivity (red).   
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Figure 4.13 Validation experiment; positive control for the COX-2 antibody- abdominal aorta 
incubated in vitro overnight +/- LPS 
 
Figure 4.13 continues on the next page. 
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Figure 4.13 (Continued) Validation experiment; positive control for the COX-2 antibody- 
abdominal aorta incubated in vitro overnight +/- LPS 
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Figure 4.13 Positive control validation experiments for the COX-2 antibody- abdominal aorta incubated in 
vitro overnight +/- LPS.  Representative cropped images (200x200μm) of COX-2 immunoreactivity (red) in 
segments of an abdominal aorta incubated overnight in 37°C +/- LPS (E.coli serotype 0111:B4, 10μg/ml). Some 
segments of abdominal aorta were incubated with the COX-2 blocking peptide (the precise epitope which the 
Cayman 160126 COX-2 antibody was raised against). Nuclei was visualised by DAPI (blue) and merge (blue and 
red) represents both DAPI stained nuclei (blue) and COX-2 immunoreactivity (red). (C) Quantified COX-2 
immunoreactivity as mean fluorescence from n=1 abdominal aorta (average values from 2 pictures per tissue 
imaged) from an aged matched control rat (6-7 months old).  
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Figure 4.14 Prostanoid profile in aged matched control rats versus rats with chronic heart 
failure and from an in vitro assay with overnight incubation +/- LPS   
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Figure 4.14 Prostanoid profile in aged matched control rats versus rats with chronic heart failure and from 
an in vitro assay with overnight incubation +/- LPS. Stimulated prostacyclin (measured as the stable 
breakdown product 6-ketoPGF1α by EIA), thromboxane (measured as the stable breakdown product TXB2 by 
EIA) and prostaglandin E2 (by HTRF) release from rat aorta after 1.5 hours equilibration and 30 minutes calcium 
ionophore (A23187, 50μM) stimulation. 100 μM diclofenac was added to the wells of some thoracic aorta 
segments during the stimulation phase (30 minutes). (A) Data is presented as the mean ± S.E.M from n=5 
thoracic aortic rings from aged matched control rats and rats with chronic heart failure (all rats were 6-7 
month old). (B) Data is presented as the mean ± S.E.M from n=1 an aged matched control rat abdominal aorta 
incubated overnight in 37°C +/- LPS (E.coli serotype 0111:B4, 10μg/ml). Data was analysed by using one-way 
ANOVA with Bonferroni’s multi comparison post-test and p>0.05 was taken as non-significant and denoted by 
ns.  
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Figure 4.15 COX-1 and COX-2 immunoreactivity in aortic arch endothelium from normal 
chow fed WT versus ApoE-/- mice 
 
Figure 4.15 COX-1 and COX-2 immunoreactivity in aortic arch endothelium from normal chow fed WT versus 
ApoE
-/-
 mice. Representative cropped images (200x200μm) of COX-1 and COX-2 immunoreactivity (red) in 
normal chow fed (A) WT mice (C57BL/6J, bred in-house) and (B) ApoE
-/-
 mice (C57BL/6J background). Aortic 
tissue was fixed according to the transcardial perfusion fixation procedure. Red arrow indicate the proximal 
part of the descending arch that were stained with COX-1 and mid aortic arches that were stained with COX-2. 
Nuclei visualised with DAPI (blue) and endothelial cells outlined with CD31 (green). Merge represent blue, 
green and red channels merged. 
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Figure 4.16 Quantified COX-1 and COX-2 immunoreactivity in the endothelial versus smooth 
muscle layer of aortic arch endothelium from normal chow fed WT versus ApoE-/- mice 
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Figure 4.16 Quantified COX-1 and COX-2 immunoreactivity in the endothelial versus smooth muscle layer of 
aortic arch endothelium from normal chow fed WT versus ApoE
-/-
 mice. Pooled data comparing COX-1 and 
COX-2 immunoreactivity in (A) the endothelial layer and (B) the underlying smooth muscle layer in normal 
chow fed WT mice (C57BL/6J, bred in-house) and ApoE
-/-
 mice (C57BL/6J background). Aortic tissue was fixed 
according to the transcardial perfusion fixation procedure. 1 image was taken from every COX-1 stained 
descending aortic arch and 1 image was taken from every COX-2 stained mid aortic arch (see representative 
images in Figure 4.15).  COX immunoreactivity was quantified as mean fluorescence. Secondary control 
background was subtracted from each image before analysis. Data is presented as the mean ± S.E.M of n=6 
images of the endothelial layer and n=4 images of the underlying smooth muscle layer from n=6 young adult (3 
month old), 3 female and 3 male WT mice (C57BL/6J, bred in-house) and 2 female and 4 male ApoE
-/-
 mice. 
Data was analysed using one-way ANOVA with Bonferroni’s multi comparison post-test and *p<0.05 was taken 
as significant and denoted by * and p>0.05 was taken as non-significant and denoted by ns.  
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Figure 4.17 Manually made tile composite of 3x4 images showing the superficial morphology 
of a plaque like structure in an ApoE-/- mouse fed an atherogenic diet 
 
Figure 4.17 Manually made tile composite of 3x4 images showing morphology of a plaque in an ApoE
-/-
 
mouse fed an atherogenic diet. Images from a perfusion fixed (according to the transcardial perfusion fixation 
procedure) aortic arch dissected from a female ApoE
-/- 
mouse. The tile was manually created by moving the 
field of view to the next field along and then puzzled together as a tile. (A) Photo of the vessel that was imaged. 
The plaques show up in the photo as white as do the aortic root/valves (that was calcified and hardened).  Red 
dotted line marks dissection cutting points. (B) A schematic of the mounted (opened and flattened) aortic arch, 
marking the location of the greater and the lesser curvature as well as the position of the tile composite (3x4 
images,  coordinates 1.1-4.3). (C) The entire tile of 3x4 images. DAPI stained nuclei (blue) and CD31 
immunoreactivity (green). The brightness and contrast has been enhanced for viewing purposes (+20 and +40).  
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 Figure 4.18 COX-1 and COX-2 immunoreactivity in plaques in the descending arch and mid 
arch endothelium from an ApoE-/- mouse fed an atherogenic diet 
 
Figure 4.18 COX-1 and COX-2 immunoreactivity in plaques in the descending arch and mid arch endothelium 
from an ApoE
-/-
 mouse fed an atherogenic diet. Images from a perfusion fixed (according to the transcardial 
perfusion fixation procedure) aortic arch dissected from a female ApoE
-/- 
mouse (fed an atherogenic diet). The 
tile was manually created by moving the field of view to the next field along and then puzzled together as a tile. 
Photos of the vessel that was imaged where the plaques show up as white and red dotted line marks dissection 
cutting points to the descending arch and the mid arch respectively. Nuclei was visualised with DAPI (blue), 
endothelial cells outlined with CD31 (green), COX-1 and COX-2 immunoreactivity (red) and the three merged 
together (merge). (A) COX-1 immunoreactivity in the endothelium of the descending arch in a manual tile 
composite of 4 images. (B) COX-2 immunoreactivity in the endothelium of the mid arch in a manual tile 
composite of 4 images. One of the images shown in (A) and (B) (387.5x387.5μm).was selected for more 
detailed view of (C) COX-1 immunoreactivity and (D) COX-2 immunoreactivity.   
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Figure 4.19 COX-1 and COX-2 immunoreactivity in the plaque versus normal endothelium 
and smooth muscle cell layers in ApoE-/- mice fed an atherogenic diet  
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Figure 4.19 COX-1 and COX-2 immunoreactivity in the plaque versus normal endothelium and smooth muscle 
cell layers in ApoE
-/-
 mice fed an atherogenic diet. Representative images from a perfusion fixed (according to 
the transcardial perfusion fixation procedure) aortic arch dissected from a female ApoE
-/- 
mouse (fed an 
atherogenic diet). The other n=4 mice were perfused according to the ex vivo semi-perfusion fixation 
procedure. (A) COX-1 immunoreactivity in the endothelium of the descending arch. (B) COX-2 immunoreactivity 
in the endothelium of the mid arch. Nuclei was visualised with DAPI (blue), endothelial cells outlined with CD31 
(green), COX-1 and COX-2 immunoreactivity (red) and the three merged together (merge). (C) COX-1 and (D) 
COX-2 immunoreactivity data was presented as mean fluorescence and gathered by using a 130x137μm region 
of interest (ROI) box in the LAS confocal software program which was moved to endothelium and underlying 
smooth muscle distant, adjacent and directly on top the plaque like structures. Data represent 1 ROI per region 
from images from n=5 ApoE
-/-
 mice (males and females) and was analysed using one-way ANOVA with 
Bonferroni’s multi comparison post-test and p>0.05 was taken as non-significant and denoted by ns.  
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Summary of Chapter 4 
Using tissue from female young adult (3 month old) and male mature adult (12 month old) 
WT mice, I have shown that the relative COX expression and activity pattern did not change 
with the female sex or with age. Therefore the conclusion remains the same as shown in 
Chapter 3; COX-1 greatly predominates over COX-2 both in terms of immunoreactivity and 
in bioactivity and appears to be responsible for the majority of prostacyclin production in 
vessels from male and female, young and mature mice. 
Using tissue from a chronic heart failure model in rats or from a mouse model of 
atherosclerosis, I was able to show that these types of cardiovascular disease/insult was not 
associated with gross changes in either COX isoform expression or profile of COX products 
released from vessels. Specifically, I found in tissue from rats with heart failure, no 
alteration in COX expression profile (COX-1 still predominated over COX-2) or in bioactivity 
compared to age matched controls. The profile of prostanoids released from blood vessels 
of control and heart failure rats was similar and showed the following rank order; 
prostacyclin >>> PGE2>= thromboxane. In tissue from a mouse model of early 
atherosclerosis (normal chow fed ApoE-/- mice), where inflammation markers and fatty 
streaks are present, but plaques have not yet formed (Daugherty, 2002; Zhang et al., 1992), 
again there was no difference in COX-1 or COX-2 immunoreactivity. At more advanced 
stages of this atherosclerosis model (ApoE-/- fed an atherogenic diet for 10 weeks) where 
plaques are readily detectable, COX-1 and COX-2 immunoreactivity was found to be 
enriched in areas of atherosclerotic plaques. Despite profound plaque presence in aortic 
tissue from these mice it was found by my colleague Dr Nicholas Kirkby that COX-1, and not 
COX-2 was still responsible for driving gross prostacyclin production in vessel segments ex 
vivo. 
 
In summary, these experiments indicate that, in terms of total vessel activity, COX-1 still 
predominates over COX-2 in the endothelium as animal’s age as well as when serious 
cardiovascular disease is present. The implications of these observations are discussed in 
detail in my General Discussion chapter (Chapter 6). 
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Functional consequences of COX-1 and COX-2 gene deletion 
in aortic arch endothelium 
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Rationale behind Chapter 5 
The results from the previous chapters indicate that COX-1 is the predominant COX isoform 
in aortic arch endothelium in terms of expression levels (immunoreactivity) and bioactivity 
(prostacyclin production) during both health and disease (in the mice and rat models 
tested). There was however detectable, albeit sparse, COX-2 immunoreactivity in the lesser 
curvature of the mouse aortic arch. Therefore, even though COX-1 appears to be the 
predominant, constitutively expressed isoform, responsible for the majority of the 
endothelial prostacyclin production, COX-2 may still play an important and bioactive role 
localised to regions of the vasculature susceptible to inflammation and atherosclerosis such 
as the lesser curvature of the aortic arch.  
In this chapter, I have applied this information and investigated the functional 
consequences of COX-1 and COX-2 gene deletion in aortic arch endothelium of COX-1-/- and 
COX-2-/- mice.  
In order to get an overview of any morphological differences in the aortic endothelium 
between the genetically modified animals and the WT animals studied in this chapter, I have 
compared endothelial CD31 immunoreactivity and DAPI stained nuclear density in the 
greater and lesser curvature of aortic arches from WT, COX-1-/- and COX-2-/- and normal 
chow fed ApoE-/- mice.  
Diminished or reduced prostacyclin release in the vessels of COX-/- animals may influence 
NF-κB activity since prostacyclin analogues have been reported to inhibit NF-κB 
translocation/activation in macrophages (Raychaudhuri et al., 2002), T-cells (Zhou et al., 
2007a) and dendritic cells (Zhou et al., 2007b). This is important and relevant to my thesis 
since activated NF-κB is thought to play a key role in the development of vascular 
inflammation and atherosclerosis (Collins et al., 2001). Interestingly, the endothelium lining 
the lesser curvature of the aortic arch has been shown to be ‘primed for activation’ with 
elevated levels of nuclear NF-κB and cell adhesion molecules, which may have relevance to 
the increased susceptibility of atherosclerotic plaques forming in this area (Hajra et al., 
2000). I have therefore investigated how NF-κB activity in the endothelium is affected by 
COX-1 or COX-2 gene deletion. For these studies I have used untreated and LPS treated mice 
in order to compare control versus inflammatory conditions.  
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Prostacyclin is also known to greatly influence platelet function and adhesion and thereby 
contribute to the anti-thrombotic surface of the endothelium (Moncada et al., 1977). In this 
chapter I have therefore investigated platelet adhesion to the endothelium of the greater 
and lesser curvature regions of aortic arches from WT, COX-1-/-, COX-2-/- and normal chow 
fed ApoE-/- mice.  Platelets express CD31; however, as illustrated extensively in this thesis, 
CD31 is also present on endothelial cells. In order to selectively identify platelets adhered to 
endothelium using imaging, I used an antibody against CD41 (or platelet glycoprotein IIb), 
which is a selective marker for platelets and platelet precursors, that is reported to be 
expressed on the platelet plasma membrane, intraluminal side of the platelet open 
canalicular system and on the platelet α-granule membrane in platelets (Schmitt et al., 
2001).  
The aims and research questions of this chapter can be summarised as follows: 
 
What are the functional consequences of COX-1 and COX-2 gene deletion in aortic arch 
endothelium? 
 
 Compare CD31 immunoreactivity and DAPI nuclear density in the greater and lesser 
curvature of aortic arches from WT, COX-1-/- and COX-2-/- and normal chow fed and 
high cholesterol chow fed ApoE-/- mice using immunohistochemistry and enface 
confocal microscopy. 
 Investigate the relative role of COX-1 and COX-2 deletion in expression and 
activation of NF-κB in the endothelium of the greater and lesser curvature of the 
aortic arch using tissue from WT, COX-1-/- and COX-2-/- mice.  
 Study the adherence of platelets to the endothelium in the greater and lesser 
curvature in aortic arches from WT, COX-1-/- , COX-2-/- and normal chow fed and high 
cholesterol chow fed ApoE-/- mice.  
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Methods 
Animals 
WT, COX-1-/- and COX-2-/- mice 
WT, COX-1-/- and COX-2-/- mice were bred, maintained and genotyped as described in the 
General Methods Chapter 2. For this chapter, animals were male and female young adult (3-
4 month old) mice.  All WT mice were from the C57BL/6J strain and were bred in-house with 
a shared background to match the COX-1-/- and COX-2-/- mice (backcrossed to C57BL/6J, 
Harlan, UK more than 7 times) see General Methods Chapter 2. These COX colony WT 
controls will be referred to as ‘C57BL/6J, bred in-house’. Mice either left untreated or 
injected with LPS (serotype 055:B5, 4mg/kg; i.p for 30 minutes) to activate nuclear 
translocation of NF-κB (Hajra et al., 2000). The mice were then killed by CO2 asphyxiation 
and aortic arches were dissected out and fixed with 2% formaldehyde according to the 
‘transcardial perfusion fixation procedure’ and NF-κB, CD31 and CD41 immunoreactivity was 
measured in the endothelium of the aortic arch as detailed in the General Methods Chapter 
2 (Tables 2.18, 2.19, 2.20). The mice in the NF-κB study were 3-4 month old n=3 male and 
n=2 female mice. The mice in the CD31/nuclear density/CD41 study were all ~3 months old 
n=3 female and n=3 male WT, COX-1-/- and COX-2-/- mice (n=6 animals in total).    
 
ApoE-/- mice 
ApoE-/- mice 
In this thesis I have performed experiments in both normal chow fed ApoE-/- mice 
(ApoEtm1Unc from a C57BL/6J background) as well as ApoE-/- mice that have been fed an 
atherogenic diet, in order to consider a model of early atherogenesis as well as more 
advanced and established atherosclerosis respectively (for more details see General 
methods Chapter 2).  
 
Normal chow fed ApoE-/- mice as a model of early atherogenesis  
The normal chow fed ApoE-/- mice (2 female mice and 4 male mice) and WT controls 
(C57BL/6J, bred in-house, 3 females, 3 males) were killed by CO2 asphyxiation and aortic 
arches were dissected out and fixed with 2% formaldehyde according to the ‘transcardial 
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perfusion fixation procedure’ and staining protocols for CD41 immunoreactivity as described 
in the General Methods Chapter 2 (Table 2.20).  
 
High cholesterol chow fed ApoE-/- mouse in a pilot study of CD31 immunoreactivity, nuclear 
density and CD41 immunoreactivity in a model of accelerated atherosclerosis  
For illustrative purposes and as a pilot study, I was able to image and quantify CD31 
immunoreactivity, nuclear density and CD41 immunoreactivity in the aortic arch of a high 
cholesterol chow fed ApoE-/- mouse which had gone on to develop profound atherosclerosis 
(after being fed an atherogenic diet for 10 weeks). This female mouse was perfused 
according to the ‘transcardial perfusion fixation procedure’ and staining protocols for CD41 
immunoreactivity as described in the General Methods Chapter 2 (Table 2.20).  
 
Blood smears 
Blood smears were prepared on glass slides as described in the General Methods Chapter 2. 
In brief, heparinised blood was withdrawn from mice by venopuncture of the vena cava. 
One small drop of blood was placed on an electrostatic coated slide and carefully smeared 
across using the edge of another slide (at a ~45° angle), to evenly spread a thin layer of 
blood across the slide (this procedure was performed by my colleague Dr Nicholas Kirkby). 
The slides were then fixed in 100% methanol followed by 2% formaldehyde and washing 
steps. The slides then underwent the same CD41 staining protocol as the aortic arches.  
 
En Face imaging of the arch lumen 
In this chapter I have imaged NF-κB, CD31 and CD41 using antibodies and the stain DAPI to 
visualise nuclei as described in the General Methods Chapter 2.  
NF-κB (as p65) was imaged in male and female 3 month old WT, COX-1-/- or COX-2-/- mice 
that were left untreated or treated with LPS (serotype 055:B5, L16529, Sigma) 4mg/kg; i.p 
for 30 minutes which is enough time for nuclear translocation/activation of NF-κB in 
endothelial cells (Hajra et al., 2000). The mice were sacrificed (by CO2 asphyxiation) and 
subject to the systemic transcardial perfusion fixation procedure and staining protocol 
outlined in General Methods Chapter 2 (Table 2.19).  
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CD41 positive platelets were imaged in 3 month old male WT, COX-1-/- or COX-2-/- mice and 
normal chow fed ApoE-/- mice (and one high cholesterol chow fed ApoE-/- mouse) that were 
left untreated and subject to the systemic transcardial perfusion fixation procedure and 
staining protocol outlined in General Methods Chapter 2 (Table 2.20). Dr Nicholas Kirkby 
performed the in vivo part of the experiment, which made it practically possible to perform 
the experiment fully blinded to the identities of the mice (all vials were labelled with 
numbers). Once all the study was completed and all the images had been blind scored, the 
identity of the mice was revealed.  
 
The endothelial layer of aortic arches were imaged en face with confocal microscopy (Leica 
SP5 inverted confocal microscope, 40x oil objective), with the same confocal settings 
maintained throughout the study and 2-3 images were captured from each greater and 
lesser curvature region. Immunoreactivity was quantified as mean fluorescence using LAS 
AF software and Image J Software was used to crop images and to calculate nuclei area and 
CD31 mean fluorescence and the area/diameter and number of CD41 positive platelets in 
blood smears and adhered to the endothelium of the aortic arches. 
Quantification of endothelial CD31 immunoreactivity and DAPI stained nuclear density 
Both the experiment and the quantification procedure were performed blinded (from the 
same data set as the CD41 study).  DAPI and CD31 settings were kept constant at 550Gain 
and -2% Offset and 880Gain and -2% Offset respectively. 2 images were captured from the 
greater and the lesser curvature respectively. CD31 immunoreactivity was quantified as 
mean fluorescence in images that were cropped using Image J software (from 
387.5x387.5µm in size to 200x200µm) using a saved region of interest (ROI) box 
(200x200µm, 1059x1059 pixels) that was dragged to an area in focus selected based on 
endothelial integrity (in an area devoid of damage from handling). This area was then 
earmarked for cropping and quantification of the DAPI stained nuclei. The DAPI stained 
nuclei in the cropped ROI image were thresholded using the ‘default’ criteria in the 
thresholding function (thresholded images show the thresholded DAPI positive objects in 
red) and the DAPI positive nuclear density (or total area), was calculated based on the total 
sum of the thresholded objects (exceeding a size of 2µm2). The average number of DAPI 
positive nuclei and average size of these nuclei was estimated based on the same data as 
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the total sum was calculated from and any object with an area less than 2 µm2 was excluded 
from the analysis.  
Quantification of endothelial NF-κB immunoreactivity using Velocity 5 software 
1) Total (global) levels of NF-κB immunoreactivity; total fluorescence in a cropped area 
of focus selected for endothelial integrity based on DAPI and CD31 (cropped from 
387.5x387.5µm to 225x225µm) – minus the total fluorescence in the secondary 
control (non-specific binding) will be referred to as ‘total NF-κB immunoreactivity’. 
2) Nuclear NF-κB immunoreactivity; nuclear bodies, imaged as ‘independent’ DAPI 
positive objects were quantified in the same cropped images (225x225µm). At least 
50 separate nuclei were analyzed from each image. Using Velocity 5 software the 
amount of nuclear NF-κB immunoreactivity, captured as ‘red’ co-localized with ‘blue’ 
within the selected nuclei, was calculated. An average amount of NF-κB 
immunoreactivity per nuclei imaged was then calculated for each image and referred 
to as ‘Nuclear NF-κB immunoreactivity (average nuclear fluorescence)’.  
 
Quantification of non-nucleated CD41 positive platelet like bodies in blood smears 
The total number and total area taken up by CD41 positive platelets in blood smears from 
WT, COX-1-/- , COX-2-/- and normal chow fed ApoE-/- mice was estimated from images taken 
from a consistent location on the blood smear slide. These images were thresholded using 
the ‘default’ criteria in Image J and the selected CD41 positive platelets (1μm in size to 
infinity) were included in the analysis.  
 
Quantification of non-nucleated CD41 positive platelet like bodies in the mouse aortic arch 
CD41 was used as a platelet marker to stain platelets adhered to the endothelium in aortic 
arches from WT, COX-1-/- , COX-2-/- and ApoE-/- mice. 2 images were taken from each area 
(greater and lesser curvature) from each aortic arch. My colleague, Ms Claire Potter, helped 
out with manual blind scoring of the distinct red CD41 positive adhered platelets and the 
results from both of our blind scores were averaged. The blind scoring was done by using 
the LAS AF software program to zoom in (with all of the channels zoomed in 
simultaneously), to manually count the number of DAPI negative, CD31 positive and CD41 
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positive distinct platelet like bodies close to but clearly separate from other nucleated cells 
in the aortic endothelium.  
 
The quantification of the CD41 positive platelets were then repeated by a more automated 
method using Image J software, where a full field (387.5x387.5µm) was thresholded using 
the ‘intermodes function’ and adjusted to around 70 (out of 255) on the thresholding scale 
of brightness and saturation. This was manually adjusted for each image (blinded to the 
identity of the animal), to a threshold level that included the full area of any CD41 positive 
signal present in the image, but excluded unspecific background noise. At this setting: 
‘intermodes function’ at 70 out of 255, all of the secondary control images were zero for all 
measurements. The total number of CD41 positive platelets present in each image was then 
quantified based on the sum of these thresholded CD41 positive objects that exceeded a 
size of 1µm2.  
 
The average size in diameter of these more or less round objects was estimated based on 
the formula for the area of a circle= π x radius2, where the average area (µm2) was divided 
with π (π=3.14), and the square root of this result was multiplied with 2 to get an estimate 
of the diameter of the circle like (roundish) CD41 positive platelets in the aortic arches and 
in the blood smears.      
 
Analysis and statistics 
Data is presented as the mean ± S.E.M and was analysed using Graph Pad Prism 5 using 
statistical tests described in the figure legends. A p value of <0.05 was taken as significant 
and denoted by * and p>0.05 was considered non-significant and denoted by ns.   
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Results 
CD31 immunoreactivity and nuclear density in WT versus COX-1-/-, COX-2-/- and normal chow 
fed ApoE-/- mice 
CD31 positive endothelial cells in all of the WT, COX-1-/-, COX-2-/- and normal chow fed ApoE-
/- mice displayed the typical morphology associated with each region where endothelial cells 
lining the greater curvature were evenly spread out and elongated whereas they were more 
randomly orientated with a cobble stone appearance in the lesser curvature (Figure 5.1 and 
5.2). There was abundant CD31 immunoreactivity in both the greater and the lesser 
curvature in aortic arches from WT, COX-1-/-, COX-2-/- and normal chow fed ApoE-/- mice 
(Figure 5.1, 5.2, 5.3A). The CD31 immunoreactivity did not differ between the two regions 
within each animal group, except for in COX-2-/- mice where significantly higher levels were 
detected in the lesser curvature compared to the greater curvature (Figure 5.3A). There was 
no significant difference in CD31 immunoreactivity in any of the COX-1-/-, COX-2-/- and 
normal chow fed ApoE-/- mice compared to the WT mice (Figure 5.3A).  
Furthermore, as reported for tissue from WT animals in data shown in Chapter 3, the 
nuclear density (quantified as the total area of the DAPI positive thresholded nuclei) was 
significantly higher in the lesser curvature compared to the greater curvature in all the types 
of mice studied (Figure 5.1, 5.2, 5.3B). The nuclear density in either region did not 
significantly vary between the types of mice (WT mice versus the COX-1-/-, COX-2-/- and 
normal chow fed ApoE-/- mice) (Figure 5.3B). The number of DAPI positive thresholded 
nuclei were significantly increased in the lesser curvature compared to the greater 
curvature in all of the mice, but again did not vary between the different types of mice 
(Figure 5.4A). The average size (µm2) of the thresholded DAPI positive nuclei was also 
significantly larger in the lesser curvature compared to the greater curvature in all mice 
tested except for in the normal chow fed ApoE-/- mice (Figure 5.4B).  
NF-κB immunoreactivity in untreated versus LPS treated animals 
NF-κB immunoreactivity was detected in both the greater and the lesser curvature of all 
types of mice studied (Figure 5.5 and 5.6). Under control (untreated) conditions, NF-κB 
immunoreactivity appeared to be predominately located within the cytosol of endothelial 
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cells (Figure 5.5) and following LPS stimulation (4mg/kg i.p. for 30 minutes), there was a 
clear translocation of NF-κB immunoreactivity from the cytosol to the nucleus (Figure 5.6). 
LPS treatment resulted in significantly higher levels of both total (global cytosolic and 
nuclear levels) and nuclear NF-κB immunoreactivity in both the greater and the lesser 
curvature regions of WT mice (Figure 5.8A+B+C+D) and in COX-1-/- and COX-2-/- mice (Figure 
5.8B+C+D) except for total NF-κB immunoreactivity in the greater curvature which was not 
significantly different in the COX-1-/- and COX-2-/- mice following LPS treatment (Figure 
5.8A).  
 
Non-specific background immunoreactivity 
The non-specific background immunoreactivity in the endothelium of WT descending aortas 
stained only with the secondary antibody (goat anti-rabbit Alexa Fluor 568) was low and 
without any specific looking pattern (Figure 5.7). This secondary control mean fluorescence 
(from WT descending aortas) was subtracted from each image before the values were 
included in graphs and statistical analysis.    
 
Global levels of NF-κB immunoreactivity in aortic arches from WT versus COX-1-/- and COX-2-
/- mice 
Global levels of NF-κB immunoreactivity (total NF-κB immunoreactivity) were increased in 
endothelial cells in both the greater and the lesser curvature in aortic arches from untreated 
COX-1-/- mice, compared to levels detected in WT control animals (Figure 5.5 and 5.8A). A 
similar pattern of increased NF-κB immunoreactivity was seen in tissues from untreated 
COX-2-/- mice compared to WT mice, although this difference did not reach statistical 
significance in the lesser curvature of untreated COX-2-/- mice compared to WT mice (Figure 
5.5 and 5.8B).  
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Nuclear (NF-κB immunoreactivity in aortic arches from WT versus COX-1-/- and COX-2-/- mice 
Nuclear NF-κB immunoreactivity was significantly increased in endothelium of both the 
greater and the lesser curvature in aortic arches from untreated COX-1-/- mice compared to 
WT mice (Figure 5.5 and 5.8C+D)). A similar pattern of increased NF-κB immunoreactivity 
was seen in tissues from untreated COX-2-/- mice compared to WT mice, although this 
difference did not reach statistical significance in the lesser curvature of untreated COX-2-/- 
mice compared to WT mice (Figure 5.5 and 5.8C+D)).  
 
Following LPS stimulation, there was a marked increase of nuclear NF-κB in the greater 
curvature of COX-2-/- mice, that was significantly much larger than the nuclear levels 
recorded in the WT mice (Figure 5.8C+D). Nuclear NF-κB in the greater curvature of COX-1-/- 
mice was however not different from WT following LPS stimulation (Figure 5.8C). Both the 
COX-1-/- and the COX-2-/- mice had significantly more nuclear NF-κB levels in the lesser 
curvature compared to WT mice following LPS treatment (Figure 5.8D).  
 
Regional differences in NF-κB immunoreactivity 
As previously reported, nuclear NF-κB immunoreactivity was higher in the lesser curvature 
then in the greater curvature regions in aortic arches from both untreated and LPS treated, 
control WT mice (Table 5.10). In my thesis I show this is also the case for NF-κB 
immunoreactivity in endothelium of COX-1-/-, but not COX-2-/- mice (Table 5.10).  After LPS, 
both global levels and nuclear NF-κB immunoreactivity was higher in endothelium of the 
lesser curvature than the greater curvature regions arch tissue from all genotypes of mice 
used, including COX-2-/- (Table 5.9 + Table 5.10). 
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Platelet adhesion to the aortic endothelium visualised by CD41 immunoreactivity                
Validation of the CD41 antibody in blood smears 
The utility of the CD41 antibody used in this chapter was validated in a pilot study where 
blood smears from a WT mouse were stained and imaged. These studies confirmed that the 
platelets were clearly visible with red CD41 immunoreactivity whereas DAPI positive, 
nucleated cells (blood leukocytes) did not stain with CD41 (Figure 5.11A). When the same 
CD41 staining protocol was tested in aortic arches from WT mice, there were a few positive 
CD41 platelet like bodies, that seemed adhered to the endothelium in the vessel wall 
(Figure 5.11B). This protocol was then repeated using blood from n=2 separate mice from 
each genotype and images compared head to head. Again, blood from WT as well from 
COX-1-/-, COX-2-/- and ApoE-/- mice showed clear CD41 positive platelets (Figure 5.11C). 
There were no CD41 positive platelets detected in the secondary control blood smears or 
aortic arches (stained only with secondary control).   
 
CD41 positive platelets adhered to the endothelium of aortic arches from WT versus COX-1-/-, 
COX-2-/- and normal chow fed ApoE-/- mice 
Throughout this thesis I have used CD31 as a positive stain for endothelial cells. However, 
CD31 is also expressed on platelets, and as such is known as platelet endothelial cell 
adhesion molecule-1 (PECAM-1). In imaging platelets for this part of my thesis I have used 
CD41, which is also a platelet marker, but unlike CD31 is not expressed on endothelial cells. 
Platelets have no nucleus and don’t stain positively with DAPI (once activated). Therefore, 
platelets adhered to the endothelium of the aortic arch were characterised as CD41 and 
CD31 positive, DAPI negative bodies. Platelets adhered to the endothelium (in between or 
close to nucleated endothelial cells) were observed in both regions of the aortic arch from 
each genotype of the mouse studied (Figure 5.12 and 5.13). Both manual (Figure 5.14B) and 
automated (using Image J software) (Figure 5.14A) blinded quantification showed a clear 
signal for increased platelet adhesion in the lesser curvature region of aortic arches from 
COX-2-/- mice (Figure 5.14A+B). Within group analysis showed that the number of CD41 
positive platelets did not vary between regions of the arch for individual genotypes, except 
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for in the COX-2-/- and in the normal chow fed ApoE-/- mice where there was a significant 
increase in the lesser curvature compared to the greater curvature (Figure 5.14A+B).   
The average size (in diameter) of the CD41 positive platelets in the aortic arch (Figure 5.15A) 
were on average around the same size as the average sized of the platelets recorded from 
the blood smears from these mice (around 3µm) (Figure 5.15B). 
Pilot study of CD41 positive platelets adhered to the endothelium of the aortic arch in an 
ApoE-/- mice fed an atherogenic diet 
The data above reports platelet adhesion in tissue from COX-/- mice and from ApoE-/- mice, 
fed on a normal chow diet, which will display markers of vascular inflammation, but may not 
yet have developed atherosclerotic plaques (Daugherty, 2002; Zhang et al., 1992). However, 
during the course of this study, I had the opportunity to image platelets in a lipid enriched, 
atherosclerotic plaque containing aortic arch from an ApoE-/- mouse fed an atherogenic diet 
to induce atherosclerosis. In this pilot study I manually made a tile of images from adjacent, 
consecutive regions of the aortic arch (also in Chapter 4, Figure 4.17). These showed a clear 
plaque-like structure running along the lesser curvature of the aortic arch (Figure 5.16). 
When the CD41 positive platelets adhered to the superficial CD31 positive endothelial layer 
of the plaque was quantified (by the automated protocol in Image J), there appeared to be 
more CD41 positive platelets adhered to the plaque enriched areas of the arch compared to 
‘normal looking’ adjacent endothelium in the greater curvature regions (Figure 5.16). The 
plaque enriched areas were also associated with an increased nuclear density (quantified by 
number of thresholded DAPI positive nuclei and the total area of these nuclei) (Figure 5.17).  
There was also CD41 positive (and CD31 positive) platelets inside the core of the plaque and 
in the deeper layers underneath; where the CD41 immunoreactivity was found associated 
with a nucleated cell (Figure 5.18).    
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Figures Chapter 5 
Figure 5.1 Representative images of CD31 immunoreactivity and DAPI positive nuclear 
density in the greater curvature of aortic arches from WT, COX-1-/-, COX-2-/- and normal 
chow fed ApoE-/- mice  
 
Figure 5.1 Representative images of CD31 immunoreactivity and DAPI positive nuclear density in the greater 
curvature of aortic arches from WT, COX-1
-/-
, COX-2
-/-
 and normal chow fed ApoE
-/-
 mice. Representative 
images (180x200µm) showing endothelial morphology in the greater curvature of aortic arches from n=6 male 
and female 3 month old WT, COX-1
-/-
, COX-2
-/-
 and normal chow fed ApoE
-/-
 mice fixed according to the 
transcardial perfusion fixation procedure. (A) DAPI nuclear stain (blue). (B) CD31 immunoreactivity (green) (C) 
Merge of blue and green. (D) DAPI positive nuclei thresholded by the default criteria in Image J (red) were 
selected for quantification of nuclei area and size. All of the images have been enhanced in brightness (+20) 
and contrast (+40) for clarity of viewing purposes.  
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Figure 5.2 Representative images of CD31 immunoreactivity and DAPI positive nuclear 
density in the lesser curvature of aortic arches from WT, COX-1-/-, COX-2-/- and normal chow 
fed ApoE-/- mice  
 
Figure 5.2 Representative images of CD31 immunoreactivity and DAPI positive nuclear density in the lesser 
curvature of aortic arches from WT, COX-1
-/-
, COX-2
-/-
 and normal chow fed ApoE
-/-
 mice. Representative 
images (180x200µm) showing endothelial morphology in the lesser curvature of aortic arches from n=6 male 
and female 3 month old WT, COX-1
-/-
, COX-2
-/-
 and normal chow fed ApoE
-/-
 mice fixed according to the 
transcardial perfusion fixation procedure. (A) DAPI nuclear stain (blue). (B) CD31 immunoreactivity (green) (C) 
Merge of blue and green. (D) DAPI positive nuclei thresholded by the default criteria in Image J (red) were 
selected for quantification of nuclei area and size. All of the images have been enhanced in brightness (+20) 
and contrast (+40) for clarity of viewing purposes.  
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Figure 5.3 Quantified CD31 immunoreactivity and DAPI positive nuclear density in the 
greater and lesser curvature of aortic arches from WT, COX-1-/-, COX-2-/- and normal chow 
fed ApoE-/- mice  
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Figure 5.3 Quantified CD31 immunoreactivity and DAPI positive nuclear density in the greater and lesser 
curvature of aortic arches from WT, COX-1
-/-
, COX-2
-/-
 and normal chow fed ApoE
-/-
 mice. 12 images (2 per 
region) were zoomed in (from the full field image 387.5x387.5 to 180x200µm) using LAS confocal software in a 
blinded fashion from n=6 3 month old male and female WT, COX-1
-/-
, COX-2
-/-
and normal chow fed ApoE
-/-
mice. 
The blinded quantification included (A) mean fluorescence of CD31 immunoreactivity using LAS confocal 
software and (B) the total DAPI positive nuclear area (µm
2
) in thresholded images using the default criteria in 
Image J. Data is presented as mean ± S.E.M. Within group analysis (greater curvature versus the lesser 
curvature) was performed using paired Student’s t-test and p<0.05 was taken as significant and denoted by #. 
Between groups analysis was analysed using one-way ANOVA with Dunnett’s multiple comparison post-test 
where the WT data from each region was set as the control column. P<0.05 taken as significant and denoted by 
* and p>0.05 was taken as non-significant and denoted by ns.  
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Figure 5.4 Quantified number and average size of DAPI positive nuclei in the greater and the 
lesser curvature of aortic arches from WT, COX-1-/-, COX-2-/- and normal chow fed ApoE-/- 
mice  
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Figure 5.4 Quantified number and average size of DAPI positive nuclei in the greater curvature of aortic 
arches from WT, COX-1
-/-
, COX-2
-/-
 and normal chow fed ApoE
-/-
 mice. 12 images (2 per region) were zoomed 
in (from the full field image 387.5x387.5 to 180x200µm) using LAS confocal software in a blinded fashion from 
n=6 3 month old male and female WT, COX-1
-/-
, COX-2
-/-
and normal chow fed ApoE
-/-
mice. Blinded 
quantification included (A) the number and (B) the average area size (µm
2
) of the DAPI positive nuclei selected 
by thresholding using the default criteria in Image J, where DAPI positive objects with an area ≤2 µm
2
 were 
excluded from the analysis. Data is presented as mean ± S.E.M. Within group analysis (greater curvature versus 
the lesser curvature) was performed using paired Student’s t-test and p<0.05 was taken as significant and 
denoted by #. Between groups analysis was analysed using one-way ANOVA with Dunnett’s multiple 
comparison post-test where the WT data was set as the control column. P<0.05 taken as significant and 
denoted by * and p>0.05 was taken as non-significant and denoted by ns. 
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Figure 5.5 NF-κB immunoreactivity in the greater and lesser curvature of aortic arches from 
untreated WT, COX-1-/- and COX-2-/- mice 
 
Figure 5.5 NF-κB immunoreactivity in the greater and lesser curvature of aortic arches from untreated WT, 
COX-1
-/- 
and COX-2
-/- 
mice. Representative cropped images (200x200μm) showing NF-κB/p65 immunoreactivity 
(red) in the endothelium of the greater and the lesser curvature of aortic arches from untreated (A) WT mice 
(C57BL/6J, bred in-house) (B) COX-1
-/- 
mice and (C) COX-2
-/- 
mice (3-4 month old male and female). The aortic 
arches were fixed according to the transcardial perfusion fixation procedure. Nuclei visualised with DAPI (blue) 
and endothelial cells outlined with CD31 (green). Merge represent DAPI (blue), CD31 (green) and NF-κB/p65 
(red) channels merged. Red and green represents NF-κB (red) and CD31 (green) merged. Red and blue channels 
were merged in order to identify nuclear location of red NF-κB/p65 in the blue DAPI stained nuclei.   
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Figure 5.6 NF-κB immunoreactivity in the greater and lesser curvature of aortic arches from 
LPS treated WT, COX-1-/- and COX-2-/- mice 
 
Figure 5.6 NF-κB immunoreactivity in the greater and lesser curvature of aortic arches from LPS treated WT, 
COX-1
-/-
 and COX-2
-/-
 mice. Representative cropped images (200x200μm) showing NF-κB/p65 immunoreactivity 
(red) in the endothelium of the greater and the lesser curvature of aortic arches from LPS treated (serotype 
055:B5, 4mg/kg; i.p for 30 minutes) (A) WT mice (C57BL/6J, bred in-house) (B) COX-1
-/- 
mice and (C) COX-2
-/- 
mice (3-4 month old male and female). The aortic arches were fixed according to the transcardial perfusion 
fixation procedure. Nuclei visualised with DAPI (blue) and endothelial cells outlined with CD31 (green). Merge 
represent DAPI (blue), CD31 (green) and NF-κB/p65 (red) channels merged. Red and green represents NF-κB 
(red) and CD31 (green) merged. Red and blue channels were merged in order to identify nuclear location of red 
NF-κB/p65 in the blue DAPI stained nuclei.   
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Figure 5.7 Non-specific background immunoreactivity from the secondary antibody goat-anti 
rabbit Alexa Fluor 568 in the descending aorta from a WT mouse 
 
Figure 5.7 Non-specific background immunoreactivity from the secondary antibody goat anti-rabbit Alexa 
Fluor 568 in the descending aorta from a WT mouse. Representative cropped images (200x200μm) from a 
descending aorta from a WT mouse that has only been incubated with the secondary antibody goat anti-rabbit 
Alexa Fluor 568 (Invitrogen, A11026) used to detect the rabbit polyclonal NF-κB/p65 primary antibody (Santa 
Cruz SC-372). Background mean fluorescence of WT descending aorta (incubated solely with secondary control 
antibody) was subtracted from each image of the NF-κB data set before values were included in the analysis.  
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Figure 5.8 Effect of LPS treatment to total and nuclear NF-κB immunoreactivity in the 
greater and lesser curvature of aortic arches from WT, COX-1-/- and COX-2-/- mice 
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Figure 5.8 Effect of LPS treatment to total and nuclear NF-κB immunoreactivity in the greater and lesser 
curvature of aortic arches from WT, COX-1
-/-
 and COX-2
-/-
 mice. Pooled data quantified using Velocity 5 
software for NF-κB/p65 immunoreactivity as total red fluorescence and average nuclear fluorescence in the 
(A+C) greater curvature and in the (B+D) the lesser curvature in aortic arches from untreated versus LPS 
treated (serotype 055:B5, 4mg/kg; i.p for 30 minutes) WT (C57BL/6J, bred in-house), COX-1
-/-
 and COX-2
-/-
 mice. 
Secondary control background was subtracted from each image before analysis. Data is the mean ± S.E.M of 
n=13-15 untreated and n=11-15 LPS treated (3 separate images per region) from n=5 3 month old male (n=3) 
and female (n=2) mice. Within group analysis (untreated versus LPS treated) was performed using unpaired 
Student’s t-test and p<0.05 was taken as significant and denoted by #. Between groups analysis was analysed 
using one-way ANOVA with Dunnett’s multiple comparison post-test where the WT data from each region was 
set as the control column. P<0.05 taken as significant and denoted by * and p>0.05 was taken as non-
significant and denoted by ns. 
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Table 5.9 Regional differences in total (global) NF-κB immunoreactivity in the greater versus 
the lesser curvature of untreated or LPS treated WT, COX-1-/- and COX-2-/- mice 
Total 
NF-κB 
A) Untreated  B) LPS treated 
 Greater curvature Lesser curvature Greater curvature Lesser curvature 
WT 1.6 ± 0.3 E6 2.6 ± 0.6 E6 (ns) 4.4 ± 0.7 E6 5.6 ± 0.6 E6 (#) 
COX-1-/- 4.0 ± 0.4 E6 4. 5± 0.3 E6 (ns) 3.7 ± 0.6 E6 6.2± 0.5 E6 (#) 
COX-2-/- 4.1 ± 0.6 E6 4.1 ± 0.6 E6 (ns) 5.7 ± 0.7 E6 7.2 ± 0.5 E6 (#) 
 
Table 5.9 Regional differences in total red (global) NF-κB immunoreactivity in the greater versus the lesser 
curvature of untreated or LPS treated mice of different genotypes. Pooled data quantified using Velocity 5 
software for total (global) NF-κB/p65 immunoreactivity in the greater and lesser curvature in  aortic arches 
from (A) untreated and (B) LPS treated (serotype 055:B5, 4mg/kg; i.p for 30 minutes) WT (C57BL/6J, bred in-
house), COX-1
-/-
 and COX-2
-/-
 mice. Secondary control background was subtracted from each image before 
analysis. The data is the mean ± SEM for n=11-15 images using tissue from 5 mice for each genotype.  Data 
was analysed using Student’s paired T-test and p<0.05 was taken as significant and denoted by (#) and p>0.05 
was taken as non-significant and denoted by (ns). 
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Table 5.10 Regional differences in nuclear NF-κB immunoreactivity in the greater versus the 
lesser curvature of untreated or LPS treated WT, COX-1-/- and COX-2-/- mice 
Nuclear 
NF-κB 
A) Untreated  B) LPS treated 
 Greater curvature Lesser curvature Greater curvature Lesser curvature 
WT 2024 ± 451 4031 ± 862 (#) 6564 ± 836 10731 ± 766 (#) 
COX-1-/- 5020 ± 602 6411 ± 369 (#) 8764 ± 1094 15634 ± 1067 (#) 
COX-2-/- 5207 ± 773 5398 ± 625 (ns) 13643 ± 1285 15988 ± 823 (#) 
 
Table 5.10 Regional differences in nuclear NF-κB immunoreactivity in the greater versus the lesser curvature 
of untreated or LPS treated mice of different genotypes. Pooled data quantified using Velocity 5 software for 
nuclear NF-κB/p65 immunoreactivity in the greater and lesser curvature in  aortic arches from (A) untreated 
and (B) LPS treated (serotype 055:B5, 4mg/kg; i.p for 30 minutes) WT (C57BL/6J, bred in-house), COX-1
-/-
 and 
COX-2
-/-
 mice. Secondary control background was subtracted from each image before analysis. The data is the 
mean ± SEM for n=11-15 images using tissue from 5 mice for each genotype.  Data was analysed using 
Student’s paired T-test and p<0.05 was taken as significant and denoted by (#) and p>0.05 was taken as non-
significant and denoted by (ns). 
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Figure 5.11 CD41 immunoreactivity in blood smears from untreated WT versus COX-1-/-, COX-
2-/- and normal chow fed ApoE-/- mice 
 
0
200
400
600
WT
COX-1-/-
COX-2-/-
ApoE-/-
Number of CD41 positive platelets
 in blood smears
D
n=2
N
u
m
b
er
 o
f
C
D
4
1
 p
o
si
ti
ve
 p
la
te
le
ts
 
Figure 5.11 Figure legend located on the next page. 
Chapter 5 Results 
235 
 
Figure 5.11 CD41 immunoreactivity in blood smears from untreated WT versus COX-1
-/-
, COX-2
-/-
 and normal 
chow fed ApoE
-/-
 mice. Representative images of CD41 (also referred to as platelet glycoprotein IIb or integrin 
alpha 2b) immunoreactivity in (A) zoomed in blood smears from a WT mouse (B) in aortic arch endothelium 
from a male, 3 month old WT mouse (C57BL/6J bred in-house). The aortic arch was fixed according to the 
transcardial perfusion fixation procedure. (C) Blood smears from WT (C57BL/6J, bred in-house), COX-1
-/-
, COX-2
-
/-
 and normal chow fed ApoE
-/-
 mice. All the blood smears were subject to the same staining protocol parallel to 
the aortic arch en face imaging study. Nuclei visualised with DAPI (blue) endothelial cells outlined with CD31 or 
Platelet Endothelial Adhesion Cell Molecule- 1 (PECAM-1, which is another name for CD31) (green) and 
platelets were visualised by the platelet marker CD41 (red). Blood smears were thresholded in Image J using 
the default criteria and CD41 positive bodies in the size range of 1μm to infinity were selected for analysis. At 
this setting the background fluorescence from the secondary antibody (Alexa Fluor 594 goat anti-rat Invitrogen, 
A-11007) was zero (image in C lower panel far right). (D) Pooled quantified data from blood smears using 
Image J software. CD41 positive bodies (larger than 1μm
2
) were selected for analysis and all of the images were 
thresholded using the default criteria in Image J. At this setting, the secondary control non-specific 
immunoreactivity was zero.  Data is the mean ± S.E.M of n=2 mice (1 image per blood smear). 
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Figure 5.12 CD41 positive platelets adhered to the endothelium of the greater curvature of 
aortic arches from untreated WT versus COX-1-/-, COX-2-/- and normal chow fed ApoE-/- mice 
 
Figure 5.12 CD41 positive platelets adhered to the endothelium of the greater curvature of aortic arches 
from untreated WT versus COX-1
-/-
, COX-2
-/-
 and normal chow fed ApoE
-/-
 mice. Representative zoomed in 
images of CD41 positive platelets in endothelium from the greater curvature in aortic arches from 3 month old 
male and female (A) WT mice (C57BL/6J, bred in-house) (B) COX-1
-/-
 mice (C) COX-2
-/-
 mice and (D) ApoE
-/-
 mice 
(fed a normal chow diet). The aortic arches were fixed according to the transcardial perfusion fixation 
procedure. Nuclei visualised with DAPI (blue) endothelial cells outlined with CD31 or Platelet Endothelial 
Adhesion Cell Molecule- 1 (PECAM-1) (green) and platelets were visualised by the platelet marker CD41 
(platelet glycoprotein IIb or integrin alpha 2b) (red).  
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Figure 5.13 CD41 positive platelets adhered to the endothelium of the lesser curvature of 
aortic arches from untreated WT versus COX-1-/-, COX-2-/- and normal chow fed ApoE-/- mice 
 
Figure 5.13 CD41 positive platelets adhered to the endothelium of the lesser curvature of aortic arches from 
untreated WT versus COX-1
-/-
, COX-2
-/-
 and normal chow fed ApoE
-/-
 mice. Representative zoomed in images 
of CD41 positive platelets in endothelium from the lesser curvature in aortic arches from 3 month old male and 
female (A) WT mice (C57BL/6J, bred in-house) (B) COX-1
-/-
 mice (C) COX-2
-/-
 mice and (D) ApoE
-/-
 mice (fed a 
normal chow diet). The aortic arches were fixed according to the transcardial perfusion fixation procedure. 
Nuclei visualised with DAPI (blue) endothelial cells outlined with CD31 or Platelet Endothelial Adhesion Cell 
Molecule- 1 (PECAM-1) (green) and platelets were visualised by the platelet marker CD41 (platelet glycoprotein 
IIb or integrin alpha 2b) (red).  
Chapter 5 Results 
238 
 
Figure 5.14 Average number of CD41 positive platelets adhered to the endothelium of the 
greater and lesser curvature of aortic arches from WT versus COX-1-/-, COX-2-/- and normal 
chow fed ApoE-/- mice quantified by Image J or by manual blind scoring 
0
10
20
30
40
50
WT
COX-1-/-
COX-2-/-
ApoE-/-#
# *
GC LC GC LC GC LC GC LC
GC= Greater Curvature
LC= Lesser Curvature
Data quantified in Image J
Average number of CD41 positive platelets
 adhered to the aortic arch endothelium
ns
A
N
u
m
b
er
 o
f
C
D
4
1
 p
o
si
ti
ve
 p
la
te
le
ts
0
10
20
30
40
50 WT
COX-1-/-
COX-2-/-
Data quantified manually by blind scoring:
Average number of CD41 positive platelets
adhered to the endothelium in the aortic arch
ApoE-/-
B
*
#
GC LC GC LC GC LC GC LC
GC= Greater Curvature
LC= Lesser Curvature
A
ve
ra
ge
 n
r 
o
f 
C
D
4
1
 p
o
si
ti
ve
ad
h
er
ed
 p
la
te
le
ts
 
Figure 5.14 Average number of CD41 positive platelets adhered to the endothelium of the greater and lesser 
curvature of aortic arches from WT versus COX-1
-/-
, COX-2
-/-
 and normal chow fed ApoE
-/-
 mice quantified by 
Image J or by manual blind scoring. (A) Pooled quantified data from manual blind scoring (data represent the 
average result from two blind scorers) (B) or by Image J software program (from thresholded images, excluding 
values with an area lower than 1 um
2
), showing average number of CD41 positive platelets per aortic arch 
region. The aortic arches were fixed according to the transcardial perfusion fixation procedure. Secondary 
control background was zero for both measurements from both regions. Data is the mean ± S.E.M of n=12 
separate images from n=6 male and female, 3 month old mice. Within group analysis (greater curvature versus 
the lesser curvature) was performed using paired Student’s t-test and p<0.05 was taken as significant and 
denoted by #. Between groups analysis was analysed using one-way ANOVA with Dunnett’s multiple 
comparison post-test where the WT data from each region was set as the control column. P<0.05 taken as 
significant and denoted by * and p>0.05 was taken as non-significant and denoted by ns.  
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Figure 5.15 Average size in diameter of CD41 positive platelets in blood smears versus CD41 
positive platelets adhered to the endothelium of the greater and the lesser curvature of 
aortic arches from WT versus COX-1-/-, COX-2-/- and normal chow fed ApoE-/- mice  
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Figure 5.15 Average size in diameter of CD41 positive platelets in blood smears versus CD41 positive 
platelets adhered to the endothelium of the greater and the lesser curvature of aortic arches from WT versus 
COX-1
-/-
, COX-2
-/-
 and normal chow fed ApoE
-/-
 mice. Thresholded images quantified in Image J showing (A) 
average diameter of CD41 positive platelets in blood smears from n=2 WT versus COX-1
-/-
, COX-2
-/-
 and normal 
chow fed ApoE
-/-
 mice and (B) average diameter of CD41 positive platelets adhered to the endothelium in the 
greater and the lesser curvature of aortic arches from n=12 separate images from n=6 WT versus COX-1
-/-
, COX-
2
-/-
 and chow fed ApoE
-/-
 mice.  The aortic arches were fixed according to the transcardial perfusion fixation 
procedure. Secondary control background was zero for both the blood smears and for the aortic arches from 
both regions. Data is the mean ± S.E.M. Within group analysis (greater curvature versus the lesser curvature) 
was performed using paired Student’s t-test and p<0.05 was taken as significant and denoted by #. Between 
groups analysis was analysed using one-way ANOVA with Dunnett’s multiple comparison post-test where the 
WT data from each region was set as the control column. P<0.05 taken as significant and denoted by * and 
p>0.05 was taken as non-significant and denoted by ns.  
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Figure 5.16 Manually made tile composite of 3x4 images showing CD41 immunoreactivity in 
a female ApoE-/- mouse fed an atherogenic diet 
 
Figure 5.16 Manually made tile composite of 3x4 images showing CD41 immunoreactivity in a female ApoE
-/-
 
mouse fed an atherogenic diet. Images from a perfusion fixed (according to the transcardial perfusion fixation 
procedure) aortic arch dissected from a female ApoE
-/- 
mouse. The tile was manually created by moving the 
field of view to the next field along and then manually puzzled together as a tile. (A) Red dotted line, mark 
dissection cutting points. (B) A schematic of the mounted (opened and flattened) aortic arch, marking the 
location of the greater and the lesser curvature as well as the position of the tile composite (3x4 images,  
coordinates 1.1-4.3). (C) The entire tile of 3x4 images. DAPI stained nuclei (blue) and CD31 immunoreactivity 
(green) and CD41 platelet marker (red). Number of CD41 positive platelets in each frame/image is indicated by 
a red number in the top left corner of each individual frame/image. All of the images have been enhanced in 
brightness (+20) and contrast (+40) for clarity of viewing purposes.  
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Figure 5.17 Manually made tile composite of 3x4 images showing thresholded DAPI positive 
nuclei in a female ApoE-/- mouse fed an atherogenic diet 
 
Figure 5.17 Manually made tile composite of 3x4 images showing thresholded DAPI positive nuclei in a 
female ApoE
-/-
 mouse fed an atherogenic diet. Images from a perfusion fixed (according to the transcardial 
perfusion fixation procedure) aortic arch dissected from a female ApoE
-/- 
mouse. The tile was manually created 
by moving the field of view to the next field along and then manually puzzled together as a tile. (A) Red dotted 
line, mark dissection cutting points. (B) A schematic of the mounted (opened and flattened) aortic arch, 
marking the location of the greater and the lesser curvature as well as the position of the tile composite (3x4 
images,  coordinates 1.1-4.3). (C) The entire tile of 3x4 images. DAPI positive nuclei were thresholded according 
to the ‘default function’ in Image J and shown in red. The total number of thresholded DAPI positive nuclei 
(larger than 2µm
2
) was calculated for each individual image and indicated in white text in the upper left corner 
of each image alongside the total nuclear density (total nuclear area µm
2
) for each individual image.  
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Figure 5.18  Zoomed in images of CD41 immunoreactivity in different layers of a plaque like 
structure in a female ApoE-/- mouse fed an atherogenic diet 
 
Figure 5.18 Zoomed in images of CD41 immunoreactivity in different layers of a plaque like structure in a 
female ApoE
-/-
 mouse fed an atherogenic diet. Zoomed in images from a perfusion fixed (according to the 
transcardial perfusion fixation procedure) aortic arch dissected from a female ApoE
-/- 
mouse. DAPI stained 
nuclei (blue) and CD31/Platelet Endothelial Cell Adhesion Molecule-1 (PECAM-1) immunoreactivity (green) and 
CD41 platelet marker immunoreactivity (red) in the (A) CD31 positive endothelial surface layer of the plaque, 
(B) core or inside the plaque and (C) beneath the superficial and core levels of the plaque. All of the images 
have been enhanced in brightness (+20) and contrast (+40) for clarity of viewing purposes.  
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Summary of Chapter 5 
The aim of this chapter was primarily to study the functional consequences of COX-1 and 
COX-2 gene deletion in aortic arch endothelium. However, for some of the experiments 
ApoE-/- mice was included in the study as well.  
The main findings from this chapter can be summarised as follows: 
 
CD31 immunoreactivity and DAPI positive nuclear density in the greater and lesser 
curvature of aortic arches from WT, COX-1-/-, COX-2-/- and normal chow fed ApoE-/- mice  
 CD31 positive endothelium from all of the mice displayed the typified differences in 
morphology associated with the greater and the lesser curvature regions as reported 
in WT mice in Chapter 3.  
 There was abundant CD31 immunoreactivity in both the greater and the lesser 
curvature all of the mice studied and there was no significant difference in CD31 
immunoreactivity between the groups of mice.  
 There was no difference in CD31 immunoreactivity between the greater and the 
lesser curvature of the mice (except for in the COX-2-/- mice).   
 Nuclear density (quantified as the total area of the DAPI positive thresholded nuclei) 
and number of DAPI positive nuclei was significantly higher in the lesser curvature 
compared to the greater curvature in all the types of mice studied, consistent with 
the findings in WT mice in Chapter 3. 
 The nuclear density or number of nuclei in either region did not significantly vary 
between the types of mice.   
 The average size (µm2) of the thresholded DAPI positive nuclei was also significantly 
larger in the lesser curvature compared to the greater curvature in all mice tested 
(except for in the normal chow fed ApoE-/- mice). This measurement is confounded 
by the difficulty to separate the densely packed nuclei in the lesser curvature 
compared to the greater curvature where they are evenly separated/spaced out and 
may therefore be a measure of ‘clumped together’ nuclei as supposed to individually 
larger nuclei or alternatively a combination of both.     
Overall, the genetically modified mice had similar endothelial morphology as the WT mice.    
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NF-κB immunoreactivity in WT versus COX-1-/- and COX-2-/- mice 
 Nuclear levels of NF-κB expression were significantly higher in the lesser curvature 
region compared to the greater curvature region in untreated WT mice as well as in 
LPS treated animals. These results are in line with previous findings suggesting that 
NF-κB is ‘primed for activation’ in this region of the mouse aortic arch, which has 
been linked to the increased susceptibility for atherosclerosis in this area (Hajra et 
al., 2000).  
 LPS treatment resulted in significantly higher levels of both total and nuclear NF-κB 
immunoreactivity in both regions of all the mice studied.  
 In untreated (control) conditions, both the global/total and nuclear levels of NF-κB 
immunoreactivity were increased in both regions of aortic arches from COX-1-/- mice, 
compared to levels detected in WT control animals. A similar pattern was seen in the 
greater curvature of untreated COX-2-/- mice. 
 Following LPS stimulation, there was a marked increase of nuclear NF-κB in the both 
regions of aortic arches from COX-2-/- mice compared to WT mice. Nuclear NF-κB in 
the greater curvature of COX-1-/- mice was however not different from WT mice. 
Both the COX-1-/- and the COX-2-/- mice had significantly more nuclear NF-κB levels in 
the lesser curvature compared to WT mice following LPS treatment.  
 
The results in this chapter indicates that COX-1-/- and COX-2-/- mice have elevated 
immunoreactivity levels of NF-κB, both in terms of general (total/global) expression and 
nuclear ‘primed’ or activated NF-κB compared to WT controls, in the endothelium of both 
protected (greater curvature) and susceptible (lesser curvature) regions of the aortic arch in 
both untreated (control) and LPS treated (inflammatory) conditions.  
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CD41 positive platelet adhesion to the aortic arch endothelium in WT versus COX-1-/-, COX-
2-/- and normal chow fed ApoE-/- mice 
 The selectivity of the CD41 antibody for platelet detection was validated in blood 
smears where DAPI negative, non-nucleated CD41 positive platelets were clearly 
visible whereas nucleated cells (blood leukocytes) did not stain with CD41.  
 There was a trend for more CD41 positive platelets in the blood smears from the 
COX-1-/- and COX-2-/- mice compared to the WT mice.  
 There were no CD41 positive platelets detected in the secondary control blood 
smears or in aortic arches stained only with secondary control.  
 Non-nucleated, CD41 positive, CD31 positive platelet-like bodies, that seemed 
adhered to the endothelium (in between or close to nucleated endothelial cells) 
were observed in both regions of the aortic arch from all of the mice studied.  
 There were significantly more CD41 positive platelets adhered to the endothelium in 
the lesser curvature of COX-2-/- mice compared to WT mice.  
 This observation was independent of quantification method (manual counting or 
automated quantification by Image J).   
 The number of CD41 positive platelets did not vary between regions except for in 
the COX-2-/- and in the normal chow fed ApoE-/- mice were there was a significant 
increase in the lesser curvature compared to the greater curvature. 
 The average size (in diameter) of the CD41 positive platelets in the aortic arch were 
around the same size as the platelets recorded from the blood smears from these 
mice (around 3µm). This is in line with the reported diameter for mouse platelets (1-
3µm) (Levin et al., 1994).  
According to the validation protocols, the CD41 positive objects detected appears to be 
platelets adhered to the aortic arch endothelium. More CD41 positive platelets were 
detected adhered to the lesser curvature of aortic arches from COX-2-/- mice compared to 
WT mice, indicating that the endothelium in this inflammation and atherosclerosis 
susceptible area have reduced anti-platelet properties in the COX-2-/- mice.  
Chapter 5 Results 
246 
 
Pilot study of CD41 positive platelets adhered to the endothelium of the aortic arch in an 
ApoE-/- mice fed an atherogenic diet 
 When the CD41 protocol was repeated in a pilot study using a high cholesterol chow 
fed ApoE-/- mouse, there were more CD41 positive platelets adhering to areas of the 
aortic arch (mainly the lesser curvature) enriched in a plaque-like structure 
compared to ‘normal looking’ adjacent endothelium located mainly in the greater 
curvature.  
 The plaque enriched areas was also associated with an increased nuclear density 
(quantified by number of thresholded DAPI positive nuclei and the total area of 
these nuclei).  
 There was also a CD41 positive (and CD31 positive) platelet detected inside the core 
of the plaque and in the deeper layers underneath; where the CD41 
immunoreactivity was found associated with a nucleated cell. This may have been a 
leukocyte that has taken up a CD41 positive platelet since it has been shown that 
activated platelets can interact with circulating leukocytes/monocytes which has 
been linked to exacerbate atherosclerosis (Huo et al., 2003).   
The preliminary findings from this pilot study indicate that plaques are enriched with CD41 
positive platelets compared to surrounding plaque-free areas.  
 
In summary, the genetically modified COX-1-/-, COX-2-/- and normal chow fed ApoE-/- mice 
had similar endothelial morphology (in terms of nuclear density or CD31 immunoreactivity) 
as the WT mice. Both the untreated and the LPS treated COX-1-/- and COX-2-/- mice had 
elevated levels of nuclear or ‘primed’ NF-κB in their aortic arch endothelium compared to 
WT controls. More CD41 positive platelets were detected adhered to the susceptible lesser 
curvature of aortic arches from COX-2-/- mice compared to WT mice. The implications of 
these observations are discussed in detail in my General Discussion chapter (Chapter 6). 
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It is without question that COX is a critical regulator of cardiovascular homeostasis. 
Nevertheless, we still do not fully understand how COX isoforms and their activity regulate 
vascular health and disease. It is, however, well established that platelets are enriched in 
COX-1 which drives thromboxane production crucial for platelet activation and aggregation. 
The overriding question of my thesis has been to investigate the relative expression of COX-
1 and COX-2 in endothelial cells and importantly their contribution to cardioprotective 
prostacyclin production from vascular endothelium. This is an area of controversy.  
 
Traditionally, COX-1 has long been considered the ubiquitous and constitutively expressed 
isoform present in almost every tissue of the body (including the vascular endothelium), 
responsible for the basal production of prostanoids. On the contrary, COX-2 has generally 
been viewed as the inducible isoform upregulated following inflammation; central to driving 
the increased prostanoid production during an inflammatory response. Hence, the general 
idea was that COX-1 was the constitutively expressed, predominant COX isoform in the 
vasculature whereas COX-2 was the inducible isoform, expressed at sites of vascular 
inflammation, injury or atherosclerosis.  
 
This notion was turned on its head after the Vioxx withdrawal, where COX-2 selective 
inhibitors were shown to have unexpected cardiovascular side effects. One of the early 
explanations for these adverse effects was that perhaps COX-2 is (contrary to the traditional 
view) constitutively and ubiquitously expressed within vascular endothelium and that when 
this COX-2 is inhibited with COX-2 selective inhibitors (or traditional NSAIDs), there is a 
reduction in anti-thrombotic endothelial prostacyclin which may increase arterial 
thrombotic risk.  
 
I set out to investigate this in my thesis with the hypothesis:  
 
‘COX-2 is present in vascular endothelium and regulates prostacyclin release 
and functional responses in health and disease’ 
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During the course of this PhD I have made every effort to investigate objectively whether 
COX-2 is constitutively expressed in the endothelium of blood vessels and/or if the 
expression and activity pattern changes with different cardiovascular paradigms such as 
aging, chronic heart failure or atherosclerosis. Given that COX-2 has been shown to be a 
shear stress regulated gene, I studied COX-1 and COX-2 expression and activity in the aortic 
arch since this is a complex vascular structure where the hemodynamic effect of different 
kinds of shear stress patterns on endothelial form and function can be studied within the 
same tissue. Additionally, since the lesser curvature of the aortic arch has been shown to be 
an atherosclerosis susceptible region where NF-κB is ‘primed for activation’, this was an 
area of the vasculature that I was particularly interested in examining since COX-2 is a NF-κB 
regulated gene.        
The en face aortic arch mouse model 
Throughout my thesis, I have been struck by how consistent the endothelial morphology 
have been in the greater and the lesser curvatures of the aortic arches that I have studied. 
The endothelial cells lining the greater curvature were typically elongated, evenly spread 
out and aligned with the direction of the blood flow whereas those cells lining the lesser 
curvature were more randomly orientated with polygonal shapes. The most striking 
distinction between the two regions was the increased nuclear density in the endothelial 
layer of the lesser curvature. These morphological differences indicate that each region has 
its own separate hemodynamic environment resulting in unique endothelial phenotypes.  
The characteristic endothelial morphology in the two regions has been described previously 
(Hajra et al., 2000; Jongstra-Bilen et al., 2006) in isolated, zoomed-in images showing 
propidium iodide stained nuclei and silver nitrate stained endothelial junctions. However, 
the tiles presented in this thesis are the first to provide an overview of the full range of 
endothelial phenotypes exhibited in the aortic arch including the ‘interface region’ between 
the greater and the lesser curvature, which has not been described previously. This 
‘interface region’ had both aligned and randomly orientated endothelial cells; which appear 
to be a mixture of flow-responsive endothelial phenotypes with similar morphology to 
endothelial cells in both the greater and the lesser curvature of the mouse aortic arch. 
There was a progressive increase in nuclear density (quantified by total nuclear area) from 
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the greater curvature via the interface region to the lesser curvature. Since there was no 
difference in nuclear density of the underlying smooth muscle between the two regions, this 
observation appears to be restricted to the endothelial layer.   
The increased nuclear density could reflect either a higher endothelial cell turnover in the 
lesser curvature and/or a higher number of infiltrated nucleated cells into the intimal layer 
of this region. It has been proposed that the increased nuclear density can be accounted for 
by infiltrated intimal leukocytes (Jongstra-Bilen et al., 2006). As I have used the blue 
fluorescent nucleic acid stain DAPI, which preferentially stains AT-rich double stranded DNA 
in the minor groove (Kubista et al., 1987) to label the nuclei, it does not allow for 
discrimination of different nucleated cell types that may be present in the aortic intima of 
my images. Furthermore, even if anti-CD31 antibodies are typically used to identify 
endothelial cells in immunohistological preparations, CD31 is not only expressed on 
endothelial cells and hence does not facilitate for discrimination between endothelial cells 
and other CD31 positive cell types potentially resident in the intimal wall.  
For example, platelets have been shown to express approximately 5000 CD31 molecules per 
cell, leukocytes around 85000 molecules but to put this in context; endothelial cells have 
nearly 1 million CD31 molecules expressed on their surface (Newman, 1994). Accordingly, 
although CD31 is not specific to endothelial cells, their surface is highly enriched in this 
membrane glycoprotein. Therefore, the abundant CD31 immunoreactivity, along with 
endothelial-like morphological characteristics in both regions of the aortic arch suggest that 
most of the nucleated cells detected in these regions of the aortic intima are endothelial 
cells. The exact ratio of endothelial cells to other cell types potentially present in the nuclear 
dense lesser curvature remains to be determined, perhaps by scanning electron microscopy.  
The distinct difference in nuclear density between the greater and the lesser curvature is 
important to bear in mind when comparing immunohistology from the two regions. In some 
cases, elevated levels of immunoreactivity in the lesser curvature compared to the greater 
curvature, could simply be due to the increased number of nucleated cells/nuclear material 
in this region. Importantly, however, there was no difference in the nuclear density or CD31 
immunoreactivity between the WT, COX-1-/-, COX-2-/- or normal chow fed ApoE-/- animals 
studied in Chapter 5 and is therefore less likely to be a confounding factor when comparing 
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immunohistological results between these animals. This also confirms that the images were 
comparable in terms of endothelial integrity with intact CD31 positive endothelium in both 
regions of the aortic arch from all the different types of mice studied.  
In Chapter 3, there was a significant difference in CD31 immunoreactivity between the 
greater and the lesser curvature in WT mice, but this was not the case when the protocol 
was repeated in more WT mice in Chapter 5. There was, however, a significant difference in 
CD31 immunoreactivity between the two regions in the COX-2-/- mice, but on the whole, 
these levels did not differ from WT mice.  
It is important to keep in mind that CD31 is abundantly expressed in every region of the 
aortic endothelium and that although the CD31 staining pattern varies between the two 
regions, the overall mean fluorescence values come out very similar. The CD31 
immunoreactivity tends to be distributed throughout the cytoplasm as well as outlining the 
intracellular junctions between the endothelial cells in the greater curvature, whereas it 
seems more localised to the intracellular junctions in the lesser curvature. This distinct 
distribution may be due to the hemodynamic differences between the two regions, since 
CD31 has been identified to play an important role in how endothelial cells sense  and 
respond to shear stress (mechcanoreception and mechanotrasduction) through interactions 
with the cytoskeleton and subsequent cytoskeletal rearrangements (Newman et al., 2003). 
Interestingly, CD31 knockout mice have impaired NF-κB responses in aortic arch 
endothelium (Tzima et al., 2005) and CD31-/-ApoE-/- mice have reduced atherogenic indices, 
which suggest that CD31 is a critical mediator of  atherosclerosis (Stevens et al., 2008).  
Overall, the distinct endothelial morphology in the lesser and greater curvature of the 
mouse aortic arch is likely to reflect the hemodynamic environment that these cells are 
constantly exposed to. Flow measurements in the mouse aortic arch have revealed that 
there are clear differences in shear stress magnitude and directionality between the two 
regions of the aortic arch: unidirectional shear stress of approximately 600 dynes/cm2 in the 
greater curvature compared to oscillatory or multidirectional shear stress of around 150 
dynes/cm2 in the lesser curvature (Suo et al., 2007). Although this is 20-fold higher in 
magnitude compared to the shear stress estimated in the human aortic arch (Weinberg et 
al., 2007), the relative difference in shear stress magnitude and the different patterns of 
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shear stress directionality in the greater and the lesser curvature of the aortic arch seems to 
be consistent between mice and men (Suo et al., 2007).  
 
Towards the end of my PhD I had the rare opportunity to obtain a human aortic arch post 
mortem from one donor (the same female donor that I imaged the pulmonary artery from 
in Chapter 3). It was fascinating to handle something so much larger than the mouse and rat 
tissues that I had become used to. When I cut the aortic arch open to examine the intima, it 
made a brittle, crunchy sound due to the calcified and ulcerated atherosclerotic lesions 
present and located mainly around the carotid branches. It was, however, interesting to 
note that plaque like structures were located also in the lesser curvature of the human 
aortic arch (although at a position slightly higher up compared to the mouse aortic arch), 
whereas the greater curvature seemed relatively free from plaques (Figure 6.1).  
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Figure 6.1 Photos showing atherosclerotic lesions in a human aortic arch  
 
Figure 6.1 Photos showing atherosclerotic lesions in a human aortic arch. This aortic arch comes from the 
same female donor from whom the pulmonary artery was dissected from (imaged for COX-1 and COX-2 in 
Chapter 3). The aortic arch was fixed in 2% formaldehyde once it reached our lab from a biobank in the US ~36 
hours after time of death. (A) Photo of the aortic arch before it was cut open. (B) Photo illustrating how the 
aortic arch was cut open. (C) The opened and pinned out aortic arch. Black arrows indicate plaque-like 
structures in the lesser curvature and plaque free areas in the greater curvature. This donor was a 67 year old 
Caucasian female smoker (1 pack a day for 49 years) with a known medical history of COPD, essential 
hypertension and diabetes mellitus. Cause of death was spontaneous intracerebral haemorrhage.   
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Even if no firm conclusions can be drawn from just this one specimen, large population 
studies also suggest that atherosclerosis does feature in the lesser curvature and carotid 
branch points in human aortic arches (Figure 6.2) which can be a source of cerebral 
atheroemboli and is thereby regarded as a risk factor for ischemic strokes (Amarenco et al., 
1994). Atherosclerosis in the aortic arch is considered to be an indicator of generalised 
atherosclerosis and thereby increased morbidity and mortality (Dávila-Román et al., 1999). 
There is a strong correlation between increasing age and hypertension and ulcerated aortic 
arch plaques. In one autopsy study including 500 patients, 31% of the patients who were 60 
years or older that had suffered an ischemic stroke had ulcerated plaques in their aortic 
arch compared to only 1% of the patients under 60 years of age (Amarenco et al., 1992).  
 
Figure 6.2 Multidetector computed tomographic (CT) angiography of atheroma in a human 
aortic arch 
 
Figure 6.2 Multidetector computed tomographic (CT) angiography of atheroma in an aortic arch. Sagital 
reconstruction of an aortic arch from an 84 year old man with a 5mm thick atheroma in the lesser curvature of 
the aortic arch (indicated by black arrows). Figure modified from (Boussel et al., 2011). 
 
In conclusion, despite obvious species differences between mice and men, the aortic arch 
appears to have surprisingly similar features in terms of shear stress patterns and 
susceptibility to atherosclerosis, which hopefully (to some extent) gives the mouse aortic 
arch model translational value when interpreting how results from this model may relate to 
the human situation.  
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Once I was confident with the mouse en face aortic arch model and when I had overcome 
the initial technical difficulties of careful micro-dissection to avoid inflicting damage to the 
very fragile endothelial monolayer, it was time to interrogate the question of relative COX-1 
and COX-2 expression in the polarised endothelial phenotypes represented in this complex 
vascular structure.  
 
COX expression in the aortic arch: which COX isoform predominate(s) in ‘normal’/healthy 
vascular endothelium? 
In the first results chapter of this thesis (Chapter 3), my main objective was to investigate 
which COX isoform predominates in healthy aortic arch endothelium. Since it has been 
suggested that COX-2 may have rapid offset kinetics (Funk et al., 2007; Grosser et al., 2006), 
it was essential to perform immediate perfusion fixation of these aortic arches without post-
mortem delay, in order to eliminate the risk of protein decay and loss of any constitutive 
COX-2 during the experimental procedure.  
The difference in immunoreactivity between the two isoforms was striking; in every aortic 
arch that I imaged, abundant COX-1 immunoreactivity greatly predominated over very 
sparse COX-2 immunoreactivity.  
The intracellular staining pattern of the COX-1 immunoreactivity appeared diffused 
cytoplasmic and intense perinuclear. This is similar to what has been described previously 
(Morita et al., 1995) and immunoelectron studies have demonstrated that COX-1 mainly 
locates with the endoplasmic reticulum (ER) and the nuclear envelope; this is where the 
arachidonic acid is converted to PGG2 and PGH2 (Rollins et al., 1980).  
Although COX-1 immunoreactivity predominated over COX-2 immunoreactivity in all areas 
of the aortic arch, modest levels of punctate COX-2 immunoreactivity were consistently 
detected ‘enriched’ in the endothelium lining the lesser curvature of the aortic arch 
compared to the greater curvature where COX-2 immunoreactivity was nearly always 
absent.  
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Considering that COX-2 is a NF-κB regulated gene and NF-κB has been shown to be ‘primed 
for activation’ and probably to various degrees ‘constitutively’ active in the lesser curvature 
of the mouse aortic arch (Hajra et al., 2000), low (but nevertheless potentially important) 
levels of constitutive COX-2 expression localised to this inflammation and atherosclerosis 
susceptible region was perhaps to be expected. Consistent with this finding, a gene 
expression study of the lesser curvature of porcine aortic arches indicated that Ptgs2 (COX-
2) gene expression was elevated in this micro-domain of the vasculature compared to 
straight segments of the descending aorta (Passerini et al., 2004). It has been suggested that 
in these focal regions, COX-2 is likely to contribute to cardioprotective prostacyclin 
production (Funk et al., 2007).   
Following LPS driven COX-2 induction (after LPS injection), the COX-2 staining pattern in the 
mouse aortic arch endothelium was more perinuclear. This is consistent with reports about 
COX-2 (as an immediate early gene) being localised to the inner membrane of the nuclear 
envelope where COX-2 activity is often associated with nuclear activities such as cell 
differentiation or replication (Morita et al., 1995).        
There was no difference in COX-1 immunoreactivity between the greater and the lesser 
curvature in untreated WT mice, but there was however, somewhat surprisingly, increased 
COX-1 immunoreactivity in the lesser curvature following LPS treatment. This could reflect 
an increased number of infiltrating COX-1 positive leukocytes to this susceptible area 
considering that aortic tissues were harvested 4 hours after LPS injection. The same could of 
course also be the case for the increased COX-2 immunoreactivity, and different more 
specific cell markers and/or scanning electron microscopy could be used to evaluate the 
ratio of endothelial versus non-endothelial cell types present in the lesser curvature 
following LPS treatment. However, as stated in earlier sections, it is still most likely that the 
majority of cells present in the intima of both regions of the mouse aortic arch are 
endothelial cells.  
COX expression in the endothelial layer versus the smooth muscle layer 
Both the COX-1 and COX-2 immunoreactivity detected in my experiments seemed localised 
to the endothelial layer when compared to the underlying smooth muscle layer. However, 
since I did not included a positive control (or smooth muscle marker) for detection of the 
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smooth muscle cell layer, other than the small and penetrable stain DAPI, it cannot be 
certain that the COX-1 or COX-2 antibodies and/or their fluorescent tag (AlexaFluor594) 
really penetrated through the endothelial layer down to the underlying smooth muscle layer 
of these tissues.  
There was, however, clear COX-1 and COX-2 immunoreactivity in the deeper smooth muscle 
layers of the plaque-like structures detected in the ApoE-/- mice fed an atherogenic diet 
(Chapter 4). This still does not fully serve as a positive control for smooth muscle staining, 
since it is possible that the endothelium on top of plaque lesions may be easier to penetrate 
for the COX-1 or COX-2 antibodies and/or their fluorescent tag (AlexaFluor594) compared to 
‘normal’ endothelium.  
After all, the endothelial layer has been the focus of my investigation as it has been 
reported that both COX immunoreactivity and prostacyclin synthesis is more than 20 times 
higher in endothelial cells compared to smooth muscle cells, despite equal levels of 
prostacyclin synthase expression (DeWitt et al., 1983), clearly indicating that the 
endothelium is the predominant source of prostacyclin synthesis in vascular tissue. This is 
the main reason why I have focused on the role of COX-1 and COX-2 in the endothelial layer 
and not the smooth muscle layer in the tissues studied.  
 
COX expression in female mice and mature adult (aged) mice 
In order to consider any gender differences in COX expression, the COX staining protocol 
was repeated in tissue from female mice (Chapter 4). The same pattern was evident in the 
female mice (as in the male mice studied in Chapter 3); COX-1 immunoreactivity 
predominated over very sparse COX-2 immunoreactivity in the endothelium of all the areas 
of the aortic arch and the lesser curvature was again significantly enriched in COX-2 
immunoreactivity compared to the greater curvature.  
This was also the case in mature (12 month old) mice, and although these animals were not 
studied head to head in the same study, there was no apparent difference compared to the 
younger (3 month old) mice (Chapter 4).  
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COX expression in human endothelium    
Towards the end of my thesis I was able to repeat the COX en face protocol in a validation 
experiment using human pulmonary artery to investigate relative COX-1 and COX-2 
immunoreactivity in human endothelium. Even if I was only able to perform one experiment 
it was still interesting to note the similarities in COX-1 and COX-2 immunoreactivity and 
staining pattern between the human and mouse vessel. 
I tried to repeat the en face protocol in aortic arch tissue from the same donor (photos 
shown in Figure 6.1), but unfortunately, technical mounting difficulties due to the thickness 
of the human aortic arch tissue prevented it so I was not able to examine if the observations 
of constitutive COX-2 in the lesser curvature of the mouse aortic arch would be similar in 
the human aortic arch. A specialised fixing and mounting protocol for thick human tissue 
would need to be developed but theoretically it should be possible to image human aortic 
arch tissue with en face confocal microscopy.   
The pilot data obtained from the successful imaging of human pulmonary artery 
endothelium in this thesis is consistent with findings reported in the literature where COX-1 
and COX-2 expression have been examined in other types of human blood vessels: 
 Human internal mammary artery from 4 patients undergoing coronary bypass 
surgery. Endothelial COX-1 immunoreactivity was shown to greatly predominate 
over COX-2 at all time points (immediately after surgery and after 6 or 24 hours in 
culture). COX-2 immunoreactivity was only detected after culture and following 
induction with inflammatory stimuli (Foudi et al., 2009).  
 Saphenous vein, internal mammary artery and radial artery removed after coronary 
bypass surgery and immediately snap frozen. COX-1 protein was shown to greatly 
predominate over COX-2 protein (Mitchell et al., 2006a). 
 Aorta and carotid artery from 5 patients with non-atherosclerotic vessels had 
immunostainable COX-1 but no or little COX-2 (Schönbeck et al., 1999). 
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 Extensive study of large arteries from 20 supposedly healthy people who died in 
accidents where the post-mortem delay was 24 hours or less. Abundant endothelial 
COX-1 immunoreactivity was detected in the vascular endothelium in every subject 
(with little variation between cases) whereas COX-2 was found only in occasional 
endothelial cells in large arteries and this immunoreactivity varied more between 
subjects (Zidar et al., 2008).  
 Aorta from post-mortem study of 5 young individuals without gross or microscopic 
evidence of atherosclerosis. COX-1 mRNA was detected but no COX-2 mRNA (Belton 
et al., 2000).  
 Aorta from post-mortem study of 3 females, where the tissue was fixed within 6 
hours of fatality. Intense co-expression of COX-1 and prostacyclin synthase were 
observed throughout the aortic endothelium without detecting any COX-2 (Kawka et 
al., 2007). 
These studies provide convincing evidence for COX-1 being the predominant isoform 
expressed under normal conditions in human endothelium. However, it does not rule out a 
role for localised COX-2 in susceptible regions of the vasculature that may be more difficult 
to detect, unless the focus is to specifically study these micro-domain areas. Furthermore, 
all of these studies presented COX immunoreactivity data from sectioning, which offers 
limited study of a particular transverse section at any one point in the tissue compared to 
the en face imaging which gives a better overview over a larger area of endothelium where 
susceptible areas can be studied in parallel to protected areas.  
However, minor foci of COX-2 immunoreactivity have been reported in carotid artery 
endothelium (at the branch point with the aortic arch) in tissue from dogs (Kawka et al., 
2007). It would therefore be interesting to specifically focus on studying COX-2 expression 
(and activity) in the endothelium lining the lesser curvature (and/or branch points) of the 
human aortic arch to see if the findings in mice and dogs translate to human tissue and 
what relevance any constitutive COX-2 may have in this area of the human vasculature.  
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In vitro modelling of the effects of shear stress on COX-1 and COX-2 expression 
During my PhD I have also been involved in one of my colleagues Ms Claire Potter’s PhD 
project of setting up an orbital shaker shear stress model to study if the endothelial 
morphology and COX expression results from the aortic arch could be reproduced in vitro 
(Potter et al., 2011). Other in vitro shear stress models have previously examined COX 
expression after relatively short time points (between 6-24 hours) (Di Francesco et al., 2009; 
Okahara et al., 1998; Topper et al., 1996). However, we were concerned that applying shear 
stress to statically cultured endothelial cells could initially be conceived as an inflammatory 
insult and that perhaps 7 days on the orbital shaker would better reflect the effects of 
chronic shear stress. After 7 days, porcine aortic endothelial cells (cultured on filters) were 
randomly orientated in the middle of the well where the shear stress was multidirectional 
with low pulsatility (theoretically similar to the lesser curvature in the mouse aortic arch), 
but aligned and elongated nearer the periphery of the well where the shear stress was 
unidirectional with high pulsatility (theoretically similar to the greater curvature of the 
mouse aortic arch) (Potter et al., 2011).  
The COX-1 immunoreactivity was again shown to greatly predominate over COX-2 in all 
areas of the well (Potter et al., 2011). Interestingly, there was no increase in COX-2 
immunoreactivity in the centre of the well (the area that theoretically was exposed to a 
similar shear stress pattern as the lesser curvature of the aortic arch). It is of course difficult 
to accurately model the complex hemodynamic environment that endothelial cells are 
chronically exposed to in the aortic arch in vitro, however it raises questions about the COX-
2 that I found to be constitutively expressed in the lesser curvature of the aortic arch:  
 Is COX-2 chronically induced by a particular shear stress profile? 
 Is COX-2 constitutively expressed due to ‘primed’ NF-κB in this region? 
 Is the detectable COX-2 immunoreactivity actually from COX-2 expressed on 
leukocytes that have adhered to this susceptible area of the aortic arch due to the 
altered adhesion molecule expression reported in this area (Hajra et al., 2000; Iiyama 
et al., 1999; Suo et al., 2007)? 
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Whatever the answer may be, one of the main findings with my thesis is that COX-2 seems 
to be constitutively expressed in the lesser curvature of the mouse aortic arch and the final 
results chapter of my thesis (Chapter 5) was dedicated to investigating what functional role 
this localised COX-2 might have.         
Validation studies 
Throughout the thesis, I have performed numerous validation experiments to test the 
robustness of the COX-1 and COX-2 immunoreactivity data reported above. When the COX-
2 immunoreactivity turned out to be very modest and sparse in untreated healthy mice, I 
injected some mice with LPS in order to purposely upregulate COX-2 for immunodetection 
and this resulted in clear COX-2 immunoreactivity in both regions of the aortic arch, hence 
serving as a positive control for the COX-2 antibody (Chapter 3).  
Negative controls included secondary antibody control (which was always low without any 
specific pattern) and the use of blocking peptides which significantly reduced or ‘blocked’ 
the COX-1 and COX-2 immunoreactivity detected (Chapter 3).  
I also examined COX-1 and COX-2 immunoreactivity in the COX-1-/- and COX-2-/- mice 
respectively. COX-1 immunoreactivity in the normal cytoplasmic and perinuclear staining 
pattern was detected in all types of mice (including the COX-1-/- mice, both young and 
mature, Chapter 3 and 4). This is possibly due to that the COX-1 antibody was raised against 
an amino acid sequence that comes before the neomycin insert disruption and is therefore 
likely to pick up a truncated version of the COX-1 protein that may be present in the aortic 
arch endothelium of these mice.  
However, since the COX-1 active site has been disrupted in the COX-1-/- mice, it is highly 
unlikely that any truncated protein has functional COX-1 enzymatic activity. This was 
confirmed by the lack of prostacyclin production capacity in COX-1-/- vessels (from both 
young and mature mice, Chapter 3 and 4).  
COX-2 immunoreactivity was however significantly reduced and without the typical LPS 
induced nuclear envelope staining pattern in the COX-2-/- mice compared to the WT or the 
COX-1-/- mice. This was expected considering that the COX-2 antibody was raised against an 
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amino acid sequence after the genetic disruption, and is therefore less likely to pick up any 
truncated version of COX-2 in the COX-2-/- animals (Chapter 3).  
One validation study that I have not performed (that would potentially be important to 
consider) is examining any masking effects that the formaldehyde fixing protocol might have 
on the COX-1 or COX-2 antigens and what effect any antigen retrieval methods would have.  
I found a paper that reported that in their protocol, the COX-1 immunoreactivity did not 
depend on antigen retrieval methods, whereas the COX-2 immunoreactivity on the other 
hand to some extent did (Zidar et al., 2008). 
As my focus was on the relative immunoreactivity of COX-1 and COX-2, I wanted to keep the 
immunohistology protocol identical between the two and I feared that introducing different 
antigen retrieval methods would potentially introduce new unknown errors which could 
make it more difficult to draw any firm conclusions.   
Any masking effects that the fixing procedure might have on COX-2 detection may therefore 
be a potential limitation with my results, but it also serves as an important reminder that 
immunoreactivity is far from an absolute measure of protein expression and needs to be 
backed up with bioactivity data to investigate the physiological role of a protein. 
Importantly, the COX-1 and COX-2 immunohistochemistry detected in the aortic arch 
endothelium, does not predict the amount of prostacyclin that is produced by each isoform.    
Prostacyclin bioactivity assays: which COX isoform drives endothelial prostacyclin production 
in healthy blood vessels? 
In order to be able to measure meaningful amounts of prostacyclin, blood vessels need to 
be stimulated with calcium ionophore in order to activate cPLA2 which liberates arachidonic 
acid from the membrane phospholipids and starts the COX and prostacyclin synthase driven 
production of prostacyclin. Basal release (before calcium ionophore stimulation) is typically 
very low or undetectable, unless extensive handling during dissection has mechanically 
triggered the release.  
In every bioassay that I have performed during my thesis, thoracic or aortic arch tissue from 
WT or COX-2-/- mice have always released comparable levels of prostacyclin following 
stimulation with calcium ionophore. This release was readily inhibited by the NSAID 
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diclofenac, which validated that this represents a COX driven prostacyclin production in the 
vessel during the bioassay (rather than any carryover of prostacyclin from a non-endothelial 
source). Vessels from COX-1-/- mice however, never released any prostacyclin other than a 
very low level similar to the unstimulated baseline, despite stimulation with calcium 
ionophore. This pattern was the same no matter if the vessels came from male or female, 
young adult (3 month old) or mature adult (12 month old) mice (Chapter 3 and 4).  
In order to consider the possibility that any constitutively expressed COX-2 may have rapid 
offset kinetics, the ~2 hour equilibrated protocol was modified to ~30 minute total 
incubation so that acutely stimulated prostacyclin release could be measured (without any 
post-mortem delay). Again the pattern was the same; prostacyclin was robustly released 
from stimulated aortic tissue from WT and COX-2-/- mice, but not from COX-1-/- mice. It also 
made no difference if the 6-ketoPGF1α was measured by RIA or EIA (Chapter 3 and 4).  
In conclusion, according to this bioassay model of stimulated prostacyclin release; COX-1 
appears to drive the vast majority of the production of prostacyclin in both the thoracic 
aorta and the aortic arch, in male and female, young and mature mice.  
 
Reports from the literature about urinary markers of prostacyclin and the use of inhibitors  
Controversy surrounds the area of which COX isoform drives vascular prostacyclin 
production. The most relevant papers are listed below:  
 
 The urinary marker that is thought to reflect ‘systemic’ prostacyclin (PGI-M) is 
reported to be greatly reduced in COX-2-/- mice compared to WT mice, but unaltered 
in COX-1-/- mice (knockouts or knockdowns) (Cheng et al., 2006). Similarly, urinary 
PGI-M was also reported to be significantly decreased in WT mice treated with 
celecoxib or COX-2Y385F-/- mice (where the COX site is inactivated, but not the POX 
site) (Cheng et al., 2006). Urinary markers of thromboxane (TX-M) was however 
unaltered in both types of COX-2-/- mice and celecoxib treated mice, but significantly 
reduced in both types of COX-1-/- mice (Cheng et al., 2006).  
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 As described in the general introduction (Chapter 1); COX-2 selective inhibitors 
(celecoxib and rofecoxib) (and) NSAIDs depress urinary PGI-M substantially (but 
incompletely) in healthy volunteers (Catella-Lawson et al., 1999; McAdam et al., 
1999).  
 On the other hand, when the prostacyclin breakdown product 6-keto PGIF1α was 
measured in the aorta of rats treated with a COX-1 selective inhibitor, the levels 
were significantly reduced compared to aorta from rats left untreated or treated 
with a COX-2 selective inhibitor (Kawka et al., 2007).  
 Furthermore, when forearm blood flow was measured in healthy volunteers, there 
was no change in endothelial vasodilator responses following 7 days of treatment 
with rofecoxib (Verma et al., 2001).   
 Another study of microvascular injury in healthy volunteers, concluded that 
rofecoxib did not lead to reduced prostacyclin generation in healthy humans and 
that COX-1 and not COX-2 appears to be the source of prostacyclin in the human 
microvasculature (Tuleja et al., 2003).  
 
Thus, the results from my thesis are in conflict with some reports and in support of others. A 
major area of debate surrounds the validity of the urinary markers of prostacyclin (PGI-M) 
and thromboxane (TX-M). It has been argued that it represents a non-invasive sampling 
technique to measure the endogenous generation of prostacyclin and thromboxane 
(FitzGerald et al., 1981) and that urinary markers of 6-keto PGF1α is thought to mainly reflect 
renal prostacyclin whereas urinary markers of PGI-M supposedly represent an index of 
endogenous systemic (extra-renal) prostacyclin generation (FitzGerald et al., 1983).  
 
This assumption has been criticised, however, because the exact origin of the PGI-M cannot 
be determined considering that prostacyclin is first rapidly (within minutes) hydrolyzed to 6-
keto PGF1α, and then metabolised by β-oxidation in the liver. Furthermore, it has been 
argued that the kidney also possesses β-oxidation capabilities (since isolated rabbit kidney 
perfused with prostacyclin yields PGI-M) and that PGI-M may therefore reflect both 
systemic and renal prostacyclin (Flavahan, 2007; Van Hecken et al., 2000). It could therefore 
be possible that the PGI-M levels detected in COX-1-/- mice (Cheng et al., 2006) could 
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potentially be derived from a non-endothelial source, for instance COX-2 derived 
prostacyclin in the kidneys of these mice.   
 
Yet it is difficult to think of an alternative accurate measurement of thromboxane and 
prostacyclin in human (or animal) biological fluids due to their short half-lives, the pattern of 
their synthesis; platelet thromboxane is generated in dramatic bursts whilst endothelial 
prostacyclin is produced more tonically (Mitchell et al., 2006a) and artifacts due to invasive 
sampling techniques (FitzGerald et al., 1983).  
 
Moreover, prostacyclin is unlike many other prostanoids not extensively metabolised by the 
lung and it was first suggested that prostacyclin was a circulating platelet inhibitory (short-
lived) hormone. This was, however, updated with experiments showing that the 
endogenous secretion rate of prostacyclin in humans is very low and that plasma levels of 
the breakdown (hydrolysis) product 6-keto PGF1α is in pico grams range, indicating that 
prostacyclin may be more important for prevention of local platelet-vessel wall interactions 
than as a systemic circulating anti-platelet agent (FitzGerald et al., 1981).  
 
Local levels of prostacyclin may in fact be a more relevant measure than systemic levels. 
This was why I focused on measuring stimulated prostacyclin (as 6-keto PGF1α) released 
from aortic vessels (parallel to the vessels that I imaged) rather than measuring urinary PGI-
M from these animals. It is, however, important to remember that the bioassay I used in this 
thesis is more likely to reflect the overall prostacyclin producing capacity in these vessels ex 
vivo rather than actual endogenous production rates in vivo, since a potent stimulus with 
calcium ionophore was used to maximise the prostacyclin production in each tissue. In this 
model, COX-1 appears to drive the overall prostacyclin production. Yet, there is a possibility 
that localised and relatively low but still bioactive levels of prostacyclin is produced by the 
constitutive COX-2 detected in the lesser curvature. Theoretically, this COX-2 derived 
prostacyclin may be too low and/or too localised to detect in the protocols that I have used 
with the whole vessel, where COX-1 activity may be superseding and hiding any potential 
contribution from COX-2.  
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For instance, COX-2 has been shown to have a lower threshold for hydroperoxide activation 
(required for the priming event from the POX site) than COX-1 (Murakami et al., 1999), 
which could be an advantage in the endothelium where the hydroperoxide tone is low 
(Boutaud et al., 2002). It would be interesting to measure if the hydroperoxide tone differs 
between the greater and the lesser curvature and if so, the predominant COX-1 detected in 
the lesser curvature may be less relevant than the much lower levels of COX-2 in terms of 
local prostanoid production in this area.  
 
Lipid peroxide tone has also been shown to influence the pharmacology of several NSAIDs 
which appear to inhibit endothelial prostacyclin production more potently than platelet 
thromboxane production (in vitro), attributed to a lower endogenous peroxide tone in 
endothelial cells compared to platelets (Mitchell et al., 2006a). This may be relevant to how 
these drugs can create an increased thrombotic environment, inhibiting endothelial COX-1 
(and local levels of COX-2) more strongly than platelet COX-1.  
 
Since I have always stained for COX-1 and COX-2 in separate pieces of tissues (and never 
studied colocalisation), it cannot be ruled out that COX-1 and COX-2 may form heterodimers 
(Yu et al., 2006), which may have implications for their respective stereochemistry and 
bioactivity.   
 
Overall, the functional role of the localised constitutive COX-2 that I have detected in the 
lesser curvature of the aortic arch needs to be evaluated. Considering that prostacyclin 
synthase is the predominant prostanoid synthase in vascular endothelium, it would be fair 
to assume that prostacyclin may be the local COX-2 product in this region, but it could 
equally be PGE2 or PGD2 or any other prostanoid. Perhaps the bioactivity profile of this COX-
2 could be studied more easily by isolating the lesser curvature region of the aortic arch, 
and inhibiting overriding COX-1 activity with a COX-1 selective inhibitor (i.e. SC-560) 
(Wallace et al., 2000).  
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COX expression and bioactivity profile during cardiovascular disease; animal models of heart 
failure and atherosclerosis 
In the final year of my PhD an opportunity arose for me to take part in a tissue share of rats 
with post-infarction chronic heart failure, to examine if the relative COX expression or 
bioactivity profile changes following cardiovascular disease (Chapter 4). This was also an 
opportunity for me to see if my observations in mice could be extended to another species 
(rats).  
The post-infarction rats were clearly compromised with distinct manifestations of chronic 
heart failure such as ventricular hypertrophy and impaired contractile function (Lyon et al., 
2011; Lyon et al., 2009). In the aged matched control rats, abundant COX-1 
immunoreactivity alongside modest COX-2 immunoreactivity (in similar perinuclear staining 
patterns as in the mice) was detected in aortic arch tissue and in carotid artery branches. 
Overnight incubation with LPS resulted in intense COX-2 immunoreactivity which served as 
a positive control that the COX-2 antibody could detect rat COX-2. Both the COX-1 and the 
COX-2 immunoreactivity were readily blocked by the addition of blocking peptide. Following 
the bioassay protocol of stimulated prostanoid release, prostacyclin was most abundantly 
released from the thoracic aorta (compared to modest levels of PGE2 and thromboxane).  
I was surprised to see that there was no difference in either COX-1 or COX-2 
immunoreactivity or prostanoid profile between the control rats and the rats with chronic 
heart failure. This indicates that although these animals had clear signs of gross 
cardiovascular disease, maybe it was not the correct model to use in terms of vascular 
inflammation, since even at strain, COX-2 was not upregulated on a chronic basis.  
I then returned to earlier theories about the aortic arch and decided to apply the question 
about the effects of cardiovascular disease/vascular inflammation to an atherosclerotic 
model where plaques were clearly present in the vascular endothelium (Chapter 4 and 5). 
Even without specific markers for the plaque-like structures, they were strikingly nuclear 
dense and morphologically clearly different to the surrounding endothelium. The plaque-
like structures were spanning most of the lesser curvature (consistent with that this region 
has an increased susceptibility to atherosclerotic plaques) and continued along the lesser 
curvature into the mid arch and the descending arch.  
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Due to the bulkiness of plaques, atherosclerotic tissues are often imaged by sectioning 
rather than examined en face. It was exciting to see that it was possible to repeat the en 
face method also in aortic arches from ApoE-/- mice that had been fed an atherogenic diet 
and that had clear advanced plaques. Viewing the atherosclerotic aortic tissue en face 
provided a better overview over a larger area of atherosclerotic endothelium, allowed for 
investigation of the inside layers of the plaque and enabled study of the surrounding and 
surprisingly ‘normal looking’ endothelium. Intense COX-2 immunoreactivity was detected, 
clearly localised to the atherosclerotic plaque-like structure. This could have been 
endothelial in origin and/or expressed on infiltrating leukocytes (for instance 
monocytes/macrophages). As I did not have any other cell markers than CD31 and DAPI, the 
exact origin and/or distribution of COX-2 immunoreactivity between different cell types 
could not be established.  
Considering that it is already well recognised that COX-2 is expressed in atherosclerotic 
plaques (Schönbeck et al., 1999), these findings serve more as an additional positive control 
(other than LPS induction) for what positive COX-2 immunoreactivity can look like in a 
mouse vessel when imaged en face. Interestingly, the surrounding ‘normal looking’ 
endothelium was still clear of COX-2 immunoreactivity but importantly, predominant COX-1 
immunoreactivity was still clearly present, abundantly expressed on the plaque-like 
structure and elsewhere.  
A colleague of mine (Dr Nick Kirkby) furthered the investigation about the role of COX-2 in 
atherosclerosis by creating double knockout ApoE-/- COX-2-/- mice (where both ApoE and 
COX-2 have been knocked out). It is worth noting that there were significantly more plaques 
in the lesser curvature of aortic arches from ApoE-/- COX-2-/- mice compared to ApoE-/- COX-
2+/+ mice fed an atherogenic diet.  This data support an athero-protective role for the 
localised COX-2 in the lesser curvature.  
Furthermore, there were also differences in systemic cholesterol levels. Similar results were 
reported by another group in a different study that showed that after 3 weeks on an 
atherogenic diet, (‘normal’ ApoE+/+) COX-2-/- mice had increased lipid deposition in their 
aorta (Narasimha et al., 2007). Serum levels of cholesterol indicated that the COX-2-/- mice 
were hyperlipidemic compared to WT mice and after 4 weeks, 10 out of 15 of the fat fed 
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COX-2-/- mice had died (Narasimha et al., 2007).  These results indicate that COX-2 might 
have an important role in cholesterol metabolism (in the liver or elsewhere) and that 
deletion of this COX-2 (or potentially through pharmacological inhibition with NSAIDs or 
COX-2 selective inhibitors) could (independently or in conjunction with any alterations in 
global or local prostacyclin levels) contribute to an increased atherogenic risk.  
This could be highly relevant considering extended treatment with celecoxib or rofecoxib 
was associated with a risk transformation, where the cardiovascular hazard evolved slowly 
over time in 1-2% of patients, which may be linked to an acceleration of atherogenesis 
(Bresalier et al., 2005; Fries et al., 2006; Solomon et al., 2005).  
Keeping these observations about an athero-protective role of COX-2 in mind, this takes us 
to the final part of my thesis which concerned the physiological consequences of COX-1 or 
COX-2 deletion in the aortic arch.  
 
COX-1 or COX-2 deletion in the aortic arch: consequences for NF-κB activity  
In the final results chapter of my thesis (Chapter 5), I set out to investigate NF-κB activity in 
the aortic endothelium of the COX-1-/- or COX-2-/- mice. The rational was that the globally 
diminished prostacyclin (in the COX-1-/- mice) or locally reduced prostacyclin and/or other 
COX products and/or altered cholesterol metabolism in the COX-2-/- mice, may influence NF-
κB activity in these animals. This is particularly relevant to study since activated NF-κB is 
thought to play a key role in the development of vascular inflammation and atherosclerosis 
(Collins et al., 2001).  
The NF-κB protocol was validated with LPS treatment that consistently resulted in nuclear 
translocation of NF-κB from the cytosol to the nucleus in the endothelium of both the 
greater curvature and the lesser curvature in all the animals. Nuclear levels of NF-κB 
immunoreactivity were significantly higher in the lesser curvature region compared to the 
greater curvature region in both untreated and LPS treated WT mice. This is consistent with 
reports that NF-κB is ‘primed for activation’ in the lesser curvature of the aortic arch which 
may have relevance to the increased susceptibility of atherosclerotic plaques forming in this 
area (Hajra et al., 2000).  
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Despite finding very low levels of COX-2 in the greater curvature of the aortic arch, levels of 
‘primed’ or nuclear NF-κB immunoreactivity were significantly higher in this ‘protected’ 
region from untreated COX-2-/- mice compared to WT mice. The same was true for COX-1-/- 
mice. Following LPS stimulation, nuclear NF-κB was again higher in the greater curvature in 
COX-2-/- mice compared to WT mice (but were not different in COX-1-/- mice). Both COX-1-/- 
and COX-2-/- mice had significantly more nuclear NF-κB levels in the lesser curvature 
compared to WT mice following LPS treatment. Therefore, the aortic endothelium of both 
COX-1-/- and COX-2-/- mice appears to have primed (nuclear) and potentially more active NF-
κB compared to WT mice.    
One can speculate that the ‘primed’ NF-κB in the COX-1-/- mice may be due to the lack of 
prostacyclin restraint on NF-κB translocation (through negative feedback inhibition), as has 
been shown in other cell types with prostacyclin analogues (Raychaudhuri et al., 2002; Zhou 
et al., 2007a; Zhou et al., 2007b). In fact, the primed NF-κB in the COX-2-/- tissue was 
somewhat more surprising, considering that on a gross level, COX-2 did not appear to 
contribute to prostacyclin release from these tissues. Still, as mentioned in earlier sections, 
it is possible that the activity of the highly localised COX-2 in the lesser curvature that I may 
have failed to detect in my bioassays of gross sections of tissue, could in fact modulate local 
NF-κB activity. Alternatively, loss of COX-2 in a remote site (e.g. the kidney or the liver) may 
predispose the circulation of COX-2-/- mice to inflammation due to indirect phenotypic 
manifestations (such as altered cholesterol metabolism described in earlier sections).  
Either way, both the cause(s) and any consequence(s) of the ‘primed’ NF-κB in the COX-1-/- 
and COX-2-/- mice still remain to be established. Furthermore, the ‘primed’ NF-κB in the 
COX-2-/- mice may contribute to the increased susceptibility to plaques in the lesser 
curvature of the ApoE-/- COX-2-/- mice (as investigated by my colleague Dr Nick Kirkby). The 
‘primed’ NF-κB in the protected greater curvature of the COX-2-/- mice did not however 
result in any more plaques forming in this ‘protected’ area of the ApoE-/- COX-2-/- mice.  
It is worth mentioning that I did performed a pilot study in WT mice In order to investigate if 
pharmacological treatment of with an NSAID (diclofenac administered via the drinking water 
for consecutive 3 days) could mimic the elevation in NF-κB seen in the COX-1-/- and COX-2-/- 
mice. This data was not included in this thesis, but initial results indicated that there was no 
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obvious difference in nuclear NF-κB immunoreactivity in diclofenac treated animals 
compared to untreated controls (in either untreated or LPS treated conditions). Either this 
pilot study failed to achieve sufficient inhibition of COX-1 (and COX-2) and/or longer more 
chronic dosing is required and/or it might suggest that this is a phenotypic effect in these 
animals (due to developmental compensations or any other indirect consequences of the 
chronic lack of COX-1 or COX-2) that may or may not be relevant to scenarios of ‘normal’ 
dosing of NSAIDs humans.  
Nevertheless, the ‘primed’ NF-κB in the aortic endothelium of COX-1-/- and COX-2-/- mice is 
still an interesting observation which is important to bear in mind when studying aortic 
endothelium from these mice, however, further investigation is warranted into the causes 
and consequences of the ‘primed’ NF-κB.  
 
Thrombotic potential in the COX-1-/- and COX-2-/- mice: platelet adherence to aortic arch 
endothelium  
Since platelets and endothelial cells share many cell surface markers it was initially 
challenging to think of a platelet selective marker that could be used in the mouse aortic 
arch en face model. It was therefore a welcome finding  when the platelet marker CD41 
specifically stained platelet-like objects but not the endothelium (Chapter 5). These CD41 
positive platelet-like objects were of the same size and shape as the CD41 positive platelets 
detected in the blood smears which validated that the CD41 positive objects detected 
adhered to the endothelium in the aortic arch were platelets.  
After this validation, it was time for en face investigation of the number of CD41 positive 
platelets adhered to aortic arches from WT, COX-1-/-, COX-2-/- and normal chow fed ApoE-/- 
mice.  
The whole experiment and quantification was performed blinded and just to be sure that 
the manual scoring was accurate, I re-calculated the results (still blinded) through 
automated quantification in Image J.  
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The result came out the same either way; there was significantly more CD41 positive 
platelets adhered to the lesser curvature in aortic arches from COX-2-/- mice than WT mice 
(or any other mice).  
This was a fascinating result that gave rise to a whole new set of research questions; firstly, 
how long had the CD41 positive platelets been adhered to this susceptible region of the 
aortic arch? 
It is difficult to draw any firm conclusions about this, but at least at the point in time of the 
perfusion fixation, they were clearly there. It is however probably important to examine 
what effect different perfusion methods might have on this type of platelet adhesion, to 
test if there is a difference between no perfusion at all versus manually maintained pressure 
perfusion (as was performed in this thesis) versus regulated pressure perfusion (i.e. 
~100mmhg maintained with a perfusion rig set up).  
Perhaps it would have been more ideal if the mice had been perfused with a perfusion rig 
set up (consistently at ~100mmhg). Still, even though the animals used in this study were 
perfused manually (via a needle inserted through the heart, flushed through with PBS and 
fixative at high pressure) all the aortic arches were completely clear of blood and the 
procedure was performed by randomising the order of animal type perfused.   
Furthermore, a single ApoE-/- mouse that had been fed an atherogenic diet was included in 
the study as a positive control to see if more platelets would adhere to plaque enriched 
areas compared to ‘normal’ areas of adjacent endothelium as reported previously (Davies et 
al., 1988; Huo et al., 2003). In this pilot study, there were more CD41 positive platelets 
detected, mainly localised to the plaque enriched areas which serves as an initial (positive 
control) validation for this model of platelet adhesion.  
It was also interesting to note that despite elevated levels of ‘primed’ NF-κB in the aortic 
arch endothelium of COX-1-/- mice (alongside greatly diminished prostacyclin synthesis in 
these vessels),  there was no difference in the number of CD41 positive platelets adhered to 
the aortic arch endothelium in these mice compared to WT mice. This is probably due to a 
lack of both COX-1 driven platelet thromboxane production and COX-1 driven endothelial 
prostacyclin in COX-1-/- mice. It has been shown that vascular injury-induced platelet 
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activation was increased in IP-/- mice, decreased in TP-/- mice, and the augmented platelet 
response seen in the IP-/- mice was abolished in mice deficient in both receptors (IP-/-TP-/- 
mice) (Cheng et al., 2002).  
The final figure in Chapter 5 (5.18 that shows images of CD41 positive platelets on the 
different layers of the plaque-like structure in the ApoE-/- mouse fed an atherogenic diet), 
shows in panel C a nucleated cell in complex with a CD41 positive platelet. This unexpected 
finding highlighted the possibility that the CD41 positive platelets may have been adhered 
on their own and/or alternatively in a complex with a leukocyte that may have adhered to 
the (nuclear dense) lesser curvature endothelium. It has been suggested that circulating 
platelet-leukocyte aggregates promote atherosclerotic lesion formation (Huo et al., 2003).  
With that said, there was no significant difference in overall nuclear density in the lesser 
curvature between the COX-2-/- and WT mice used in this study. Hence, the number of 
potential resident leukocytes in the lesser curvature is probably similar between these 
animals, which indicate that it is more likely to be an increased number of individual 
platelets that have adhered to susceptible endothelium in the COX-2-/- mice rather than 
platelet-leukocyte complexes.  
In conclusion, despite normal prostacyclin production capacity in aortic arches from COX-2-/- 
mice, it seems like the aortic endothelium in the lesser curvature of COX-2-/- mice is more 
susceptible to platelet adhesion. This may either be due that the platelets are more reactive 
in the COX-2-/- mice and/or alternatively due to a more ‘sticky’ or activated endothelium in 
this particular region of these animals. Findings from another study support the latter, 
where it was suggested that selective COX-2 inhibition may diminish anti-platelet properties 
of the endothelium (Buerkle et al., 2004).  
Speculatively, the increased number of CD41 positive platelets adhered to the lesser 
curvature endothelium of COX-2-/- mice (and the augmented susceptibility for 
atherosclerotic plaques in the lesser curvature of ApoE-/-COX-2-/- mice) may be due to the 
lack of localised COX-2 that may have important anti-thrombotic and anti-atherogenic 
effects in this particular region of the aortic arch.  
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Summary  
In every protocol that I have used, I have ubiquitously found abundant COX-1 
immunoreactivity predominating over very sparse COX-2 immunoreactivity in both regions 
of the mouse aortic arch. This pattern has been very similar in all the blood vessels 
investigated in this thesis. Moreover, in every bioassay that I have performed, stimulated 
prostacyclin release has been abundant in aortic vessels from WT and COX-2-/- mice, but 
more or less absent in vessels from COX-1-/- mice.  
Therefore, it seems very clear that in these protocols COX-1 appears to be the overriding 
COX isoform for vascular prostacyclin production. With this in mind, it would be all too easy 
to conclude that COX-2 has no role in cardiovascular health and disease, at least in terms of 
endothelial prostacyclin production from large vessels, especially when considering that the 
majority of research in this area concludes that COX-2 inhibition has deleterious vascular 
effects.  
The question remains exactly how the vasculature responds to COX-2 inhibition? It was 
surprising to note that despite finding minimal contribution of COX-2 to vascular 
prostacyclin production (when studied in large vessels); loss of COX-2 had profound effects 
on NF-κB activation as well as increased platelet adhesion to susceptible areas of 
endothelium in the mouse aortic arch.  
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Conclusion 
In conclusion to the hypothesis of this thesis:  
‘COX-2 is present in vascular endothelium and regulates prostacyclin release 
and functional responses in health and disease’ 
This hypothesis needs to be updated, since COX-1 was undeniably the predominant 
endothelial COX isoform found in every blood vessel that was examined and COX-1 also 
appears to be responsible for the majority of prostacyclin production in vascular 
endothelium.  
With that said, seemingly modest levels of localised, constitutively expressed COX-2 in 
micro-domain ‘hot spot’ areas of the vasculature (such as the atherosclerosis and 
inflammation susceptible lesser curvature of the aortic arch) may still contribute to 
prostacyclin production and/or to the production of another prostanoid, on a local level, to 
limit inflammation, atherosclerosis and platelet adhesion.  
The results presented in this thesis provide a lead for further investigation into the clinical 
relevance of these findings, to see if, alongside other cardiovascular risk factors; chronic use 
of NSAIDs or COX-2 selective inhibitors may inhibit the activity of anti-thrombotic and 
athero-protective, constitutively expressed COX-2 localised to susceptible areas of the 
vasculature, increasing the risk of arterial thrombotic outcomes such as myocardial 
infarction or stroke. 
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